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Abstract 
 
Breast cancer is a prevalent disease within today’s modern society, affecting 1 in 8 women and 
1 in 870 men within a lifetime. With the introduction of mammographic breast screening in 
1987 and marked improvements to targeted therapies, mortality rates declined, highlighting 
the need for early diagnosis and tailored treatment to halt disease progression in its foremost 
stages. Histology assessed biopsies, alongside initial two-view mammographic imaging, are 
paired as the current diagnostic “gold standard”.  The need to incorporate several techniques, 
applying an “all-angles” approach to diagnostics, provides an effective, streamlined diagnostic 
pathway, reducing patient wait times between testing and results – crucial in preventing disease 
progression.  
Optical spectroscopic techniques for the characterisation of biomolecular compounds and 
structures present within tissue are fast becoming the biomedical analysis tools of choice, 
coming to the forefront of clinical applications. Raman spectroscopy is one such technique 
providing highly chemically specific results, in a non-ionising and non-invasive way. When used 
in conjunction with metal nanoparticle probes, the inherently weak Raman signals of the 
biomolecules surrounding the nanoparticle surface undergo extensive levels of enhancement 
– an eponymous technique, Surface Enhanced Raman Scattering (SERS). 
This thesis is split into two principal areas of study. The first explores extrinsic SERS 
nanoparticles at depth within optical phantoms, “imaged” in a Transmission orientation, 
mimicking the composition of the breast within a cranio-caudal mammographic imaging 
position. The second concerns the micro-Raman quantification of gold nanoparticles, 
functionalised to a biocompatible level for the active targeting of hydroxyapatite – a calcium 
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apatite form which, when dominant within breast microcalcifications, act as a biomarker for 
malignancy. 
Key aspects drawn from the results include a greater understanding of Raman reporter gold 
nanoparticles at depth, and how the absorption profile of the sample material affects the 
garnered intensity profile. The synthesis of a novel nanoparticle probe was also founded, with 
promising future applications in terms of targeting and theranostic capabilities. Furthermore, a 
protocol into the implementation of an automated mapping system within an open optical set-
up is given, detailing the software, hardware and electrical installation requirements. 
The advantages of Raman spectroscopy integration within current diagnostic practices are 
highlighted, with limitations such as nanoparticle biocompatibility issues, the inherent optical 
properties of biological tissues, and system conditions touched upon. 
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1. Introduction 
 
 rapidly developing area in the field of biomedical research, optical techniques such as 
Raman and Infra-Red (IR) spectroscopy are fast becoming invaluable tools in cancer 
diagnostics. Specifically, Raman microspectroscopy and surface enhanced Raman spectroscopy 
(SERS) have gained widespread acceptance for their ability in characterizing biological samples. 
The on-going development of these techniques and constituent areas, such as the physio-
chemical advancement of nanoparticles as photonic probes, has broadened the scope of 
samples able to undergo analysis from in vitro to minimally invasive in vivo, providing much 
motivation for the work presented in this thesis.  
This introductory chapter presents the outline of the thesis together with some historical 
context of the spectroscopic techniques employed towards biomedical diagnostics. 
1.1 The History of Raman Spectroscopy 
The classical theory of light scattering without frequency change was postulated by Lord 
Rayleigh in 1871, through explanation of the age-old-question: “why is the sky blue?”.1 
Theorised by Austrian theoretical theorist Smekal in 1923,
2
 the phenomenon of inelastic light 
scattering, producing light of a higher and lower wavelength, was experimentally discovered 
by C.V. Raman and K.S. Krishnan in 1928, by focussing sunlight through a telescope onto a 
sample.
3
 A narrow band filter creates a monochromatic light source used to excite molecules 
producing scatter: elastically as Rayleigh scattering, and inelastically as the Raman effect – an 
extremely rare event where the frequency of ~1 in 10
6
 photons exhibits a change in 
wavelength. 
High-powered water-cooled mercury arcs were traditionally used as light sources – 
cumbersome and impractical, Raman was strictly a scientists’ gadget.1 Invented by Theodore 
A 
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Maiman in 1960,
4
 the advent of coherent “light amplification by stimulated emission of 
radiation”, or the laser, allowed Raman spectroscopy to become more instrumental. 
Subsequent technological advancement created accessible instrumentation at an affordable 
price and convenient size. This further increased applicability, however the inherently 
insensitive nature of the technique limited its growth.  
In 1973, a British group of scientists consisting of electrochemist Martin Fleishmann, Raman 
spectroscopist Patrick J. Hendra and postdoctoral fellow James McQuillan endeavoured to 
study in-situ electrochemical processes of species adsorbed on the surface of electrodes.
5
 Initial 
studies involving mercury chloride on platinum electrodes was limited in ability of signal 
detection.
6
 In an effort to enhance the Raman signal, a strong Raman scatterer, pyridine, was 
selected as the adsorbate, and silver as an electrode material suitable for electrochemical 
surface roughening to create a large surface area.
7
 In a landmark discovery, the Raman signal 
had been enhanced by a factor of ~10
6 
comparative to pyridine in solution, with adsorption 
in two distinct configurations.
8
 The finding was further confirmed in 1977 by David Jeanmarie 
and Richard Van Duyne with their prediction of an electromagnetic effect acting as the 
mechanism;
9
 and, Albrecht and Creighton in their proposal of a chemical, charge-transfer effect 
taking place.
10
 Both groups independently verified the enhanced signal could not be solely 
attributed to an increased concentration of the pyridine molecule. 
This localised enhancement phenomenon, known as Surface Enhanced Raman spectroscopy 
(SERS), allowed Raman to become a fully realised analytical technique for real-life applications, 
from bulk samples down to single molecules.  
More recently, the characterisation of the layers within bulk, turbid samples came with the 
development of Spatially Offset Raman spectroscopy, or SORS, in 2005 by Pavel Matousek et 
al. at the Rutherford Appleton Laboratory in the UK.
11
 The technique, involving the collection 
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of scattered photons lateral to the illumination source, has been used in combination with 
SERS to great effect, developed into the new expertise of SESORS.
12
 
The development of Raman spectroscopic techniques to real-world applications has expanded 
dramatically over the past three decades. Delving into a variety of fields including: art and 
archaeology including the determination of age and legitimacy of paintings;
13–15
 the detection 
of small quantities of illegal drugs or explosives adsorbed upon surfaces;
16–19
 and tamper-
reducing drug characterisation from within pharmaceutical blister packaging.
20–22
 One of the 
largest growing areas, however, is the field of biomedical diagnostics, explored further within 
this thesis. 
1.2 Overview of Thesis 
This thesis is split into two major sections: theory and experimental.  
The theory chapters allow the reader to gain greater understanding of the context of the work 
in terms of the pathophysiology and current diagnostic and therapeutic landscape surrounding 
breast cancer in Chapter 2; the Raman spectroscopic theory with particular emphasis on SERS 
and SORS in Chapter 3; and how nanoparticle biocompatibility plays a vital role in the success 
of an in vivo agent in Chapter 4. 
The preliminary experimental chapters, Chapters 5 and 6, outline the gold nanoparticle 
chemistry undertaken, of both synthesis and functionalisation, and the manufacturing of post-
menopausal breast, optically representative turbid phantoms, respectively. Following is the 
detailed experimental set-up within Chapter 7, which explores the engineering of 
optomechanical automation; the application of instrumental signal enhancement; and the 
tempering of nanoparticle dose in terms of biocompatibility. These three chapters preface the 
main experimental results and analysis.  
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Multiplexed gold nanoparticles present at varying depths is explored in Chapter 8, determining 
the possibility of in vivo depth measurements at a biologically sound dose. The signal recovery 
of the labelled nanoparticles at depth within a representative, 3D breast model under 
mammographic conditions is also considered, applying the technique in a complimentary way 
to the current mammographic imaging methods. 
Chapter 9 delves into active targeting nanoparticle functionalisation, with a combination of 
Raman reporter, polyethylene glycol and alendronate, a bisphosphonate. Type II 
microcalcifications have been presented as a major biomarker for breast carcinomas, especially 
within acidic environments with possible malignancy. The results obtained show that not only 
do these functionalised nanoparticles give the desired SERS signal, but that they do selectively 
target calcium phosphate present within malignant microcalcifications. 
Chapter 10 is the culmination of the thesis results, discussing and concluding on the findings, 
with potential future works also considered. 
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2. Breast Cancer 
 
ancer is the cause of 42% of premature deaths in England with a total of 477,667 new 
cases registered in 2014, totalling 234,664 men and 243,003 women. Of these new 
cases, breast carcinomas were most prevalent, accounting for 9.7% of all cancers. Incidence 
rates for men have remained stable since the late 1970s, however incidence has increased in 
women by 11% from 2000 to 2013.
23
 Through the advent of mammography screening in 
1987, and an increase of breast cancer awareness through major campaigns, crucial early 
diagnosis of the disease has risen, with 10-year survival rates climbing from just 40% in the 
early 1970s, to 78% of women in 2015.
24
 
In this chapter, an examination of the population in England affected by breast cancer is detailed 
in Section 2.1. Anatomical pathways of the breast and the biological mechanisms leading to 
carcinoma is presented in Sections 2.2 and 2.3. Sections 2.4 and 2.5 consider the necessity of 
early diagnosis and the current diagnostic imaging methods practiced in the clinical setting, 
respectively. Therapeutic pathways leading from diagnosis are discussed in Section 2.6. Base 
knowledge of the current diagnostic and therapeutic practices, and where improvements to 
these methods could be made, shapes the experimental design of this thesis. Section 2.7 
highlights the importance of working within the remits of current practice, to enhance the 
current diagnostic capabilities available through the incorporation of complimentary 
techniques. 
2.1 Epidemiology and Aetiology 
Breast cancer mainly affects women, one in eight of the UK population, with a small percentage 
of the male population also under threat of the disease – 46,085 women and 332 men of new 
diagnosis in England, 2014.
23
 Women aged 45 – 69 comprised the largest proportion of 
C 
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disease incidence of left and right breasts combined, with an overall increase in registrations of 
all ages, from 2004 to 2014, of 14.3%.
25
  
 
 
In North America and Western Europe the age-standardized incidence rate is four-fold of that 
in developing countries, contributed mainly by a “Western” diet and lack of physical activity, 
resulting in obesity.
27
 Other avoidable risk factors including smoking, consumption of alcohol, 
and hormonal differences, such as the oral contraceptive pill and pregnancy at a later stage in 
life. A combination of these elements are estimated to contribute to around 27% of female 
breast cancer cases in the UK.
28
  
An unavoidable risk factor is familial history. The likelihood of incidence increases with the 
number of relatives known to have developed breast cancer – zero affected members has a 
base risk of 7.8%; whilst one member holds a 13.3% increase, two members rises to 
21.1%.
29
 Early diagnosis is crucial for the survival rates of women who fall in this category, with 
Figure 2.1: Newly diagnosed incidence rate of breast cancer (left and right breasts) in women in 
England from 2004 to 2014.
26
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sufficiently high risk patients often opting for a bilateral mastectomy to eliminate the possibility 
of occurrence. 
 
 
From 2004 to 2014, the mortality rate across all age groups in England  decreased by 7.7%, 
most significantly in the 50 – 64 age group by 18.7%.25 A reduction in breast cancer mortality 
rates of women in the UK is recognised by the implementation of the mammography 
screening program in 1987, as visualised in Figure 2.2.  
An in-depth consideration into breast physiology gives a greater understanding into the 
significant role mammography plays in the diagnosis of intramammary carcinomas. 
2.2 Breast Anatomy 
Situated on the upper chest wall, the breast overlies the pectoral muscle in both men and 
women. Breast buds are formed during embryonic development. Until adolescence, the male 
and female breasts consist of an inactive network of lobes (glandular tissue) leading to the 
nipple, fatty (adipose) and connective (stromal) tissues.
30
 Puberty initiates the development of 
the female breast into the mammary gland (Figure 2.3). Mammogenesis is regulated through 
 
 
 
Figure 2.2: Mortality rate per 100,000 women in the UK from 1971 to 2014; the grey dotted line 
at the year 1987 marks the introduction of the Breast Cancer Screening Programme. Adapted from 
Cancer Research UK. 
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growth hormones, oestrogen and progesterone, developing the ability to lactate and feed 
young – prolactin begins and maintains the production of milk in pregnant and nursing women.  
 
Figure 2.3: Anatomy of the mammary gland. NOTE: Lactiferous sinuses (underlined in red) were 
proved to not existent through ultrasonography.
31,32
 
 
 
The anatomy of the breast is largely unchanged from the dissections of lactating breast cadavers 
conducted by Sir Astley Cooper in 1840.
33
 The functioning, glandular anatomy of the breast 
contains alveoli consisting of dense clusters of secretory epithelial cells, which cluster together 
to form lobules. These lobules are connected to lactiferous ducts which have an inner layer of 
epithelial cells encased in myoepithelial cells.
34
 Investigation with ultrasound has determined an 
average of 5 – 9 ducts open at the nipple, fewer than the 15 – 20 previously understood.32,35 
Adipose layers are meshed throughout the glandular tissue at a ratio of 1:1 in non-lactating 
breasts
31
 increasing to 1:2 in lactating women.
32
 Large breasts consist of a greater amount of 
adipose tissue. A network of stromal tissues – the extracellular matrix, blood vessels and 
Copper’s ligaments, eponymously named – support the layers of glandular and adipose 
tissue.
34
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Figure 2.4: Lymphatic drainage system and lymph node regions surrounding the breast.
34
 
 
 
The breast also consists of a lymphatic system dealing with immune responses to pathogens. 
Inflamed or enlarged lymph nodes, including all detailed in Figure 2.4, are a clinical marker for 
breast cancer. Neoplastic cells are able to spread through lymphatic and blood vessels forming 
metastases’, most commonly in the bone, lung and liver.36 
2.3 Pathology 
2.3.1 Physiology  
In a single breast, 25% of neoplasms occur in the upper outer quadrant, between 4 – 8% 
occur in the other three quadrants and only 1% in the nipple/areola and axillary areas.
23
 The 
earliest stage of breast cancer is confined to the epithelial cells within the lining of either the 
ducts or lobes, known as ductal/lobular carcinoma in-situ (DCIS/LCIS). Further growth leads 
to infiltrating or invasive carcinoma. LCIS is less likely to turn into an invasive carcinoma, often 
considered as neoplasia. Necrotic and pleomorphic cells are indicative of more aggressive 
cancers, more likely to be associated with DCIS. Figure 2.5 shows how DCIS develops into 
an invasive carcinoma, requiring a network of blood vessels, enabling a rapid growth rate. 
Supraclavicular 
High axillary  
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Mid-axillary  
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      Level II 
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Brachial 
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Figure 2.5: Physiological characteristics of an aggressive cancer type tumour.
37
 
 
 
Malignant tumours, as small as 3 mm, rely on this rapid angiogenesis to curb hypoxic and 
necrotic regions from inevitably developing.
38
  Poor lymphatic clearance and dilated, leaky 
vasculature creates a high level of interstitial fluid pressure (IFP) within the tumour. This leads 
to an enhanced permeability and retention effect (EPR): drawing oxygen and nutrients in and 
a large percentage retained, keeping a high level of growth.
39
 The recently updated TNM 
(Tumour – Lymph Nodes – Metastasis) staging system for breast cancer is as follows: 
TNM Staging Classification 
 TX Primary tumour not assessable 
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T0 No primary tumour 
Tis DCIS 
T1 ≤20 mm in greatest dimension 
 T1a ≤1 mm 
 T1b >1 but ≤5 mm 
 T1c >5 but ≤10 mm 
 T1d >10 but ≤20 mm 
T2 >20 but ≤50 mm 
T3 >50 mm in greatest dimension 
T4 Tumour with direct extension to the chest wall and/or skin 
 T4a Extension to chest wall 
 T4b Ulceration and/or satellite nodules and/or oedema 
  T4c Both T4a and T4b 
  T4d Inflammatory Carcinoma 
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  Clinical (cN) 
 cNX RLNs cannot be assessed (e.g. previously removed) 
 cN0 No RNL metastases 
 cN1 Movable metastases in ipsilateral Level I, II axillary lymph node(s) 
   cN1mi Micro-metastases >0.2 mm but ≤2 mm 
 cN2 Clinically fixed or matted metastases 
   cN2a Metastases in axillary lymph nodes fixed to one another or other structures 
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   cN2b Metastases in ipsilateral internal mammary nodes, fixed 
cN3 Multiple Node involvement 
  cN3a Metastases in ipsilateral infraclavicular lymph node(s) 
  cN3b Metastases in ipsilateral internal mammary and axillary lymph node(s) 
  cN3c Metastases in ipsilateral supraclavicular lymph nodes(s) 
 Pathological (pN) 
pNX RLNs cannot be assessed 
pN0 No RNL metastasis identified, or Isolated Tumour Cell (ITCs) 
  pN0(i+) ITCs only (malignant cell clusters ≤0.2 mm in RNLs) 
  pN0(mol+) Positive molecular findings; no ITCs detected 
pN1 Micro-metastases 
  pN1mi Micro-metastases >0.2 mm but ≤2 mm 
  pN1a Metastases in 1–3 axillary lymph nodes, at least one metastasis ≤2 mm 
  pN1b Metastases in ipsilateral internal mammary sentinel nodes, excluding ITCs 
  pN1c pN1a and pN1b combined 
pN2 RLN Metastases present 
  pN2a Metastases in 4–9 axillary lymph nodes (at least one tumor ≤2 mm) 
  pN2b Metastases in clinically detected internal mammary lymph nodes 
 pN3 Extensive RLN metastases present 
   pN3a Metastases in 10+ axillary lymph nodes (at least one tumor ≤2 mm); 
or 
metastases to the infraclavicular (Level III axillary lymph) nodes 
   pN3b pN1a or pN2a in the presence of cN2b, internal mammary nodes by imaging; 
or 
pN2a in the presence of pN1b 
   pN3c Metastases in ipsilateral supraclavicular lymph nodes 
 M0 No clinical or radiographic evidence of distance metastases 
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  cM0(i+) No clinical or radiographic evidence of distant metastases in the presence of 
tumor cells or deposits ≤0.2 mm detected by molecular techniques in 
circulating blood, bone marrow, or other nonregional nodal tissue in a 
patient without symptoms or signs of metastases 
cM1d Distant metastases detected by clinical and radiographic means 
cM1 Any histologically proven metastases in distant organs; or if in 
 
Table 2.1: Tumour – Lymph Nodes – Metastasis (TNM) Staging Chart.40 
This is the most common tumour staging system. To further differentiate tumours, the 
biomolecular characteristics are a crucial sub-classification in determining the patient specific 
treatment pathway. 
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2.3.2 Molecular Subtypes 
Overexpression of three distinct types of molecular receptors define four main subtypes of 
breast cancer arising within cells. Oestrogen (ER), progesterone (PR) and human epidermal 
growth factor (HER2) receptors are overexpressed independently, resulting in either Luminal 
A, Luminal B, HER2 or Basal-like carcinomas, as described in the table: 
 
Table 2.2: Breast cancer subtype chart describing the presence of oestrogen, progesterone and human 
epidermal growth factor receptors. 
 
The four subtypes are largely associated with invasive ductal carcinoma (50-80%) and invasive 
lobular carcinoma (5-15%).
40
 Luminal subtypes account for around 70% (type A representing 
50-60% whilst type B represents 10-20%) of all invasive breast cancers, with HER2 and Basal-
like, or triple negative, types completing the last percentage with around 15% each.
41
 The 
subtype HER2 has the best prognosis whilst Basal-like is most critical due to the aggressive 
nature and tendency to relapse post-treatment.
42
 Luminal and HER2 subtypes are identified 
by ER, PR and HER2; Basal-like cancers have few or no hormone receptors, aptly described 
as “triple negative”, meaning non-responsiveness to targeted therapies.43 However, the 
subtype has a strong association with hypoxia inducible factor 1 protein (HIF-1α) and carbonic 
anhydrase XI mRNA, which is overexpressed in hereditary breast cancer (BRCA1 and 2 
mutation).
44
 Patients with this familial history of breast cancer are annually monitored using 
magnetic resonance imaging (MRI).
45
 
Subtype Receptor Expression 
Luminal A and B ER and/or PR +ve | HER2 -ve 
HER2  ER and/or PR -ve | HER2 +ve 
Triple Negative or Basal-like ER and/or PR -ve | HER2 -ve 
 36 
 
2.3.3 Microcalcifications 
Breast microcalcifications are an important disease identifier presenting in around 93% of DCIS 
cases and having a strong association with lymph node invasion.
46
 The significance of clustering 
and size is a reliable indicator as to whether the occlusion is benign or malignant.
47
 Occurring 
within the lobes and ducts of the breast, the calcifications occurring within each have different 
appearances upon x-ray, as seen in Figure 2.6. 
Large, smooth, “tea cup” shaped calcifications which appear less clustered are associated with 
lobular areas, and tend to be classed as benign; smaller, pleomorphic and highly clustered 
calcifications are associated with ducts, and treated as suspicious or malignant. As Figure 2.6 
shows, both types of calcifications can be present at the same time. 
 
Figure 2.6: (a) Mammogram of a spiculated mass of invasive DCIS with both lobular and ductal 
microcalcifications present; graphics representing (b) benign lobular calcifications and (c) malignant 
ductal calcifications. 
 
 
A study by Frappart et al. looked at microcalcifications within benign and malignant breast tissue 
specimens using a microprobe and electron microscopy. Analysis found two distinct types: 
weddellite crystals, or calcium oxalate dihydrate, or Type I calcifications, and calcium 
phosphates characteristic of hydroxyapatite (HAP) make up Type II. Type I appears almost 
entirely in benign tissue and rarely non-invasive LCIS, whilst Type II is mainly associated with 
malignant tissue.
48
  
(a) (b) 
(c) 
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More recently, investigation with Raman and Infrared spectroscopy has considered the 
chemical composition of the microcalcifications. HAP undergoes carbonate (−𝐶𝑂3
  2−
) 
substitution, with hydroxy groups (-OH) known as Type A, or the phosphate groups (−𝑃𝑂4
 3−
) 
Type B. HAP specifically in breast malignancies undergoes B-type substitution,
49
 with a higher 
substitution percentage lending to an increase in tumour malignancy.
50
 
2.3.3.1 Bisphosphonates 
Bisphosphonates (BPs) have a high affinity and selective uptake for the bone mineral 
hydroxyapatite.
51
 BPs are administered for the skeletal disorders osteoporosis, however high 
doses administered either intravenously or orally can lead to osteonecrosis of the jaw.
53-55
  
Fundamentally, the BPs with the highest binding affinity to HAP contain a nitrogen ending, R
2
 
side chain. The ability of BPs to resorb bone is dramatically affected by the slightest change to 
the structure of this side chain.
54
 
 
Figure 2.7: Alendronate binding sites on basic HAP structure demonstrated: -O
-
 from the -PO4
3-
 
groups bind to the -Ca
2+
; strong H-bonding interaction occurs between -NH
2
 and oxygen groups. 
 
132° 
HAP 
Alendronate 
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There are two main binding sites on BPs: the free -O
-
 form an ionic bond with the Ca2
+
 ions 
within the HAP, whilst the N-H hydrogen bonds to the free -OH
-
 within the HAP. 
Alendronate binding to HAP is visualised in  
Figure 2.7. The binding angle at the hydroxyl site greatly affects the binding affinity: a larger 
angle forms a stronger electrostatic attraction.  
In recent advances, BPs have been proven to help reduce pain encountered with bone cancer, 
reduce tumour growth rates within breast and prostate tissue, and slow or even halt the 
development of bone metastases.
55–58
 Recent studies have suggested the use of BP labelled 
AuNPs in order to provide a targeted contrast agent when using x-ray to image bone 
malignancies.
59
 
2.4 Early Diagnosis 
The early diagnosis of cancer is crucial in reducing mortality and morbidity, providing patient 
peace-of-mind and relief from underlying symptoms.
60
 The World Health Organisation has 
three steps to early diagnosis: cancer awareness and access to healthcare; clinical evaluation, 
diagnosis and staging; and access to treatment.
61
 A Walters et al. study looking at breast cancer 
survival over a seven-year period in six developed countries found that the UK 3-year survival 
rate was 87-89%, comparative to 91-94% in four other countries including Australia, Canada 
and Sweden.
62
 The National Awareness and Early Diagnosis Initiative (NAEDI) was launched 
across England in 2008 to bring awareness to the need for early diagnosis – however, the 
British trait of a tendency to avoid seeking medical advice or aid is difficult to overcome. 
Healthcare and treatment within the UK is widely accessible, although delay between 
symptom onset to diagnosis, and diagnosis to treatment greatly affects patient mortality.  
A systematic review by Richards et al. found that patients who had a 3 – 6 month delay 
between symptoms and diagnosis of breast cancer had a 7% worse 5-year survival rate than 
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those with a shorter delay.
63
 Aiming to reduce this delay, the latest NICE guidelines for 
suspected cancer has set the national target of referral within 2 weeks of initial patient 
assessment.
64
 
 
Figure 2.8: Graphic detailing whether early diagnosis is beneficial or conceivable for: (a) breast 
cancer, where early diagnosis is likely even before symptom onset with the use of screening, delaying 
or completely offsetting mortality; and (b) colorectal cancer, where symptomatic diagnosis is unable 
to improve mortality. Adapted from 
61
 
 
Despite increased awareness and improvements to early diagnosis, with some cancers, such 
as pancreatic or colorectal, the patient can remain asymptomatic until the disease has 
progressed to a level of poor prognosis, see Figure 2.8. In 2015, a Delphi study was 
undertaken to find expert consensus by ranking 21 common cancers by how beneficial early 
diagnosis would be for patient mortality and/or morbidity.
60
 After two-rounds, the final ranking 
conclusively placed breast cancer at the top with the greatest potential benefit. Pancreatic, 
Healthy 
cells 
Abnormal 
cells 
In-situ 
cancer 
Invasive 
cancer 
Cancer 
spreads 
Death 
Diagnosis 
Symptom 
Onset 
Survival Time 
Healthy 
cells 
Abnormal 
cells 
In-situ 
cancer 
Invasive 
cancer 
Cancer 
spreads 
Death 
Symptom 
Onset 
Screening 
Early 
Diagnosis 
Survival Time (a) 
(b) 
 40 
 
brain and oesophageal had the lowest rankings – unlike breast cancer, as seen in Figure 2.8, 
screening is unviable and treatment options are sparse making early diagnosis nowhere near 
as beneficial.
65
  
From these findings, it can be said that the early diagnosis of breast cancer is clearly favourable 
and justified, as a major factor in increased survival rates and reduced recurrence rates. 
However, when determining the effectiveness of screening for early diagnosis, it is important 
to analyse the age-specific mortality of the patients, rather than survival rates. This is due to 
lead time bias, as shown in Figure 2.9. 
 
Figure 2.9: Visualisation of lead time bias affecting breast cancer survival rate statistics 
 
In this example two patients with an identically timed onset of breast cancer succumb to the 
disease at the same age, however one patient was diagnosed earlier than the other due to 
screening. The period between the two patients for early and usual diagnosis is the lead time 
bias, in dashed red, hence markedly increasing the survival rate of this patient, in green, 
comparative to the usually diagnosed patient. Instead of this patient living for a longer time, as 
assumed with survival rates, the early diagnosed patient is just knowingly living with the disease. 
Hence, the age-specific mortality should be preferentially used to analyse screening studies. 
The cost of different diagnostic and therapeutic pathways of breast cancer, per person per 
year, in the UK is visualised in the bar charts below, Figure 2.10. 
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Many breast cancer cases will involve all four cost factors outlined above, totalling £18,352.30 
for a single patient in the year since diagnosis. Multiple adjuvant therapies, repeat check-up 
mammograms and sometimes more global surgery is required, increasing costs further. As 
such, it is imperative to diagnose and treat breast cancer as early as possible. 
2.5 Current Diagnostic Methods 
Diagnostic imaging methods of breast cancer range from mammography to ultrasound, and 
MRI, with histopathology as the “gold standard” in confirming diagnosis. A 2016 update to the 
NICE Quality Statements now requires “timely diagnosis” via a multimodality, triple diagnostic 
assessment, comprised of a physical examination, a mammogram or ultrasound imaging, and 
biopsy, in a single hospital visit.
71
  
2.5.1 Clinical Examination 
Regular self-breast examination (SBE) is encouraged as a low-cost, low-risk, self-performed 
method to catch breast cancer in the early stages to decrease morbidity and mortality.
72
 
Despite little evidence confirming this, it is a useful tool in breast awareness encouraging 
women to take responsibility in their health.
45
 The low-cost of self and clinical breast 
Figure 2.10: Charts outlining the annual cost of diagnostics (clinical examination, ultrasound, MRI and 
mammography breast cancer screening and ultrasound guided biopsy) and breast cancer 
therapeutics (adjuvant therapy using Trastuzumab, a HER2 chemotherapy drug, and breast surgery) 
of per person in the UK. Figures are extracted from reports between 2009 - 2016.
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examination (CBE) has hence become an invaluable screening method poorer areas of 
developing countries where diagnostic imaging is costly resource.
73
  
In a CBE both breasts and the lymph nodes from the axillae to above the clavicles are assessed. 
The clinician checks for numerous “red flags”: breast symmetry; movement of any palpable 
lumps; dimpling of the skin; inflammation or soreness in the lymph nodes; and unusual 
inversion or crusting of the nipple.
74
 This clinical examination is age followed up by either 
mammography, for post-menopausal women, or ultrasound, for pre-menopausal women or 
those with dense breast tissue.  
2.5.2 Mammography 
Mammography is the “gold standard” screening and diagnostic imaging method as it is tailored 
to the detection of slow-growing tumours within the general affected population of women.
27
 
Ionising radiation is used to produce a high contrast image of the breast tissue allowing 
visualisation of dense masses and microcalcifications which may be present. Mammograms are 
a risk factor in themselves - a single bi-lateral mammogram contributes a lifetime risk of inducing 
fatal breast cancer of 1.3–1.7 cases in 100,000 women aged 40 years at exposure.75 
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Figure 2.11: Annotated image of a mammography x-ray unit imaging patient in a cranial-caudal view. 
 
 
The two views are “cranial-caudal” or CC taken from above, and an oblique view 
“mediolateral-oblique” or MLO. The breast is compressed by the paddle, as seen in Figure 
2.11, at around 110 – 120 Newtons to gain a diagnostically “good” to “perfect” image under 
parameters set by the NHS Breast Screening Programme (NHSBSP) publication “Quality 
Assurance Guidelines for radiographers”.76 
Breast compression plays a key role in improving the image quality in several ways. An overall 
reduction in breast thickness will produce a thinner, uniform mass which requires a lower 
radiation dose. This minimizes x-ray scatter reducing the signal to noise ratio (SNR) whilst 
improving contrast
77
. Compression spreads the tissue layers apart allowing easier 
visualisation
78
; and the reduction of patient movement will create a sharper image.
77
 A further 
imaging technique of spot compression, as in Figure 2.12, focuses on a small area of the breast 
to maximise separation of the tissue allowing better contrast and visualisation of margins and 
microcalcifications.
78
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Figure 2.12: Left MLO projection using spot compression on a dense breast to highlight two large, 
posterior densities.
79
 
 
 
In recent years, Digital Breast Tomosynthesis (DBT) has been employed as an additional 
mammographic technique, enabling tomographic, pseudo-3D imaging of the breast 
combatting the “anatomical noise” created by overlying breast tissue features.82 This ability to 
easily visualise and better discriminate between tissues has been proven to markedly increase 
sensitivity leading to earlier detection of neoplasms in two meta-analysis studies in post pre- 
and post-menopausal women.
83,84
 
Risk factors in using mammography include the use of ionising radiation to obtain an image, 
false-positives - the patient does not have the disease despite positive results from both 
mammography and biopsy - of which there were 3.3% in 2011-12 leading to over-diagnosis 
and over-treatment.
80
 These risks are not only detrimental to the patient psychologically and 
physically, but also raises expenditure within the NHS. The specificity and sensitivity of 
mammography screening is vastly reduced when contending with patients who are 
premenopausal, present with glandular tissue, or have breast implants – ultrasound is the 
preferred imaging method for these patients.
81
 On average, the chance of a false positive result 
Spot Compression 
Paddle 
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after each mammogram is 10.7%, leading to an unnecessary biopsy; false negative diagnosis 
affects 20 – 26% of patients, delaying their true diagnosis.27 
2.5.2.1 Screening 
In the UK, women aged between 50 – 70 are invited every three years for breast screening. 
Between 2008 and 2009, 2,116,588 women were screened by the UK NHSBSP. In 17,045 
cases cancer was detected (8.1 per 1,000 women screened), of which 13,532 (79%) were 
invasive.
82
 The development of cancer from staging the invasive carcinoma at screening, to the 
surgically removed tumour size, shown in Figure 2.13, highlights the need for a streamlined 
diagnosis-to-treatment pathway. 93.1% of all breast screening patients were seen within the 
62-day period between referral from an NHS screening service and first definitive treatment, 
between 2015 and 2016.
83
 
 
 
One of the most important factors in determining the success of a screening programme is 
patient uptake and re-attendance, and the diagnostic accuracy of the technique.
80
 In 2013, a 
 
Figure 2.13: Invasive breast cancer discovered through screening, percentage categorized into: left 
pie chart – invasive cancer staging; right pie chart – size of the tumour surgically removed. 
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systematic review by Whelehan et al found that 25% – 46% cited pain due to compression 
as the main reason why they did not re-attend, which is comparable to approximately 47,000 
to 87,000 women per year in England alone.
84
  Growing rates of obesity in postmenopausal 
women is not only an associated risk factor but is affecting the required Newtons of 
compression needed to gain a diagnostic image. A positive trend has occurred in the standard 
CC breast thickness size. Traditionally, the average, compressed breast thickness was defined 
as 45 mm. After a review in 2005 this rose to 53 mm, which is now argued to be increased 
to ~60 mm.
85
  A study in 2015 looked at variations of breast compression in three UK sites, 
Manchester, Chester and Burnley, where the obesity prevalence rate is 61.5%, 64.2% and 
69.2% respectively.
86
 The mean CC thickness across all three sites was 50.4 mm, whilst the 
largest recorded thickness was 62.61 mm, with increased and variable compression force 
applied.
87
 Difficulty penetrating the breast tissue sufficiently for a diagnostic image leads to a 
higher rate of false positives and false negatives. 
2.5.3 Ultrasound 
Ultrasound (US) is an imaging technique which produces non-ionising, ultra-high-frequency 
soundwaves (standard clinical range 5-15 MHz) from piezoelectric crystals. A voltage is applied 
across the crystals causing them to oscillate, emitting ultrasonic waves from the medical 
transducer into the patient. The transducer detects the returning echoes from the tissue and 
interprets them into a monochromatic image. US is a highly sensitive technique capable of 
differentiating benign cysts and solid mass likely to be malignancies, usually presenting as 
anechoic and hyperechoic respectively.  
Ultrasound has a higher sensitivity to non-palpable breast masses and premenopausal, dense 
breasts.
88
 A large trail study found that US detected an additional 3.7 cancers per 1000 women 
post mammography screening, with the risk of false positives decreasing significantly.
89
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Figure 2.14: Doppler ultrasound imaging of (a) a malignant tumour with irregular vasculature and (b) 
a breast microcalcification, highlighted with the red arrow, creating a twinkling artifact.
90
 
 
 
Doppler US is a useful tool for assessing vascular abnormalities within a mass – leaky and 
enlarged vasculature present in malignant masses are easily identified this way.
91
 
Microcalcifications are reflective to Doppler US giving the appearance of turbulent blood flow, 
known as a twinkling artefact as seen in Figure 2.14(b).
90
  
The detection of microcalcifications with US is limited. A main attribute to this is the spatial 
resolution of the system – increasing the transducer to a high-frequency, 30 – 70 MHz, 
provides better visualisation, but this is traded with a lower level of depth penetration into the 
tissue.
97-99
 US also requires highly trained sonographers to image breast lesions effectively and 
in guiding the needle used for percutaneous biopsies. 
2.5.4 Biopsy and Histopathology 
There are two main types of breast biopsy – fine needle aspiration (FNA) and core biopsy, as 
pictured in Figure 2.15.  FNA, as the name suggests, uses a fine needle to aspirate a small 
volume of tissue from a suspicious lesion. Core biopsies, and vacuum-assisted core biopsies, 
use a much larger needle to extract a larger, cylindrical volume of tissue.
93
 Though providing 
a larger sample, core biopsies require local, or sometimes general, anaesthetic which comes 
with a patient risk of allergic reaction to the anaesthesia. 
(a) (b) 
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Figure 2.15: Graphics showing the procedures for (a) fine needle aspiration and (b) core needle 
biopsies.
94,95
 
 
 
As the gold standard, breast biopsies are taken to histopathology where they are sectioned 
and stained for diagnosis under the microscope. The piece of biopsy tissue first undergoes 
gross examination, with and without a microscope. The tissue is embedded in paraffin wax, 
sliced to 4 µm on a microtome to visualise the cells adequately at a high spatial resolution.
96
  
Stains are applied to highlight different cellular features – haematoxylin stains cell nuclei blue, 
whilst eosin stains cytoplasm, connective tissue and other extracellular substances pink or red 
– for analysis under a microscope. The nature of the tissue is decided to be either benign, 
“uncertain” or malignant. Tissues classified as uncertain follow the same pathway as those 
classed as benign – leading to false negatives but also a reduction in patient over-treatment. If 
a malignancy is found, the molecular subtype is investigated to determine the hormone 
receptor status necessary for therapy. 
A precedence in the importance of microcalcifications to diagnosis via histopathology has been 
set within the 2016 updated clinical guidance for breast cancer screening.
93
 If present within 
the x-ray imaging, the representative microcalcifications must be demonstrated within the core 
biopsy specimens. Failure to do so requires a repeat biopsy or an advanced diagnostic surgical 
biopsy, to ensure the microcalcification is excised for evaluation. This sets a high priority and 
(a) (b) 
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pressure on the practitioner to capture the required tissue and microcalcifications upon the 
first instance. 
Historically, agreement of diagnosis between histopathologists is a highly-disputed matter – 
interobserver studies of Stage I breast carcinomas over the past twenty years has increased 
from a 79.5% agreement in 1995
97
, to 90.3% in 2015.
98
 Development of fixation techniques 
and an increase in knowledge and experience has led to more agreeable diagnoses. 
Communication between histopathologists and radiologists is key to ensuring a correct 
diagnosis is reached.
96
 
2.5.5 Magnetic Resonance Imaging 
MRI is a non-ionising imaging technique using strong magnetic fields and radio frequency (RF) 
pulses to analyse the motion of protons within hydrogen atoms on axial, sagittal and coronal 
planes. Bilateral breast coils are used to transmit and receive a homogeneous RF signal across 
the breast. Coils produce a high-quality image, keeping the fat signal supressed for good soft 
tissue contrast and reducing the SNR.
99
 Contrast enhanced MRI for breast imaging uses 
gadolinium to speed up the relaxation time of hydrogen atoms in water, improving the clarity 
of lesions in the imaging and changing diagnostic decisions for up to 40% of patients.
107
 
Gadolinium has, however, been linked to nephrogenic systemic fibrosis (NSF), causing 
thickening and scarring of the skin and internal organs in patients with poor kidney function.
107
 
As such, the use of several gadolinium based contrast agents is restricted to patients with a high 
estimated Glomerular Filtration Rate (eGFR).
107
 MRI images are significantly more sensitive and 
specific than mammography or ultrasound, 90.3% and 89.7% respectively, although this can 
increase the rate of false positives.
89,69
 MRI is costly, at a price per patient of £216 in 2010, 
making it unviable for use as a screening method for the entire population.
69
 However, annual 
surveillance is offered to women with a familial history, aged 30 years onwards.
100
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2.6 Therapeutics 
Breast cancer patients with early diagnosis typically follow the route of surgery followed by a 
second, or adjunctive, therapy to maximise the initial treatment effectiveness. For advanced 
cancer patients, the adjunctive therapy is used to control tumour growth and suppress the 
symptoms. Radiotherapy, chemotherapy and hormone therapy can also be used as a neo-
adjuvant, shrinking the tumour prior to surgery reducing risk of complications.   
2.6.1 Lumpectomy or Mastectomy  
Lumpectomy is breast-conserving surgery where the tumour and a radial margin of 2 mm of 
surrounding tissue is excised to be examined histopathologically, under the NHSBSP 
standards.
101
 Partial mastectomy or quadrantectomy involves a larger area of breast removal – 
preservation of the lactiferous ducts is a high priority since surgical disruption could affect the 
drainage of a large area of glandular tissue. For large tumours and elevated risk patients, as 
previously discussed, mastectomy removes the entire breast(s) which can include the 
surrounding lymph nodes.  
2.6.2 Adjuvant Treatment 
 Radiotherapy targets high energy x-ray photons directly into the tumour, disrupting the DNA 
within the cells and stopping proliferation. Post lumpectomy or mastectomy, radiotherapy is 
the most common adjuvant treatment, applied to the whole of the remaining breast or chest 
wall respectively. Major side effects of the combined treatment are localised skin burning, 
lymphoedema, reducing movement in the arm and shoulder of the affected side, and inducing 
increased osteoblastic and osteoclastic activity, leading to a higher risk of fragility fractures.
111 
Chemotherapy is the use of cytotoxic drugs which target highly-proliferating cells in the body, 
non-specifically destroying both malignant and healthy cells. Hair follicles, nail beds and the 
intestinal epithelium cells are most commonly affected, leading to hair and nail loss, reduction  
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in appetite and nausea. 
 
 
Typically, an amalgamation of two or three drugs are used to attack the cells at distinct stages 
of cell cycle growth. A widely used drug, Doxorubicin, has been shown to have poor 
penetration depth into the hypoxic regions of breast cancer tumours, as shown in Figure 
2.16.
102
 Chemotherapy is most effective when used in combination with radiotherapy which 
has the ability to penetrate deep into the tumour growth. 
Hormone therapy lowers or blocks the growth effects of Luminal A and B, and HER2 cancer 
subtypes. Historically, the competitively-binding estrogen receptor drug Tamoxifen had been 
used in 75 – 80% of patients to reduce recurrence rates of ER-positive breast cancer.112 More 
recently an enzyme that synthesizes estrogen from androgens has been developed into a 
treatment drug, Aromatase Inhibitor (AI). AIs have provided an alternative means of hormone 
therapy in women whose ovaries cannot produce significant amounts of aromatase.
112,113
 For 
patients who have a Triple Negative or Basal like cancer, exhibiting no receptor expression, 
hormone therapy is not employed. Targeted therapy interrupts the pathways of, or blocks 
growth proteins characteristic to the breast cancer cell. Antibodies are targeted to the specific 
 
Figure 2.16: A three-colour composite fluorescence microscopy image shows scarce  uptake of 
Doxorubicin, administered via the blood vessels, into the hypoxic regions of a breast cancer 
tumour.
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protein type, such as HER2 and epidermal growth factor receptor (EGFR), making the 
treatment less destructive compared to chemotherapy. 
2.7 Summary 
Breast cancer incidence continues to grow across the globe. Campaigns to increase disease 
awareness, minimize the delay between symptoms to diagnosis, and implement effective 
treatment has resulted in significant improvements in breast cancer survival rates across the 
UK. The value of detecting cancer early is clear, and significant improvements can be made in 
the clinical applications surrounding cancer diagnosis.  
Current medical imaging techniques are inefficient in disease detection, often requiring the 
carcinoma to reach a late stage before visualisation can occur – even in the highly successful 
asymptomatic screening programme, around half of all cases present as Stage II. The ability to 
gain mammographic images of diagnostic quality causes procedural pain through compression, 
and hence lower patient return rates, due to increased rates of obesity. Ultrasound imaging 
caters to those patients with denser breasts, yet requires an additional, invasive biopsy. MRI is 
a highly sensitive imaging technique; large costs play a key role in the selectivity of patients for 
which the procedure can cater for, limiting its use. 
False positive diagnosis is responsible for the over treatment of patients. Human error and 
differential diagnosis is inevitable with radiologists interpreting images and histopathologists 
determining the presence of malignancy within the biopsy. 
Multimodality imaging allows a more thorough approach to diagnostics. It is therefore 
important to increase the potential of current diagnostic methods by introducing techniques 
which are complimentary to present procedures, providing unique and further information. 
Current imaging methods assess and discriminate breast tissue and cellular features on a 
morphological basis. The biochemical analysis of the tissue, detecting the molecular changes 
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prior to a physiological change, is a diagnostic technique currently unexplored in the hospital 
setting. Moreover, the use of a diagnostic and therapeutic, or theranostic, combined technique 
is yet to be considered as a clinical practice. 
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3. Raman Spectroscopy 
 
o gain an understanding of how vibrational spectroscopy is applicable in the analysis of 
biological samples, it is important to first discuss the main theoretical principles 
surrounding Raman spectroscopy, discussed in Section 3.1  . Surface Enhanced Raman 
spectroscopy (SERS), the history of which is briefly covered in the introductory chapter, is a 
critical technique employed within this body of work – its mechanisms and adaptations are 
covered in Section 3.2. Further emerging biomedical “imaging” techniques are further 
discussed in Section 3.3.  
3.1 Theory of Raman Scattering 
Light interacting with matter can be either absorbed, taking a molecule from a ground to 
excited state, or scattered. When an oscillating photon of light interacts with a molecule, the 
negatively charged electron cloud is distorted by the oscillating electric field and the molecule 
is shifted to a higher, virtual energy state. The oscillating molecular dipole will emit a new 
photon at the same frequency or wavelength to the incident one if there is no change in 
polarisability of the molecule during this oscillation. In this case the scattered light is equal to 
that of the incident light – elastic, Rayleigh scattering. However, if there is a change in the 
polarisability of the molecule, a discrete change in energy to the molecule can take place, 
changing its molecular vibrational state. The molecule can gain or lose energy from the photon, 
moving to a higher (Stokes) or lower (anti-Stokes) state.
103
  
At ambient temperature, room or body, the lowest vibrational ground state level is prevalent. 
Hence Stokes' is the predominantly produced and therefore more favourable Raman 
scattering in the analysis of molecular content.  
T 
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Figure 3.1: A Jablonski diagram showing the energy level transitions involved during Infrared 
absorption, Rayleigh, Raman Stokes and anti-Stokes scattering (h𝒗𝟎 = incident laser energy; h𝒗𝒗𝒊𝒃 
= vibrational energy; ∆𝝊 = Raman shift; 𝒗𝒗𝒊𝒃 = vibrational frequencies.)
104
 
 
 
If a molecule has a vibrational mode whereby a dipole moment oscillates at the frequency of 
the incident radiation absorption will occur, demonstrated in Figure 3.1 as for IR absorption in 
from ground to molecular vibrational levels. Mid-IR photons are highly absorbed by biological 
materials and are incompatible with deep in vivo measurements planned here forth in this 
thesis. Conversely Raman scattering relies on a change in polarizability of a molecule. 
 
3.1.1 Polarizability 
The ease of which a molecule can be distorted is known as the polarizability, 𝛼, which is 
dependent on the number of electrons and how many energy levels they occupy. Atoms with 
a large nucleus have a strong polarizability – the electron cloud is distant from the nucleus 
allowing an ease of distortion. 
The principles of Raman scattering can be mathematically described. Polarizability, 𝛼, induces 
a dipole moment, 𝜇𝑖𝑛𝑑, under the applied electric field, 𝐸, as seen in Equation (1) below. 
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 𝜇𝑖𝑛𝑑 = α E (1) 
 
At a molecule's nuclear geometrical equilibrium, 𝛼0, and at a distance away from the 
molecule's equilibrium geometry, ∆𝑟, the polarisability 𝛼 is  
 𝛼 =  𝛼0 + 
𝛿𝛼
𝛿𝑟
∆𝑟 (2) 
 
with the derivative 
 
𝛿𝛼
𝛿𝑟
 (3) 
 
explaining the change in polarizability depending on the change of the molecular position. If 
this value is equal to 0, the molecule being described does not have a changeable polarisability 
and is therefore not Raman active. 
The ∆𝑟 details the vibrations or rotations of the molecule undergoing polarization in terms of 
time, 𝑡, and the frequency of the vibration, 𝑣, where 𝑟𝑚𝑎𝑥 is the maximum vibrational 
amplitude, shown in Equation (4). 
 𝛥𝑟 = 𝑟𝑚𝑎𝑥 cos(2𝜋𝑣𝑡) (4) 
 
The applied electric field, 𝐸, also has a specific frequency, 𝑣𝑖𝑛, which has a maximum electric 
field frequency, 𝐸𝑚𝑎𝑥, as explained below:  
 𝐸 = 𝐸𝑚𝑎𝑥 cos(2𝜋𝑣𝑖𝑛𝑡) (5) 
 
Both Equations (4) and (5) include the term 2𝜋 to convert the frequency and time parts of the 
equation into values which oscillate from 1 to 0 to -1 in a co-sinusoidal fashion, mimicking the 
induced molecular vibration under the applied electric field. 
Substituting the Equations (2), (4) and (5) for 𝛼, ∆𝑟 and 𝐸 respectively allows for the Equation: 
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 𝑝 =  𝛼0𝐸𝑚𝑎𝑥 cos(2𝜋𝑣𝑖𝑛𝑡) + 𝐸𝑚𝑎𝑥𝑟𝑚𝑎𝑥
𝛿𝛼
𝛿𝑟
cos(2𝜋𝑣𝑡) cos (2𝜋𝑣𝑖𝑛𝑡) (6) 
 
The relationship between the two cosines is as shown: 
 𝑐𝑜𝑠 𝑎 × 𝑐𝑜𝑠 𝑏 =  
1
2
(cos(𝑎 + 𝑏) + cos (𝑎 − 𝑏)) (7) 
 
where 𝑐𝑜𝑠 𝑎 represents 2𝜋𝑣𝑖𝑛𝑡 and 𝑐𝑜𝑠 𝑏 signifies 2𝜋𝑣𝑡. “cos(𝑎 + 𝑏)” defines the Anti-
Stokes scattering of Raman, where the value is the sum of the incoming light plus the vibrational 
frequency; “cos(𝑎 − 𝑏)” is the Stokes scattering, where the incoming light minus the 
vibrational frequency is defined. 
By substituting the product of the two cosines into Equation (6) we obtain the following 
Equation: 
𝑝 = 𝛼0𝐸𝑚𝑎𝑥 cos(2𝜋𝑣𝑖𝑛𝑡) + 
𝐸𝑚𝑎𝑥𝑟𝑚𝑎𝑥
2
𝛿𝛼
𝛿𝑟
(cos(2𝜋(𝑣𝑖𝑛 + 𝑣)) + cos (2𝜋(𝑣𝑖𝑛 − 𝑣))) (8) 
 
From Equation (8) we can find the terms for both inelastic/Raman and elastic/Rayleigh 
scattering. The variable 𝑣𝑖𝑛 is the frequency of the incoming light, but also describes the 
outgoing scattered photon of the same frequency. Therefore, the polarizability of a molecule 
and hence scattering of light is dependent on the frequency of the incoming light, vibrations of 
the molecule and applied electric field, with the derivative 
𝛿𝛼
𝛿𝑟
 giving the selection rule to 
whether the molecule is Raman active.  
 
3.1.2 Hooke’s Law 
Within the molecule, individual atomic bonds are more readily Raman active than others. A 
strong double bond will allow less distortion, storing more energy compared to a single bond. 
 58 
 
Under Hooke’s law, the vibration of these individual bonds within a diatomic molecule can be 
described as: 
 𝑣𝑚 = 
1
2𝜋
√
𝐾
𝜇
 (9) 
where 𝐾 is the spring constant (N/m) of the bond between the two atoms. The molecular 
vibration, 𝑣𝑚, is proportional to the strength of the bond, whilst being inversely proportional 
to the inertial or reduced mass, 𝜇, described as: 
 𝜇 =  
𝑚1𝑚2
𝑚1 +𝑚2
 (10) 
 
where 𝑚1 and 𝑚2 are the masses of the atoms. Hence, both the atoms and individual bonds 
contribute to the characteristic, molecular vibrations. Symmetric vibrations cause the greatest 
distortion to the electron cloud, most commonly associated with Raman active molecules. 
Conversely, asymmetric vibrations cause a change in dipole and hence allow IR absorption.
103
 
Typical bond vibrations include stretching, rocking and wagging as seen in Figure 3.2. 
Figure 3.2: Six types of vibrational modes. Adapted from 
105
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3.1.3 Raman Cross Section 
Every molecule has a total Raman cross section, 𝜎𝑅𝑆, measured in units of cm
2
 denoting the 
area of the molecule readily available for particle-photon interaction. This cross section defines 
the Raman signal, 𝐼𝑅, that a density of molecules per cm
3
, 𝐷, can produce:  
 𝐼𝑅 = 𝐼0𝜎𝐷𝑑𝑧 (11) 
 
The excitation laser intensity, 𝐼0, and path length travelled through the sample, 𝑑𝑧, also affects 
the Raman scattering produced.
106
 The relationship between the intensity of Raman signal and 
the wavelength of incident light can be described as: 
 𝑃𝑆  ∝  
𝐼0
𝜆4
 (12) 
 
where it is inversely affected to the fourth power. This is known as the scattering coefficient of 
the material.
107
 The 𝜎𝑅𝑆 of a molecule is incredibly small, requiring large concentrations or 
changes in the spectroscopic technique and hence optical set-up, such as coherent anti-stoke 
Raman scattering (CARS) and stimulated Raman scattering (SRS), to provide sensitive 
measurements.
108,109
 The use of surface enhanced Raman spectroscopy (SERS) enables low 
analyte concentrations to garner a large 𝜎𝑅𝑆, whilst keeping the Raman system unaltered. 
A typical, modern Raman spectroscopy system is generally comprised of: a monochromatic 
laser source; an arrangement of optics guiding and focussing light to and from a sample; a 
spectrometer collecting and detecting the Raman photons; and computer aided analysis of the 
detector results. A Raman spectrum displays the biochemical, molecular “fingerprint” of the 
sample. Known as Raman shift, measured as a function of energy in units of wavenumbers 
(cm
-1
). The intensity of the signal is proportional to the number of Raman active bonds within 
the sample – which can be increased by orders of magnitude with the introduction of metallic 
nanoparticles for SERS. 
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3.2 Surface Enhanced Raman Spectroscopy Theory 
As discussed in the introductory chapter, SERS can be broken down into two processes: 
electromagnetic enhancement as proposed by Jeanmaire and Van Duyne; and chemical 
enhancement suggested by Albrecht and Creighton.
9,10
 This section delves into the theory 
behind SERS, and how the technique can be adapted to suit an array of biomedical applications. 
3.2.1 Mie Theory and Localised Surface Plasmon Resonance 
Colloids have historically been utilised since the fourth century (AD). The most visible example 
today is stained glass within churches and cathedrals. The process involved medieval artists 
mixing gold and silver metallic salts into the molten silica compound. The respective metals 
created red and yellow panes of glass as light shone through, as seen in Figure 3.3. Varying the 
size of metal NPs to “give rise to a variety of colours” was theorised by Michael Faraday in 
1856.  
 
Figure 3.3: 14
th
 century medieval stained-glass window at Troyes Cathedral, France. 
 
 
This could not be fully established however until the turn of the twentieth century. The optical 
properties of colloids theorised in 1908 by German physicist, Gustav Mie, through his solution 
of Maxwell’s equation.  
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The eponymous theory is used to describe the absorption, scattering and extinction cross 
section of a spherical NP. The interacting photon distorts the electron cloud forming a 
collective, sinusoidal oscillation of the free electrons, altering the Raman cross section. Mie 
theory holds two assumptions: both the surrounding media and the NPs are dielectric in 
nature; and the radius of the NP is smaller than that of the incident light wavelength (𝜆).  
The extinction cross section (𝐶𝑒𝑥𝑡) of NPs suspended within a medium is calculated as
110
: 
 𝐶𝑒𝑥𝑡 = 
24𝜋2𝑟3𝜀𝑚
    3/2
𝜆
 
𝜀𝑖
(𝜀𝑟 + 2𝜀𝑚)2 + 𝜀𝑖
  2 
(13) 
 
The dielectric constants of the real and imaginary parts of the metal is described as 𝜀𝑟, or real, 
and 𝜀𝑖, imaginary, respectively; 𝜀𝑚 describes the medium. The dielectric constants and the 
size of the NP are the main variables affecting 𝐶𝑒𝑥𝑡.  
Further, the extinction of the light is separated into two areas: scattering (𝐶𝑠𝑐𝑎) and absorption 
(𝐶𝑎𝑏𝑠) cross sections. The relationship can be described as: 
 𝐶𝑒𝑥𝑡 = 𝐶𝑎𝑏𝑠 + 𝐶𝑠𝑐𝑎 (14) 
 
Equations (15) and (16) breaks down 𝐶𝑎𝑏𝑠 and 𝐶𝑠𝑐𝑎. In the equations, 𝑘 describes the 
direction and magnitude of light through the sample (𝑘 =  2𝜋 𝜆⁄ ), whilst the nanoparticle 
volume is defined by 𝑟: 
 𝐶𝑎𝑏𝑠 = 4𝜋𝑘𝑟
3 𝐼𝑚 [
𝜀𝑛𝑝 − 𝜀𝑚𝑒𝑑𝑖𝑎
𝜀𝑛𝑝 − 2𝜀𝑚𝑒𝑑𝑖𝑎
]  ∝  
𝑟3
𝜆
 (15) 
 𝐶𝑠𝑐𝑎 = 
8𝜋
3
𝑘4𝑟6 |
𝜀𝑛𝑝 − 𝜀𝑚𝑒𝑑𝑖𝑎
𝜀𝑛𝑝 − 2𝜀𝑚𝑒𝑑𝑖𝑎
|
2
 ∝  
𝑟6
𝜆4
 (16) 
 
Whereby 𝜀𝑛𝑝 and 𝜀𝑚𝑒𝑑𝑖𝑎 are the dielectric constants of the NP and surrounding media, 
respectively. 
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This shows both scattering and absorption cross sections increase proportionally to NP size, 
hence the number of free electrons upon the NP surface, with 𝐶𝑎𝑏𝑠 increasing at half the rate 
to 𝐶𝑠𝑐𝑎. This phenomenon of electromagnetic enhancement, known as localised surface 
plasmon resonance (LSPR), is visually interpreted in Figure 3.4. 
Adsorption of a molecule to the NP surface, distance Angstrom in length, creates a further 
chemical enhancement, Figure 3.5.  
 
 
Contributing factors to the signal enhancement include: the change of molecular polarizability 
once adsorbed; a charge-transfer between the analyte and metal complex; and molecular 
resonance with the LSPR.
111–113
 Van der Waals forces leading to this physisorption upon a NP 
 
Figure 3.4: Localised surface plasmon resonance – free electron cloud oscillation occurring upon the 
NP surface, within the interacting wavelength (𝒉𝒗𝒆𝒙𝒄), enhances the local EM field.  
 
Figure 3.5: Molecule adsorbed to or orientated within Angstrom length near to NP produces 
chemical enhancement. Adapted from 
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surface affects molecular symmetry, vastly changing the Raman spectrum. This is dependent 
upon the newly found vibrational modes of the molecule, and the molecular orientation. 
The enhancement factor (EF) of a molecule within SERS is denoted by the following equation: 
 𝑆𝐸𝑅𝑆 𝐸𝐹 =  
𝐼𝑆𝐸𝑅𝑆 𝑁𝑆𝐸𝑅𝑆⁄
𝐼𝑅𝑆 𝑁𝑅𝑆⁄
 (17) 
whereby 𝐼𝑆𝐸𝑅𝑆 denotes the SERS Raman intensity, whereas 𝐼𝑅𝑆 relates to the normal Raman 
intensity; 𝑁𝑆𝐸𝑅𝑆 and 𝑁𝑅𝑆 correspond to the number of molecules under the respective 
conditions.
115
 Electromagnetic enhancement accounts for signal increase by a factor of 10
4
 – 
10
6
, whilst the magnitude of chemical enhancement accounts for a factor of ~10
2
. Single 
molecule measurements have been shown to create enhancements of up to 10
14
.
116,117
 This 
is generally not well understood.  
In utilising the SERS technique, adjustments to NP composition and morphology allows the 
adaptation of the LSPR to be fit for purpose in terms of the illumination wavelength and 
material to be analysed. 
3.2.2 Plasmon Tuning 
The two most common metals used for SERS techniques are gold (Au) and silver (Ag). This is 
due to the real dielectric function contributing to 𝐶𝑎𝑏𝑠 and 𝐶𝑠𝑐𝑎, from Equations (15) and (16), 
of both metals being highly enhanced at resonance with the incident wavelength – known as 
the Fröhlich condition.
118
 The NP dielectric constant, 𝜀𝑛𝑝, is controlled by changing the size, 
shape and material, as seen in Figure 3.6. This effectively changes the plasmon absorption, and 
hence scattering, tuning the LSPR.
109
 Binding events lead to a slight change in the surrounding 
medium, 𝜀𝑚𝑒𝑑𝑖𝑎, with the resulting change in refractive index, which also affect the LSPR 
causing a red-shift – this in itself can be used as a LSPR sensor, biomolecule detection 
method.
119
 Ag inherently surpasses Au as a SERS substrate due to higher absorption at the 
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LSPR region. However, for biomedical applications of SERS, the red-shifted LSPR position of 
AuNPs makes them a preferred plasmonic substrate, further discussed in Section 3.3.
120
 
In selecting laser wavelength, maximum enhancement is observed when wavelength is red-
shifted with respect to the LSPR, in order to achieve electromagnetic enhancement of both 
the incident and radiated fields.
121,122
  
In increase in the overall radius of spherical NPs achieves a resonant enhancement red-shift, 
as seen by the LSPR peak shift of gold and silver nanospheres in Figure 3.6. Elongation of these 
spherical NPs to a rod-like shape creates a secondary, further red-shifted plasmon peak, 
corresponding to the shorter longitudinal and longer transverse axes.
123
 Anisotropic particles 
with sharp surface features, such as nanorods and prisms, possess the “lightening rod” effect, 
whereby the localised electromagnetic enhancement can increase up to a hundred fold.
124
 
  
 
The dipole moments of NPs can be capitalised upon in the form of “hot spots”. NPs placed 
within the formation of dimers, with an interparticle gap of 0 – 1 nm, was found to red-shift 
the LSPR with approximately 2 orders of magnitude greater enhancement, known as “dipole 
coupling”.120,125 Structures with sharper tips present greater maximal enhancements, such as 
triangle NPs, which can be shaped into bowties, garner the maximum dipole coupling.
126,127
 
  
Figure 3.6: Graphs to show the optical density, attenuation of scattered and absorbed light, of silver 
(left) and gold (right) spherical NPs increasing in diameter size. This shows the tunability of the LSPR 
of NPs depending on the size and material used.
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Dipole coupling, however, as the enhancements are highly localized to the region, drop off 
rapidly with distance.
128,129
 Requiring uniform positioning, the trait is often reproducibly 
exploited within a NP array setting. 
Another large area of development is the use of core/shell NPs. Specifically in multimodal 
imaging, iron oxide core/Au-shell NPs: harnessing the superparamagnetic properties for MRI 
use and magnetic guidance through the body, whilst using the inert gold surface as a 
biocompatible material with scope for further surface functionalisation.
131–135
 The use of an Au 
shell also affects the LSPR in the form of a red-shift. Multifunctionality in AuNPs opens a wide 
range of imaging possibilities, including the use of extrinsic SERS and therapeutic capabilities.   
3.2.2.1 Raman Reporters for Extrinsic SERS 
Intrinsic SERS is the direct enhancement of a desired molecule. Conversely, extrinsic SERS is 
the NP surface chemisorption of molecules having inherently strong Raman active modes. 
These molecules are commonly referred to as Raman reporters (RRs).
12,136
 RRs including 
aromatic compounds are most widely used, with the ring breathing mode of benzene 
recognised as a highly sensitive marker. Extrinsic SERS has a number of advantages over 
intrinsic: the technique is extremely sensitive, negating the need to enhance low concentration 
biomolecules; a protective and/or targeting layer, such as silicon and polyethylene glycol (PEG), 
and/or antigens and receptor molecules can be used to encase the reporter NP, encouraging 
biocompatibility; and a number of distinctive reporters may be used concurrently for 
multiplexed Raman imaging capabilities. 
12,128,136–138
 
The mechanism of Raman-reporter-to-colloid-surface attachment commonly used is covalent 
bonding. Most studies use -thiolated RR due to the chemical stability against competing 
molecules, however nitrogen and isothiocyanate terminal group RR are also used, having an 
affinity to the gold colloid surface.
139,140
 AuNPs of larger diameters (≥50 nm) have been shown 
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to adsorb Raman reporter molecules, 2-NT and 4-MBA, with increasing efficiency and signal 
intensity, up to an enhancement factor of 10
3
, as the nanoparticle size increased.
110
 
Several sets of RR-AuNPs allow for multiplexed use within a single system.
12,138
 Coupled with 
individual and specific targeting capabilities, each RR would signal distinct areas of disease in 
either highlighting benign or malignant regions, or determining the molecular subtype of a 
carcinoma for tailored therapy. 
3.2.2.2 Nanoparticle Theranostics 
Theranostics are considered valuable techniques, allowing clinicians to diagnose and treat 
simultaneously within one patient visit. The intrinsic nature of NPs can be exploited in creating 
a theranostic NP probe. In tuning the laser wavelength to the maximum resonance of the NP 
(𝜆𝑚𝑎𝑥) , laser irradiation can occur, causing heating of the NPs in a technique known as 
photothermal therapy.
141–143
  
As described in Equations (15) and (16), the efficiency of absorption, 
𝑟3
𝜆
, dominates over the 
scattering efficiency, 
𝑟6
𝜆4
, especially with smaller NPs. As seen in  
Figure 3.7, from the study by Jain et al, nanospheres and nanorods of a smaller diameter and 
effective radius and nanoshells composed of a greater shell ratio, are more efficient at light 
absorption and hence photothermal therapy techniques.
144
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(a) (b) 
(c) (d) 
 
Figure 3.7: Tunability of the ratio of scattering to absorption of nanoparticles. Variation of 𝑪𝒔𝒄𝒂 𝑪𝒂𝒃𝒔⁄  
with (a) nanosphere diameter D; (b) nanorod effective radius reff at fixed aspect ratio R = 3.9; (c) 
nanoshell total radius R2 at fixed R1/R2 = 0.857; and (d) nanoshell core/shell ratio R1/R2 at fixed R2 
= 70 nm.
144
 
 
 
AuNP mediated photothermal therapy of human breast epithelial carcinoma (SK-BR-3 cells) 
by means of silicon core/Au shell (100:10 nm core/shell ratio) nanoshells, was first studied by 
Hirsch et al..
145
 Thermally induced cell death, via loss of cell membrane integrity and protein 
denaturation, occurred in tuning the laser wavelength to the 𝜆𝑚𝑎𝑥 = 820 nm. The 
composition of a smaller nanosphere diameter favours the 𝐶𝑠𝑐𝑎 𝐶𝑎𝑏𝑠⁄  efficiency for 
photothermal therapies; however for diagnostic purposes, the 𝜆𝑚𝑎𝑥 must be taken into 
consideration when selecting the laser wavelength and NP size in respect to the NIR “biological 
window”.144,145 
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3.3 Spectroscopic Bioimaging Techniques 
Spectroscopic techniques for the analysis of biological samples requires both the illumination 
and collection wavelengths to lie within the NIR region between 650 – 900 nm.148  
 
 
This spectral region is the “biological window”, whereby water, haemoglobin, and most 
relevant to breast tissue, fat, are at the lowest absorption coefficients, as seen in Figure 
3.8.
147,149
 To maximise the efficiency and penetration depths of spectroscopic techniques, 
selection of the illumination wavelength is an important factor. The illumination wavelength, 
which in turn affects the sample collection wavelengths, must both sit within the NIR window 
to avoid the absorption of photons allowing the maximum number Raman photons to be 
created and collected from the system. The absorption profile of eumelanin which is black- 
brown, is inherently greater than that of pheomelanin, red-yellow, which is represented in 
Figure 3.8. This is an unavoidable variance between patients and wavelength selection.  
Figure 3.8: Absorption coefficients of biological molecules and the NIR window which allows 
photons to enter and exit the media with increased ease. Adapted and modified from 
146,147
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Propagation of light through a biological medium is dictated by the scattering and absorption 
coefficients of the sample, 𝜇𝑠 and 𝜇𝑎 respectively, measured in units of cm
-1
. Adding the two 
coefficients leads to the total attenuation coefficient of the media. 
Absorption in biological tissues is due to water and macro-molecules, such as fats, melanin and 
haemoglobin.
107
 The inverse of 𝜇𝑎, 𝐼𝑎, defines the mean penetration depth into the absorbing 
medium. 
 
Figure 3.9: Possible photon pathways through tissue. Adapted from 
150
 
 
 
In biological media, light scattering is generally anisotropic, 𝑔, whereby light propagates in a 
continuous, forward direction.
151,152
 This diffusion of light through a biological sample is known 
as the reduced scattering coefficient, described as: 
 𝜇𝑠
′ = 𝜇𝑠(1 − 𝑔) (18) 
Figure 3.9 shows the diverse ways photons can be scattered or absorbed within biological 
media. 
Optical scattering within a homo- or heterogeneous biological layer, such as skin tissue, is due 
to particles refracting light to varying degrees of efficiency. The inverse parameter of 𝜇𝑠, 1 𝜇𝑠⁄  
(cm), is known as the mean free path (MFP). Combining mean penetration depth and MFP 
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length statistically predicts a photon scattering potential. For example, at ~650 nm skin tissue 
has a penetration depth of ~50 µm, and MFP of 5 mm; hence, single photon absorption 
occurs after 100 scattering events.
153
 
Laser wavelengths employed in biological sample studies range from 532 – 830 nm, and most 
typically 785, 808 or 830 nm, allowing penetration and collection of inelastic light with minimal 
photodamage occurrence.  
Research into biological specimens is vast, with the main area of study concerning carcinomas. 
The Raman fingerprint of biological tissues generally ranges between 400 – 2000 cm-1, and 
sometimes into the higher wavenumbers between 2,700 – 3,500 cm-1 most commonly 
associated with the CH2CH3 symmetric stretch of lipids and proteins.
154
 Disease changes 
significantly alters the ratio of intensity, peak broadening or peak shift within the characteristic 
Raman spectrum.  
3.3.1 Micro-Raman Spectroscopy 
The technique of micro-Raman spectroscopy utilises a microscope objective to both focus and 
collect the scattered light, termed as backscattering geometry, at a 180° angle. Samples are 
mounted onto slides for analysis.  The most commonly used substrate is quartz, having no 
photoluminescence addition to the Raman spectrum, present in standard glass microscope 
slides. 
The disease change and progression of neoplasia in various regions of the body, such as within 
brain, breast, bladder, colorectal, larynx, lung, lymph node, oesophageal, prostate, uterine and 
cervical tissues, is usually presented as fixed histopathological tissue slices or tumour micro 
arrays (TMAs).
155
 The major obstacle with micro-Raman spectroscopy of biological specimens 
is the sole reliance upon the native signal of the tissue. Low concentrations of the desired 
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biomolecule, or too much interference from auto-fluorescent molecules, is a major obstacle 
intrinsic to micro-Raman spectroscopy. 
3.3.2 Deep Raman 
Deep Raman is an umbrella term for a range of techniques developed for layered turbid 
sample analysis, from the micro to millimetre scale.  
Spatially offset Raman spectroscopy, or SORS, relies on the collection of diffusely scattered 
Raman photons to form depth measurements.  
 
As seen in Figure 3.10, photons are illuminated and collected in a point to ring fashion, or 
inversely. Principally, photons with longer scattering pathways travel a greater depth and 
breadth through biological media. Hence, a collection point distanced further from the 
illumination point will collect Raman scattering from the greatest z-direction. 
Inverse SORS is the reverse, with the illumination distributed across the ring area, allowing for 
higher and sustained laser power over the region without the issue of tissue irradiation 
occurring. SORS and inverse SORS can be achieved either in an open optics set-up using an 
 
Figure 3.10: Schematic of the two varieties of spatially offset Raman spectroscopy: standard SORS, 
single illumination point and adjustable ring collection zone; and inverse SORS, single collection point 
and ring illumination for distribution of photons across a larger area, reducing burning and allowing 
an increased laser power. 
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axicon lens, or in a closed system as a point-to-ring fibre optic bundle, discussed further in 
Section 3.3.3. 
Another type of deep characterisation method is Transmission Raman spectroscopy, or TRS, 
whereby the collection point is positioned on the opposite face from the illumination point, 
obtaining Raman scattering through the sample. Unlike SORS, media layers are unable to be 
distinguished as the sample is measured as a whole. This is the technique which will be 
employed for the measurement of the turbid, phantom samples. 
Surface Enhanced Spatially Offset Raman spectroscopy, or SESORS, combining deep Raman 
with the SERS technique opens the possibility of examining areas of disease far deeper within 
tissue – currently at a maximal transmission of ~47 mm through chicken breast tissue.12 
3.3.3 Fibre Optic Probes 
The use of fibre optic probes within the medical community is common place, allowing 
flexibility in traversing through the body and providing a safer imaging option for both patient 
and practitioner. Fibre optic probes are a precise technique with the ability to directly hone in 
on areas of interest, markedly improving the signal gained of low concentration biological 
molecules of interest. 
The inclusion of Raman fibre optic probes has been studied within current practices, such as 
colorectal, cervical and lung endoscopy.
156–158
  Recently, a  novel techniques for brain tumour 
margin determination using a Raman fibre optic probe, and lymph node characterisation with 
an internalised needle probe have been proven as a significant diagnostic possibilities.
159,160
  
Photoluminescent emissions inherent to fibre optics cause disruption across the whole 
fingerprint region.
161
 Filtering or separately allocated illumination and collection fibres are two 
techniques employed in the avoidance of subsequent signal loss from this type of fluorescence. 
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Fibre optic probes are also an inherently invasive diagnostic technique, requiring the probe to 
traverse into the body, respectively requiring local or general anaesthetic in either breaking the 
skin barrier or entering the body anally or orally. 
Other Techniques 
In vivo near-infrared diffuse reflectance spectroscopy (NIRS) was developed in 1977 by Frans 
Jöbsis as a bulk, biological analytical technique, able to non-invasively detect cerebral and 
myocardial oxygenation levels.
162
 NIRS relies on the transparency of tissue within the biological 
water window allowing the transmission and reflectance of scattered photons to the detector. 
As seen in Figure 3.8, haemoglobin, water and fat absorbs near-infrared light, as does other 
chromophore molecules such as glucose. The level of these chromophores within the tissue 
causes differential attenuation levels, allowing the prediction of blood glucose levels or 
neovascularisation synonymous with tumour growth, for example.
163,164
 
As a comparative non-invasive technique to SESORS, NIRS is a highly insensitive technique 
unable to fully distinguish the biochemical make-up of the tissue. This is a major drawback in 
the identification of disease type present, hindering the ability to tailor the patient’s treatment 
pathway or stage a cancerous legion. 
3.4 Summary 
The fundamentals of Raman spectroscopy theory have been outlined within this chapter. 
When considering the use of Raman spectroscopy within a clinical setting, several parameters 
must be met. 
Biomedical Raman imaging techniques requires thought into the selection of laser wavelength. 
Both the illumination wavelength and Raman shifted photons must avoid lying within the region 
of absorption outside the NIR window, allowing a greater amount of light into and out of the 
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biological system. Moreover, the avoidance of patient skin burning through the tempering of 
laser power and acquisition time must also be met.  
The selection of the Transmission Raman technique aligns with the current diagnostic 
technique of mammography. By capitalising on the compressed, and hence thinner, nature of 
the breast required for this diagnostic technique, the Raman photons have a shorter distance 
to travel, increasing the possibility of photon collection in comparison to absorption. 
Moreover, the use of AuNPs during mammographic imaging act as a contrast agent, increasing 
the sensitivity of the technique. Incorporating new techniques within existing practices 
streamlines diagnostic pathways. 
In the employment of SERS, plasmon tuning in terms of the selected material, and the size and 
shape of the nanoparticles is key in delivering large signal enhancement. It can be seen in Figure 
3.6 that the overall enhancement of Ag as a NP material is greater than that of Au. Despite 
this, in a biomedical imaging setting gold is a better candidate due to its stable nature and ease 
of surface chemistry for functionalisation.
109
  
The nature of extrinsic SERS is suitable in the exploitation of multiplexed imaging, a useful 
technique in the development of disease distinct AuNP targeting probes employed 
simultaneously. AuNPs of larger diameters (≥50 nm) have been shown to adsorb RR 
molecules, such as the commonly used 4-Mercaptobenzoic acid and 2-Naphthalenethiol, with 
increasing efficiency and signal intensity, up to an enhancement factor of 10
3
, as NP size 
increased.
110
 As such extrinsic SERS with AuNPs of a >50 nm size were selected for use within 
this thesis. 
Consideration into the AuNP shape was still required. The ability to utilise nanoshell NPs as 
theranostic agents through their photothermal capabilities further increases their benefit for 
medical use.   
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As such, the toxicology of AuNPs in relation to humans is explored in the following Chapter. 
NP material, size and shape selection is examined – nanoshells can be exploited as theranostic 
agents, however their robust size may be unfit for biomedical purpose – plus further 
functionalisation possibilities for use within this thesis. 
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4. Nanoparticle Biocompatibility 
 
anoparticle interaction within the body, pharmacodynamics, and hence nanoparticle 
metabolism by the body, pharmacokinetics, amounts to vast areas of research crucial 
to the ongoing effort towards in vivo use of nanoparticles for theranostic purposes.  
Several current imaging techniques use contrast agents to highlight areas of diagnostic interest. 
Computed Tomography (CT), Positron Emission Tomography–CT (PET–CT) and MRI utilise 
contrast agents, iodine, F–fluoro–2–deoxy–D–glucose (F–FDG) and gadolinium respectively. 
They can however be non-specific and toxic in nature. Intravenous iodine has a short imaging 
time, produces poor contrast in obese patients, and can cause nephropathy. F-FDG highlights 
unspecific areas of tissue with high-turnover-rates which efficiently take up glucose – this 
includes not only tumours, but also areas of inflammation and the heart. Gadolinium affects 
the magnetic field of nearby water molecules enhancing image quality. Though rarely inducing 
side effects, many gadolinium products have been discontinued due to concerns over toxicity. 
Yet contrast agents such as these are in use within the hospital setting. A precedence of 
importance in identifying patients who can metabolise nanoparticles efficiently should be 
applied to the field moving forwards. 
This chapter considers the effects of NP adaption, relating to cell clearance and tumour 
targeting efficiency. Section 4.1discusses the metabolic pathway of nanoparticles within the 
body. The selection of material, size and shape of the NPs required for effective clearance is 
evaluated in Section 4.2. Section 4.3  considers how NP pH and dispersion affects cell 
interactions. Protein corona formation, altering the likelihood of phagocytosis, is considered in 
Section 4.4. An established method for tackling an immune response is through surface 
modification using polyethylene glycol (PEG), further discussed in section 4.5. Section 4.6 
N 
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considers the best method for achieving intercellular NP uptake – targeted or untargeted. 
Finally, a consideration of all factors in tailoring nanoparticles of high biocompatibility is 
summarised in Section 4.7. 
4.1 Pharmacokinetics 
The metabolic pathway of nanoparticles is through the mononuclear phagocyte system (MPS), 
or reticuloendothelial system (RES), consisting of macrophages located in the reticular 
connective tissue of the RES organs. Nanoparticle clearance takes place mainly within the 
Kupffer cells of the liver. A study by Sadauskas et al found that 40 nm AuNPs could remain 
within the Kupffer cells of a mouse model up to six months after the primary injection.
165
  
Figure 4.1 displays the intravenous route of AuNPs, considering the size of NPs able to be 
metabolised out of the body through the liver, kidneys and spleen, or lodge within the cells of 
different regions within the lungs. 
Nanoparticle pharmacokinetics are dose dependent – low and medium doses, ~0.01 and 
~0.1 mg/Kg respectively, have been proven to reduce cytotoxicity within rat models, deemed 
as suitable comparatives to humans due to the relative liver to body weight ratio.
166,167
 
Biocompatible NPs are required to be engineered with specific performance characteristics, 
allowing a long blood circulation lifetime to increase uptake probability, whilst triggering a 
delayed, post-diagnostic or therapeutic immune response, prompting cell clearance to reduce 
cytotoxicity.
168
 The upcoming sections within this chapter detail the five areas where tailoring 
colloids can lead to a level of optimal biocompatibility. 
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4.2 Material, Size and Shape 
Nanoparticle material choice forms the basis of biocompatibility. Seemingly unreactive carbon 
nanotubes, championed as strong candidates for drug delivery,
169
 have been found to spear 
through macrophages and cause pulmonary toxicity, not dissimilar to high levels of asbestos 
contact.
170,171
 Quantum dots, highly regarded as excellent bioimaging tool, have also been 
found to have a high toxicity potential.
172
  
Inert, inorganic compounds, such as silica and gold, have been widely studied as strong 
candidates for therapeutics, including drug delivery, and diagnostics, specifically as shells, 
containing bio-toxic materials. As found by Shukla et al, gold has a low production level of 
reactive oxygen and nitrite species, reducing proinflammatory cytokine secretion, making them 
suitable candidates for nanotheranostics.
173
 Other metals, such as silver, give way to reactive 
and antibacterial properties, less suitable for in vivo use.
174,175
 
NP size also plays a significant role – as seen in Figure 4.1, NPs <8 nm in diameter, including 
nanorods, undergo glomerular filtration, whilst Kupffer cells within the liver expunge larger 
sized NPs from circulation. Accumulation within these organs has been most commonly 
associated with AuNPs sized either ≤30 nm and >100 nm.176–181 
Biocompatible sized NPs can lead to cytotoxicity when administered in large doses, with low 
doses generally considered as ~ 0.01 mg/Kg.
176
 In a study by Mironava et al, however, NPs 
which had been internalised were transferred during cell division, effectively decreasing the 
number of NPs within the overall cell population over time.
182
 
4.3 Dispersion State  
Colloidal stability is governed by the electrokinetic potential of surface-ion accumulations, 
which in turn is influenced by pH.
183
 This potential, known as Zeta potential (ζ-potential), 
denotes the level of electrostatic repulsion, characterising the dispersion stability and interfacial 
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chemistry of the NPs, including aggregation level, ligand chemistry success, and cell 
disruption.
184–187
 ζ-potential is a measurement of the electric double layer of the NP, 
comprised of the stationary “stern” layer and moving “slipping plane”, bordering the bulk 
solution.
184
  
 
Figure 4.2: A graph showing the relationship of ζ-potential to colloidal pH. The magnitude of ζ-
potential is denoted as aggregation between 0 – ±5 mV, of minimal stability between ±5 – ±20 
mV, of moderate stability between ±20 – ±40 mV, and high stability ≥ ±40 mV. Values of 
commercially purchased AuNPs, Nanocomposix (San Diego, USA), ranging from 20 nm to 100 nm 
are displayed. The physiological pH value of 7.365 is marked. Typical metal NP values adapted 
from
186,188
 
 
 
As seen in  
Figure 4.2, a decrease in H
+
 ions leads to a basic NP environment, creating an electrostatic 
force greater than the Van de Waals forces of attraction, gaining dispersion stability.
186,187
  For 
biocompatible intracellular interactions, minimal levels of NP aggregation and limited cell 
membrane disruption must occur – commercially purchased NPs used throughout this thesis 
are plotted on the graph in Figure 4.2, showing high stability levels and conformation around 
the physiological pH point. 
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Figure 4.3: Endocytosis and cell membrane interaction of different NP surface charges: (a) anionic 
NPs such as citrate capped or PVA coated; (b) cationic NPs including cetyltrimethylammonium 
bromide coated. Adapted from 
189
 
  
 
Figure 4.3 shows the interaction differences between cationic, (b), and anionic, (a), NP 
surfaces. Cationic surfaces, such as cetyltrimethylammonium bromide (CTAB) capped 
nanorods, have a high affinity to the cell membrane, increasing the rate of endocytosis into 
cells. They have been seen, however, to cause disruption to cell membranes, mitochondria 
and red blood cell morphology, leading to apoptosis.
180,190
 Conversely, anionic NPs, such as 
citrate capped, show little disturbance to cell biology with relatively less cell uptake.  
Despite a generally neutral pH across the body, the pH level within solid breast tumours is 
lowered. A recent study by Rong et al capitalised on this fact, developing NPs functionalised 
with pH sensitive cleaver links which, once residing within the acidic tumour environment, 
release doxorubicin, the triple negative breast cancer drug.
191
 Desired localisation of NPs 
within the body through intravenous injection is met with difficulties in the first instance. Studies 
have shown that once NPs have been introduced to plasma fluids, ζ-potential values tend to 
trend towards 0 mV, with up to a ±21.8 mV change.
192,193
 This is attributed to the surface 
interaction of biomolecules, specifically in the formation of the protein corona. 
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4.4 Protein Corona & Opsonisation 
A major hurdle in site-specific NP targeting for diagnostics and drug delivery is in ensuring an 
extended blood circulation life-time and the efficacy of targeting ligands. Protein corona 
formation cloaks any targeting ligands present on the NP surface, preventing target site 
recognition, whilst presenting a biological shell for opsonins to attach, flagging the particle for 
phagocytosis. 
 
Figure 4.4: Relevant processes (arrows), in both directions (on/off), for a nanoparticle interacting 
with a receptor. Biomolecules in the environment adsorb strongly to the bare nanoparticle surface 
(k1), forming a tightly bound layer of biomolecules, the ‘hard’ corona, in immediate contact with the 
nanoparticle. Other biomolecules, the ‘soft’ corona, have a residual affinity to the nanoparticle–hard-
corona complex (primarily to the hard corona itself), but this is much lower, so those molecules are 
in rapid exchange with the environment (k2). If sufficiently long-lived in the corona, a biomolecule 
may lead to recognition of the nanoparticle–corona complex as a whole by a cell-membrane 
receptor (k3). The same biomolecule alone can also be recognized by the receptor (k4). If present, 
the bare surface of the nanoparticle may also interact with cell surface receptors (k5) or other 
constituents of the cell membrane.
194
 
 
 
NPs delivered via intravenous administration encounter proteins highly abundant in blood 
plasma, such as albumin, fibrinogen, and apolipoproteins, which are primarily adsorbed. This 
initial surface formation is replaced by low concentration proteins with a higher affinity to the 
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NP surface, leading to a “hard” corona. The surrounding, loosely bound proteins form a low 
affinity, highly changeable “soft” corona.195  
Corona formation increases the likelihood of opsonisation – whereby opsonins attach to the 
NP-corona, flagging the particles as foreign bodies to be removed from the body through the 
MPS. Particle size, and hence surface curvature, dictates the amplitude of protein adsorption 
and conformation upon the NP surface.
196
 With proteins such as albumin and fibrinogen, NPs 
< 30 nm in diameter possessing a large surface area and greater curvature, a reduced level of 
interaction occurs; pseudo-flat surfaces, characteristic to nanoparticles > 60 nm, absorb these 
proteins more readily.
197
 However, high surface curvature allows proteins to retain their 
original conformation, with NPs ≤50 nm undergoing vast protein saturation with strongly 
formed hard coronas.  
The phenomenon of opsonisation through protein corona formation can be capitalised upon. 
One such technique assumes that, once taken up by the phagocytes, the NPs will be 
transported to an area of inflammation, hence accumulating within the tumour tissue.
198
 
Another involves the engineering of a biomolecule specific protein corona; creating specialised 
targeting capabilities, whilst remaining resistant to immune response. An example of such is 
the use of platelet fragments in targeting dysmorphic vasculature found in tumours.
199,200
 
Conversely, cloaking mechanisms can be employed, such as the use of polyethylene glycol 
(PEG), as discussed in the next section. 
4.5 Polyethylene Glycol 
Polyethylene glycol (PEG) is a hydrophilic, ethylene repeating polymer, creating a passive NP 
surface reducing interactions with biofluid molecules, creating a “stealth” NP.201 PEG and PEG-
ylated NPs have been widely accepted for clinical use, having low toxicity and provoking 
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minimal immune response, with over 35 US FDA-approved preclinical studies, for both 
imaging and therapy purposes, in progress.
201,202
 
Surface modification of AuNPs with PEG for biological purposes has become a staple 
technique. Examples include it’s use within enhanced anti-tumour drug delivery,203 
photothermal therapy,
190,204
 distal end tethering of targeting ligands
205
, and use within in vivo 
Raman reporter SERS studies.
206
 
The density and length of PEG molecules on the NP surface greatly affects the blood circulation 
half-life. A high density of short chain PEG molecules leads to a brush-like formation; lower 
densities, or longer chains able to fold, creates a less effective mushroom formation.
207,208
 
A mouse model toxicology study of PEGylated AuNPs by Zhang et al discovered that NPs of 
60 nm in size reflected the lowest concentration within the heart, liver, spleen and kidneys, 
comparative to the 5, 10 and 30 nm AuNPs.
176
 Unlike other un-PEGylated biocompatibility 
studies however, there were no discernible growth effects or changes to the major organs at 
every AuNP size.  
4.6 Passive vs Active Targeting 
Enhanced vascular permeability has been observed in solid tumours leading to an EPR effect, 
as briefly discussed in Chapter 2, Section 2.3.1. The key mechanisms allow NPs between 10 
– 100 nm to extravase to a higher level within carcinoma, comparative to healthy tissue 
vasculature, and to be retained within the diseased area.
201,209
 The blood flow within tumour 
tissue, already encouraging permeability due to the immature nature of the vasculature, 
increases dramatically with a higher blood pressure level. This fact can be exploited using an 
angiotensin II to induce hypertension: whilst having no effect on normal tissue blood flow, the 
lack of smooth muscle within tumour vasculature creates elevated extravasation, vastly 
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increasing the EPR effect.
39,210
 Which begs the question, does this mechanism alone provide 
sufficient passive, tumour targeting, or is active, receptor-mediated targeting required also?  
Many studies have employed disease specific biomolecules targeting ligands, such as anti-HER2 
(Human Epidermal Receptor), Tumour Necrosis Factor (TNF), and Vascular Endothelial 
Growth Factor (VEGF), which have been successful in NP-cell interactions, in both in vitro and 
in vivo studies.
203,204,211,212
 Designing the fixed-orientation of these targeting ligands is crucial in 
gaining highly effective and consistent conjugation.
213
 A study by Salvati et al discovered that 
the optimal design for 50 nm silica NPs cell penetration consisted of a targeting ligand attached 
distally upon a PEG molecule. However, a level of bio-identity was still lost once in contact 
with PBS with protein corona formation.
214
 
4.7 Summary 
In understanding how the tailoring of NPs affects biocompatibility, the development of near to 
non-cytotoxic NP probes can be achieved. Figure 4.5 displays a heat map, summarising how 
the level or inclusion of specific NP features may affect biocompatibility.  
The composition of the NP itself, in terms of size and shape, is the major factor in determining 
the success of an in vivo NP probe. Not only in terms of inaccessible site-location, mainly due 
to inability to traverse through tight vasculature for larger NPs, but also the heightened levels 
of pharmacokinetics through the kidneys or liver. As such, a size between 60 – 100 nm and 
hence a nanospherical shape was selected for this study. With nanospheres 
In relation to previous studies performing in vivo SERS and biocompatibility experiments, 
spherical AuNPs 60 – 100 nm have been found to produce an enhanced Raman signal whilst 
causing low levels of cytotoxicity.
206,215–222
  
NP stability, and hence circulation half-life, is crucial factor in ensuring enhanced permeability 
and retention is achieved at an efficient and elevated level. Ensuring a highly positive/negative 
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Zeta potential, alongside an organic pH level, are two key factors in gaining biological stability. 
The use of a “cloaking agent” such as PEG or also enforces stability, however the choice of 
chain-length and density must be considered in terms of the disease targeting specifications of 
the NPs. A biologically engineered protein corona can also be used; however, this omits the 
use of disease-specific ligand surface modification, which has also been proven to increase the 
desired site location of AuNPs. 
 
Figure 4.5: Physical characteristics of nanoparticles determine in vivo biocompatibility. The three-
dimensional phase diagram displays the qualitative biocompatibility trends revealed after in vivo 
screening of around 130 nanoparticles. The main independent particle variables that determine the 
in vivo biocompatibility are size, zeta potential and hydrophobicity. Biocompatibility is reflected in 
the colour spectrum, with red representing likely toxicity, blue likely safety and blue–green–yellow 
intermediate levels of safety. Small, cationic particles with high surface reactivity are most likely to be 
toxic (red hue) compared to than the larger relatively hydrophobic or poorly dispersed particles, 
which are rapidly and safely (blue hue) removed by the reticuloendothelial system (RES). Particles 
that promote enhanced permeation and retention (EPR) effects—and are therefore optimal for 
cancer theranostics — generally have mid-range sizes and relatively neutral surface charges.168 
 
 
Targeted delivery of drug-bearing or theranostic NPs allows site-specific treatment, avoiding 
the overall toxicity induced by chemotherapy and eliminating the use of ionising radiation 
required for radiotherapy.
234
 For example, the PEGylated liposomal encapsulation of 
Doxorubicin has been shown to improve uptake by up to 300-fold within ovarian and breast 
carcinomas, effectively improving bioavailability and reducing costs.
235
 However, when 
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considering the use of nanoparticles in vivo, it is important to weigh up the risk versus benefit 
on an individual patient basis. Much like the required eGFR assessment with iodine contrast 
use in CT for example, patients with non-alcoholic fatty liver disease (NAFLD) have a reduced 
Kupffer cell functionality, which would affect the clearance rate of circulating NPs >8 – <100 
nm.
236
 Pharmacokinetic reducing factors such as this would reduce patient eligibility for 
SESORS, further constricting its use as a specialist technique. 
Hence, the key factors ensuring an elevated level of site-specific NP delivery include the size, 
shape and zeta potential, engineered to allow the EPR effect to take place, with the addition 
of a PEG-ylated and targeting functionalisation, for extra circulation and homing capabilities. 
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Thesis Aims 
The use of optical spectroscopic techniques within the clinical arena is a fast-developing area 
of biomedical application. The need for early diagnosis, especially within symptom presenting 
diseases, is vital in combating high mortality rates associated with extended referral times from 
initial patient assessment. The amalgamation of novel techniques within current diagnostic 
techniques can lead to an improvement in the sensitivity of the original method, and/or lead 
to a reduction of patient wait time between assessments, streamlining the diagnostic pathway. 
The aims of this thesis, in relation to the transferability of the SERS Transmission Raman 
technique within a clinical setting, are as follows: 
• Highlight the need to develop novel, spectroscopic techniques with a mind to incorporate 
with, rather than replace, current diagnostic methods.  
• Cement the use of turbid, PDMS phantoms as viable optical tissue replicas. Incorporation 
of tissue layers, and even occlusions, within the phantoms elevates the optical and 
morphological representation. 
• The use of RR-AuNPs in combination with mammographic imaging to provide further 
depth information, highlighting the cancerous region independently, with use with Raman 
spectroscopy, or within x-ray imaging as a contrast agent.  
• Explore the use of these RR-AuNPs as a more biocompatible probe, able to actively target 
biomarkers synonymous with highly malignant breast carcinomas – microcalcifications.  
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5. Synthesis and Functionalisation of 
Gold Nanoparticles 
5.1 Introduction 
Exploration into the synthesis of gold nanoparticles (AuNPs) leading to Raman reporter 
labelling, and hence further functionalisation, with the necessary biocompatibility measures 
accounted for, is detailed within this Chapter. 
The chemistry and characterisation, via TEM imaging and UV/Vis analysis, of the initially 
synthesised AuNPs is discussed in Section 5.2. Leading on from this, the Raman reporter 
labelling of the commercially purchased AuNPs is explored in Section 5.3. The characteristic 
SERS signals gained from the three reporter labels (2-Naphthalenethiol, 4-Acetamidophenol 
and 4-Mercaptobenzoic acid) are detailed, with the binding mechanisms of each compared. 
The full functionalisation of the AuNPs is described in Section 5.4 with three separate 
components: a Raman reporter label, polyethylene glycol (PEG) and a hydroxyapatite targeting 
bisphosphonate molecule. The design, carbodiimide chemistry and characterisation of these 
AuNPs is discussed.  A summation of all findings within the Chapter are presented in Section 
5.5. 
These experiments form the basis of the Raman reporter AuNPs (RR-AuNPs) and active 
targeting AuNPs (2-NT-PEG-BP AuNPs) employed in the proceeding Chapters 8 and 9, 
respectively. 
5.2 Synthesis of Gold Nanoparticles 
Initially, AuNPs were synthesised using the traditional method developed by Turkevich, et 
al..
223
 The formation of gold nanospheres occurs via the addition of aqueous trisodium citrate 
to an aqueous solution of tetrachloroauric acid (𝐻𝐴𝑢𝐶𝑙4). The citrate acts as both a reducing 
agent and stabilizer of the NPs. The multi-step chemical reactions which take place are 
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described below.
224
 Prior to synthesis, all glassware used was washed with Aqua Regia (1 part 
nitric acid to 3 parts hydrochloric acid molar ratio), rinsed thoroughly three times with DI 
water, and placed in a glass drying oven until bone-dry. 
The 𝐻𝐴𝑢𝐶𝑙4 salt disproportionates upon its addition to water: 
 𝐻2𝑂 + 𝐻𝐴𝑢𝐶𝑙4  → 𝐴𝑢𝐶𝑙3 + 𝐻
+ + 𝐶𝑙− (19) 
 
This initial solution, starting out as a straw-yellow colour, is placed in a round bottom flask and 
placed in a heating mantle. The solution was stirred at a constant rate to approximately 90°C, 
cautious not to bring to the boil.  
Separately, the aqueous trisodium citrate solution is formed. Water causes the citrate to 
oxidise, producing dicarboxy-acetone and carbon dioxide as a by-product: 
 𝐻2𝑂 + C6H5O7
  −3 → 𝐶5𝐻6𝑂5 + 𝐶𝑂2 + 𝐻
− + 2𝑒− (20) 
 
The dicarboxy-acetone has a further reaction in the aqueous solution forming acetone: 
 2𝐻2𝑂 + 𝐶5𝐻6𝑂5  →  𝐶3𝐻6𝑂 + 2𝐶𝑂2 + 2(𝑂𝐻)
−
 (21) 
 
The citrate solution is slowly added to the tetrachloroauric acid solution, where the acetone 
reduces the auric salt (𝐴𝑢𝐶𝑙3) to aurous salt (𝐴𝑢𝐶𝑙): 
 𝐴𝑢𝐶𝑙3 + 2𝑒
−  → 𝐴𝑢𝐶𝑙 + 𝐶𝑙2
−
 (22) 
 
Facilitated by remaining dicarboxyacetone, the aurous salt forms a complex (3𝐴𝑢𝐶𝑙), allowing 
a second disproportionation causing the nucleation of the Au NPs: 
 3𝐴𝑢𝐶𝑙 → 2𝐴𝑢0 + 𝐴𝑢𝐶𝑙3 (23) 
The nucleation sites continue grow as more Au is adsorbed onto the surface. The reaction is 
held under reflux for 30 minutes, turning the solution to a deep, ruby red. Remaining citrate 
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particles form a negatively charged monolayer capping the NPs, giving the colloid electrostatic 
stability reducing the potential of aggregation. The colloidal solution is then slowly cooled to 
room temperature. Tin foil wrapped glass storage jars were used, protecting the colloid from 
direct light, and stored in the fridge at 4°C to prolong shelf life. 
A slight deviation to the Turkevich method was made in pursuit of “dumbbell” or peanut-like 
AuNPs. 20% of the initial 𝐻𝐴𝑢𝐶𝑙4 stock volume was heated, and then refluxed with the total 
volume of citrate solution. This created initial points of nucleation. After 20 minutes of reflux, 
the remaining 80% 𝐻𝐴𝑢𝐶𝑙4 stock solution was added, and refluxed for a further 30 minutes, 
turning the solution ruby red. This process allowed two separate nuclei to form, grow and 
adjoin. The NPs were cooled and stored in a similar fashion as previously set out.  
All NP preparation required the use of a centrifuge, Mikro 22 (Hettich, Germany), and 
deionised water (18.5 MΩ), Arium Mini (Sartorius, Germany); especially in the removal of 
supernatant and washing of the NPs between functionalisation steps, removing excess 
conjugate from the colloidal solution. 
Once synthesised, the crystal lattice, size and dispersity of colloids were investigated using 
Transmission Electron Microscopy (TEM) and Ultraviolet-Visible spectroscopy (UV/Vis). 
To characterise the structure of nano-sized particles Transmission Electron Miscroscopy 
(TEM), JEM-2100 LaB6, JEOL (Tokyo, Japan), is employed. A high powered electron beam is 
passed through the sample under vacuum. The crystalline lattice of the sample structure acts 
as a diffraction grating – the electron beam waves are diffracted through the lattice causing 
interference patterns, forming the density based image. The NP samples are prepared in 
several steps. First, a 1 mL volume of colloid is concentrated via centrifugation, removing 0.8 
mL of supernatant.  
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 Figure 5.1: Agar Scientific Carbon Film 300 Mesh Copper TEM grid – an illustrative representation 
of the grid with a highlighted area visualised with TEM.
225
 
 
 
A micropipette is used to transfer 0.1 mL the colloidal concentration onto a carbon film 300 
mesh copper grid, AGS160-3H, Agar Scientific (Stansted, UK). The TEM grid is dried for up 
to 48 hours in a sterile environment, reducing contamination and ensuring stable imaging. A 
limitation to TEM is the propensity for NP aggregation during sample preparation. 
 
Figure 5.2: TEM images of AuNPs synthesised from standard Turkevich method: (a) and (c) display 
a wide field view of the polydisperse NPs; (b) shows a near-field variety of AuNP shapes, namely 
spherical, pentagonal, and two truncated triangular nanoplates, which have been synthesised within 
the same batch; (d) a spherical, poly-lattice NP, averaging 20 nm in diameter. 
(a) (b) 
(d) (c) 
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Figure 5.3: A spherical, 20 nm AuNP with a compact poly-lattice; A truncated triangular plate with 
wider D-spacing, and a single lattice synonymous of non-spherical nanoplate. Scale bars are to 5 
nm. 
 
 
From  
Figure 5.2 (a), the standard Turkevich synthesis method mainly produced pseudo-spherical NPs, 
cuboctahedron in structure, with an average size of 20 nm.
226
 In several batches, a variety of shapes 
such as pentagons and truncated triangular nanoplates were also produced, as seen in  
Figure 5.2 (b). The crystal lattice is further investigated. 
The formation of the crystallographic planes indicates the nature of the NP shape: a tight, poly 
lattice is suggestive of spherical shape, whilst plate type NPs have a more open, single lattice, 
as  
Figure 5.3 displays.  
The modified synthesis method led to the formation of “peanut” like NPs, as seen in  
Figure 5.4 (a) and (b). The joined-double-spherical shape of the NP prompted a pursuit of this 
method. As discussed in the Chapter 3, Section 3.2, large hot-spots induced by the proximity 
of two NPs is a highly sought-after attribute.   
The lattice was investigated to ensure the two nucleation points had cross-lattice joined, which 
can be clearly seen in Figure 5.5. 
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Figure 5.5: TEM image of a peanut-like AuNP cross-nucleation point confirming the presence of a 
compact poly-lattice structure adjoining the two spherical NPs, creating a singular doublet. 
 
 
Figure 5.4: TEM images of the peanut-like/doublet AuNPs synthesised from the modified Turkevich 
method: (a) wide field of view display of the AuNPs, most are seemingly paired closely with a few 
individual NPs; (b) a near-field view of a singular doublet AuNP – the width of the adjoining 
nucleation point neck was ~5 nm, with the average dimensions of a successful doublet synthesis 
being 20 x 50 nm; (c) and (d) display the variations in NP synthesis within the batches, creating larger 
diameters of 40 nm ±10 nm, or elongated almost rod like NPs.   
1.82 Å 
(a) (b) 
(d) (c) 
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An Ultraviolet/Visible Absorbance Spectrophotometer, Evolution Array, Thermo Fisher 
(Massachusetts, USA), is used to analyse the absorbance of materials, including the LSPR and 
stability of NPs. with an effective measurement range between of 185 – 1100 nm. The UV/Vis 
is equipped with a durable tungsten lamp and a photodiode array for illumination and collection 
respectively. A blank sample of DI water is run initially to gain a normalised absorbance 
spectrum, prior to further sample measurements. 
 
 
UV/Vis testing determined the LSPR of the AuNP batches, displayed in Figure 5.7, in relation 
to a reference peak of commercially purchased 20 nm spherical AuNPs. The plasmon 
resonance of the doublet AuNP batches were expected to contain a second absorption peak 
not dissimilar to that of Au nanorods, however this did not appear for either batch. 
 
Figure 5.6: Thermo Fisher Evolution Array UV/Vis Absorbance Spectrometer – simplified optical 
set-up schematic of the equipment.
227
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Inconsistency in AuNP concentrations between batches affected the ability to determine the 
overall size and aggregation status of the batches. Hence, a normalised optical density chart, 
Figure 5.8, for solely spherical AuNPs was produced. A direct comparison of doublet AuNPs 
to the reference peak could not be made due to the difference in shape and size. The graph 
shows the synthesised AuNPs were not aggregating but were not reduced enough to form an 
overall batch size of 20 nm. Instead, a wide range of AuNPs were formed in each batch, on 
average smaller than 20 nm. Over time, AuNPs in an aqueous solution can release gold ions 
from the surface which can aggregate to form smaller AuNPs within the original batch, leading 
to further narrowing and an overall blue-shift in LSPR. 
Figure 5.7: UV/Vis spectrum of all synthesised AuNP batches, four standard Turkevich method 
spherical AuNPs and two modified Turkevich method doublet AuNPs, and a reference spectrum of 
Nanocomposix 20 nm spherical AuNPs. Spherical batches #1 – 3 matches similarly to the reference 
spectrum, confirming a ~20 nm diameter average; batch #4 has a 𝝀𝒎𝒂𝒙 of 520 nm, relating to a 
smaller average diameter. Doublet batches #1 and #2 both have a broadened LSPR peak, 
confirming the presence of elongated AuNPs, however a secondary, red-shifted peak was 
unexpectedly not present, confirming a low overall volume of doublets within each of the batches. 
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Figure 5.8: Normalised optical density UV/Vis spectrum of the synthesised Turkevich method AuNPs 
in relation to the reference spectrum of Nanocomposix 20 nm spherical AuNPs. The two green 
arrows denote the narrowing of the synthesised AuNPs in comparison to the reference peak 
indicative of a size distribution. The gradated left arrow denotes the blue-shift in LSPR by 1-2 nm for 
each of the synthesised batches. 
 
 
Consecutive batches following the Turkevich and adjusted synthesis methods produced a 
varied and desirable range of NP size and shapes. Achieving a consistency of spherical or 
doublet NPs between batches was problematic, with several batches aggregating prior to 
completion. Adjustments were made to stabilise colloids – a decrease in citrate salt 
concentration for greater nanoparticle size formation and diligence in maintaining a consistent 
synthesis temperature were two main attuned parameters. Consistency and successful 
synthesis issues were still met however. With the modified method, additional 𝐻𝐴𝑢𝐶𝑙4 would 
increase the growth size of original nucleation sites rather than conduct new formations, as 
seen in Figure 5.4 (c) and (d). Human error in not thoroughly cleaning the glassware is also a 
factor affecting successful synthesis. 
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Ensuring monodispersity and consistency between self-synthesised AuNP batches could not 
be guaranteed. Synthesis of AuNPs inconsistently produced NPs larger than ~20 nm.  
To ensure experimental consistency in the following experiments, a pragmatic decision was 
made to purchase commercially available 80 nm colloids from Nanocomposix (San Diego, 
USA). Each batch is mass produced under consistent conditions and supplied with a data sheet 
providing information on Zeta potential, a size distribution histogram and absorbance 
spectrum. All purchased batches of colloids were cross checked with UV/Vis and TEM imaging 
on site and found to be concordant with the given results. As a wholly accessible and viable 
option, further experimentation with AuNPs were performed using the NanoXact bare gold 
nanospheres, 0.05 mg/mL, in aqueous 2 mM sodium citrate solution. 
5.3 Labelling with Raman Reporters 
In preparation for multiplexed depth measurements within breast phantoms, the optical 
response of the Raman reporter labelled AuNPs was assessed. The following materials were 
obtained: 80 nm spherical AuNPs (Nanocomposix); 2-Naphthalenethiol (2-NT), 4-
Acetamidophenol (4-ATP), more commonly known as paracetamol, and 4-Mercaptobenzoic 
acid (4-MBA) (Sigma Aldrich, USA) diluted into 10 mM ethanol stock solutions, where 
subsequent aliquots were diluted to 4 µM solutions ready for conjugation. For micro-Raman 
experiments a stainless-steel slide was used for drop-drying analysis. 
For consistency, 0.5 mL of colloid was transferred via micropipette into a triple DI water rinsed 
Eppendorf, followed by the dropwise addition of the reporter solution at a 1: 0.3 volumetric 
ratio. During this process, the colloid solution was placed upon an Eppendorf mixing platform, 
Vortex VariMix (SciQuip, UK), and consequently thoroughly mixed for five minutes. Upon 
resting the colloid solution at room temperature for ten minutes to aid full binding 
confirmation, the NPs were centrifuged at 2700 RPM for 7 minutes. Once the supernatant 
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was removed and the NP pellet re-suspended in DI water, the process was repeated a further 
two times. To increase shelf life, the Raman reporter stock solutions and reporter-conjugated 
AuNPs were stored in dark conditions at 4°C. 
 
Figure 5.9: UV/Vis and TEM imaging examples of the 2-NT RR AuNPs, with the reference bare 
citrate-capped absorbance spectrum displayed in the UV/Vis imaging figure. 
 
 
For each reporter, a complete surface coverage under a non-aggregating, stable reporter-to-
colloid ratio was determined and followed in subsequent experiments. The size of the AuNP 
also affected the ratio in terms of concentrations: a concentration of 9.7 x10
9
 nanoparticle per 
mL. Variations between purchased AuNP batches were noted and adjusted for.  
The SERS spectrum of each reporter AuNP was analysed via point spectra of the drop dried 
solutions on a stainless-steel slide. The system used for point-spectra, and micro-Raman 
mapping, was a Renishaw InVia Reflex (Renishaw, Wotton-Under-Edge, UK). A diagrammatic 
of the optical set-up can be seen in Figure 5.10.  
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Figure 5.10: Renishaw InVia Reflex optical set-up – the illumination source passes through beam 
expanders allowing the small, collimated beam to fill the optics; mirrors guide the beam to the 
objective, 50X magnification displayed here, and onto the sample; the scattered light is collected and 
passed through Rayleigh scattering filters and a slit to clean the wavelength of the beam; a reflector 
prism guides the beam onto the grating, where the light is dispersed, and CCD detector array for 
computer analysis. 
 
 
Two NIR lasers at 785 and 830 nm, reaching 140 mW power at sample illumination, are built 
into the system. Two Leica microscope objectives, both with a 200 mm working focal length, 
were used: 5X/0.12 NA (numerical aperture; inversely related to working distance) for large 
area surface montages, and 50X/0.75 NA for small area montages, mapping, and point 
spectra. The laser focused spot size, assuming uniform illumination, can be described as: 
Hence, for the two working objectives and laser wavelengths, the spot sizes are: 
  Spot Size (µm) 
Objective NA 785 nm 830 nm 
5x 0.12 7.98 8.44 
50x 0.75 1.28 1.35 
 
Table 5.1: The variability of microscope objective (5x and 50x) spot sizes depending on the selected 
wavelength (785 and 830 nm) and the intrinsic numerical aperture.  
 
 𝑆𝑝𝑜𝑡 𝑆𝑖𝑧𝑒 =  
1.22𝜆
𝑁𝐴
 (24) 
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The spatial resolution of the system is in the order of 1 µm. Governed by the diffraction limit 
of light, spatial resolution it is dependent on the laser wavelength and the NA of the objective 
in use, and can be described as  
 𝑆𝑝𝑎𝑡𝑖𝑎𝑙 𝑅𝑒𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 =  𝜆/2𝑁𝐴 (25) 
Hence, an 830 nm laser wavelength through a 0.75 NA objective has a 675 nm spatial 
resolution. A shorter wavelength and a higher NA will increase the spatial resolution closer to 
the diffraction limit. 
Scattered photons are guided from the sample to the Rayleigh scattering filters. Holographic 
notch filters are used to retain a high level of Raman scattering intensity. The selected Raman 
signal travels through a 50 µm slit, is dispersed with a 600 line/mm grating and detected with 
the -70°C Peltier cooled, deep depletion CCD array (1024 x 256 pixels). The spectral 
resolution of the system is ~2 cm
-1
 (600 mm/l grating). Spectral resolution dictates the number 
of resolvable peaks a system can produce. CCD pixel quantity and size, the diffraction grating 
density, and slit size are the main factors affecting spectral resolution. A minimum of three 
pixels are required to resolve a single peak, hence a CCD array with a high quantity of small 
pixels increases resolution. The use of high density line/mm grating increases resolution but 
decreases spectral range and strength. Similarly, a small slit increases optical resolution but 
decreases signal strength. Laser wavelength also plays a crucial role – a shorter wavelength will 
increase Raman scattering efficiency, but also increase the risk of fluorescence and sample 
burning, reducing quantifiable Raman signal.  
The samples are placed on an automated stage, enabling an ease of surface montage imaging 
and mapping.
108
 The system was calibrated by taking a spectrum of a silicon wafer and using 
the reference peak of 520 cm
-1
. Arbitrary intensity Raman spectra for each of the Raman 
reporters is seen in  
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Figure 5.11.  
 
 
As Figure 5.11 shows, the three types of reporter molecule have distinct, yet similar, spectral 
features. The main, characteristic peak assignments when measured under the outlined SERS 
conditions are classified as follows: 
Peak Position (cm
-1
) 
 Vibrational Mode Reporter Assignment 
2-NT 4-ATP 4-MBA 
1066 
Benzene ring 
symmetric stretch 
  
1078   
𝜈12 Benzene ring 
symmetric stretch 
1081  
Out-of-plane C–C 
skeletal stretch 
 
1380 
Benzene ring 
symmetric stretch 
  
1587   
𝜈8𝑎 Benzene ring 
symmetric stretch 
1589  𝛿 N-H bending  
 
Figure 5.11: Micro-Raman spectrum of the three 80 nm reporter-AuNPs and the corresponding 
molecular structure of the reporters: 2-NT, 4-ATP and 4-MBA, from top to bottom. The signal 
intensities plotted across each spectrum is plotted in relation to the colour bar. The AuNP surface 
binding point for each of the reporter molecules is highlighted in red. The acquisition for each 
measurement was at a 70 mW sample illumination power, 2 seconds and 5 accumulations.  
4-MBA 
2-NT 
4-ATP 
2-Naphthalenethiol  
4-Mercaptobenzoic acid  
4-Acetamidophenol   
1066 1380 
1620 
1081 
1589 
1078 
1587 
1712 
 104 
 
1618 
Benzene ring 
symmetric stretch 
  
1712   C=O stretch 
 
Data for the characteristic peaks of 2-NT taken are from the papers by Alvarez-Puebla et 
al.
228,229
; of 4-ATP from the book section by Cinta Pinzaru and Pavel
120
; and 4-MBA from 
Michota and Bukowska paper.
230
 
4-MBA and 2-NT bind to the NP surface via a gold-thiolate bond. Conversely, the 4-ATP is 
bound via the acetamido nitrogen present. The reporter binding angle affects the orientation 
of the molecule, perpendicular or parallel to the NP surface, the latter being the case with 4-
ATP as seen in Figure 5.12. The significant enhancement of the C-C skeletal stretch at 1081 
cm
-1
 supports this suggested orientation.
120
 
 
Figure 5.12: Orientation of the 4-ATP Raman reporter molecule when bound to a gold surface, 
represented in pink. The bond angle of 108.85° between the gold-thiol and benzene ring is also 
displayed.  
 
 
The comparable intensity of the 4-MCBA and 2-NT is owed to the increased number and 
compact nature of the reporter molecules bound to the AuNP surface. A excess of 
approximately 82,700 RR molecules per AuNP was used. 
5.4 Active Targeting Functionalisation 
The development of a highly specific targeting agent for breast malignancy is critical for early 
detection and diagnosis. Research into breast cancer relevant ligands primarily study antibodies 
and receptors. A relatively untapped, relevant marker of disease is microcalcifications, which 
108.85° 
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when present, contain higher levels of hydroxyapatite (HAP) shown to be synonymous with 
malignant DCIS, discussed in Chapter 2 Section 2.3.3. Bisphosphonates (BP), a widely-used 
molecule for targeting HAP, is discussed in sub-section 2.3.3.1. 
Cole et al have a number of studies into AuNPs labelled with a type of BP, alendronate, to 
target bone tumours and microcalcifications, acting as a contrast agent for CT imaging.
59,231,232
 
Deciding upon the ligands necessary to achieve a strong SERS signal, effectively target HAP, 
and remain biologically inert was a crucial initial step. Hence, the targeted AuNPs were made 
up of three constituent parts to satisfy the needs: a strong, carbodiimide chemistry inert Raman 
reporter 2-naphthalenethiol (2-NT) was selected, 2,000 Da polyethylene glycol (PEG) to 
ensure stability and a high binding molecule affinity, and the targeting BP, alendronate. To 
achieve the full potential of the three components, the configuration and positioning upon the 
surface of the NP was essential. 
5.4.1 Raman Reporter, PEG and Alendronate Conformation 
As previously discussed in Chapter 4 Section 4.4, in terms of biocompatibility and avoiding 
protein corona formation, the most effective conformation of PEG is in a brush-like orientation. 
The overall most effective conformation of both PEG and targeting ligand is visualised in Figure 
5.13 (c). 
Using a high grafting volume of 2,000 Da PEG results in a conformation as in  
Figure 5.13 (a) occurring. The ideal tethering is seen in  
Figure 5.13 (c): the targeting BP attached upon the distal end of a dense, brush-like PEG barrier. 
Furthermore, it has been shown that distally tethered binding moieties have a significantly enhanced 
target-specific avidity of up to 4.5 orders of magnitude through multivalent interactions.
234,235
 The use 
of the shorter 2-NT molecule required for SERS could lead to a conformation similar to  
Figure 5.13 (d), leading to the BP molecule being buried within the PEG.
233
 As such, the ratio 
of 2-NT: PEG requires tempering. 
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Figure 5.13: PEG and targeting ligand NP surface attachment variations: (a) PEG in a mushroom-like 
conformation with the targeting molecule anchored to the surface of the AuNP; (b) higher PEG 
grafting densities lead to a brush-like conformation which blocks the target molecule from binding; 
(c) anchoring the targeting ligand to the distal end of the brush-like PEG; (d) shorter neighbouring 
molecules can cause the PEG molecule to relax back into a mushroom-like conformation.
233
 
 
 
Ensuring the alendronate molecules have little steric hindrance, occurring within large 
molecular groupings preventing targeted binding of smaller molecules, is key to increasing their 
ability to locate the binding points within HAP. The role of PEG tether length affecting steric 
hindrance is explored by Cole et al.
232
 The assumption of a longer chain length increasing the 
binding ability of distally-attached bisphosphonates has been disproven both in vitro and in 
vivo. Long PEG tethers can provide too much distance between the BPs, leading to distant 
and low concentrations.
236
 Further investigations by Cole et al. found an ideal tether length of 
2,000 Da, resulting in a greater binding affinity in vitro compared to 1,000 and 5,000 Da.
232
 
The design outline of the active targeting AuNP is seen in Figure 5.14. 
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5.4.2 2-NT to PEG Ratio 
The necessity of both the 2-NT and the PEG to readily bind to the NP surface with little 
competition required the use of thiolated PEG. The ratio of 2-NT to PEG molecules also 
needed to satisfy two specifications: a high enough level of 2-NT molecules to gain a significant 
SERS signal; and an appropriate amount of PEG to gain a brush-like conformation. The 
preparation method was adjusted from Qian et al.  to deliver an optimization of surface 
coverage.
206
  
A 4 µM ethanol solution of 2-NT and a 10 µM aqueous solution of 2,000 Da PEG was 
prepared. NPs : 2-NT : PEG was added as a ratio of 1 ∶  0.1 ∶  0.2. Initially, 100 µL of 2-NT 
solution was added dropwise to 1 mL of colloid, then shaken vigorously for 5 minutes. 500 
µL of PEG solution was then added dropwise and again shaken to ensure complete coverage 
of the NPs. The colloid solution was centrifuged at 3000 RPM for 7 minutes, supernatant 
removed, and washed with DI water – repeating three times to remove any remaining, 
unattached -thiols. Prior to attachment of alendronate, the 2-NT-PEG NPs were analysed 
using UV/Vis to determine whether aggregation had occurred, detailed in Section 5.4.4. 
Figure 5.14: An image portraying the overall design of the targeting NPs: 2-NT and PEG layers 
attached directly to the AuNP surface, alendronate fixed at the distal end of the PEG molecule. 
= PEG 
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Under successful conjugation conditions, an approximate ratio of 2,474 2-NT molecules to an 
excess of 58,978 PEG molecules per 80 nm nanoparticle could be attained.  
5.4.3 Carbodiimide Chemistry 
In conjugating targeting molecules to a PEG layer, one of the most common coupling 
techniques is carbodiimide chemistry.
237,238
 In this process a carbodiimide cross linker and a 
stabilizing ester facilitates a zero-length, carboxyl-to-amine reaction. Hence, a distal PEG group 
of -COOH is required.  
The two most commonly used carbodiimide structures are 1-ethyl-3-(-3-
dimethylaminopropyl) carbodiimide (EDC) suitable for aqueous crosslinking, and N',N'-
dicyclohexyl carbodiimide (DCC) for organic synthesis methods. With the pre-prepared 2-
NT-PEG NPs suspended in DI water, EDC was chosen. The carbodiimide reacts with the 
carboxyl group, forming the intermediate, active ester o.-acylisourea – Figure 5.15.  
 
Figure 5.15: Reaction pathway of initial -COOH PEG with EDC: C=N reacts to the receptive -OH 
group, forming the intermediate O.-acylisourea. 
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When in aqueous solution, o.-acylisourea is unstable. If left destabilised, hydrolysis can occur. 
Hydrolysis deactivates the binding site, regenerating the carboxyl group. This significantly 
reduces the number of reaction sites available, decreasing overall yield. Carboxylate activation 
with EDC is most efficient at pH 3.5 – 4.5.239 However, the rate of hydrolysis at this level of 
acidity is estimated to be 2 – 3 s-1.240   
 
 
Avoiding yield loss and hydrolysis requires the use of a hydrophilic, stabilising ester: N-
hydroxysuccinimide (NHS), chemical reaction pathway seen in Figure 5.16. 
EDC used in conjunction with NHS at pH 7.5, retains a high yield and significantly increases 
hydrolysis rate to 40 minutes.
241
 0.1 M phosphate-buffered saline (PBS) at pH 7.4 was used 
for the EDC, NHS and alendronate solutions – amine deprotonation occurs at an acidic pH 
halting further reactions. The final reaction pathway conjugating the alendronate to the PEG is 
seen in Figure 5.17.  
 
Figure 5.16: Reaction pathway of O.-acylisourea with NHS to form a stabilised platform for amine 
group bonding. A non-toxic urea by-product is formed through the reaction. 
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Figure 5.17: Reaction pathway of NHS stabilized PEG with alendronate amine group forming final 
resultant of carbodiimide chemistry; ester by-product is substituted in the reaction. 
 
 
The process began with 4 mL of 2-NT-PEG NP colloid decanted into a flask with a magnetic 
stirrer. PBS solutions of NHS (20 mg/mL) and EDC (15 mg/mL) were added in unison, at a 
1:2 parts ratio, to activate the carboxylic group. The solution was stirred at a constant rate for 
20 minutes. A PBS solution of alendronate (1 mg/mL) was then added at a 1:1 molar ratio of 
alendronate:PEG, and left to gently stir at room temperature for up to 3 hours. The final 
product (2-NT-PEG-BP NPs) was centrifuged at 2,500 RPM for 7 minutes, and rinsed with 
DI water, three times. 
Post-labelling, the 2-NT-PEG-BP NPs were stored at 4ºC in foil wrapped, sealed glass 
containers. Characterisation of the NPs with UV/Vis and TEM was then carried out. 
5.4.4 UV/Vis and TEM Analysis 
UV/Vis measurements were taken at each step of NP labelling: bare, with 2-NT Raman 
reporter, 2-NT with PEG, and fully functionalised with alendronate, as seen in Figure 5.18. 
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Crucially, at each labelling step the peak width remained consistent that of the bare AuNPs, 
verifying that little aggregation had occurred at each stage of labelling. The slight red-shift of the 
peaks following each stage confirmed that further surface modification had been successful, or 
that an overall increase in NP size had occurred. Both the 2-NT-PEG and 2-NT-PEG-BP 
colloids were imaged with TEM to clarify the NP labelling at each crucial step.  
The 2-NT-PEG NPs are visualised with TEM imaging in  
Figure 5.19. As can be seen, the PEG molecules appeared to have conformed upon the NP 
surface into a mushroom-like formation. This brought doubt upon the success of the 
carbodiimide chemistry in both carboxyl-to-amine binding, and effectiveness of HAP targeting 
thereafter. Analysis of the 2-NT-PEG-BP NPs brought light to the situation. 
 
Figure 5.18: Normalised UV/Vis spectra of each labelling step from bare NPs to fully targeting. Three 
batches of the targeting NPs were measured to check consistency in the carbodiimide chemistry. 
Apart from the fully functionalised batch #1, minimal aggregation occurred at all steps. 
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Figure 5.19: A range of TEM images displaying the features of the 2-NT-PEG NPs, clustered and 
individually. Larger annotations of the scale bar added for clarity. 
 
 
Figure 5.20 characterises the PEG as a brush-like conformation post-carbodiimide chemistry. 
Slight thinning of the conjugated layer on one side of the NP relates to the orientation of the 
NP with regards to the microscope. Across the main bulk of the targeted NPs viewed with 
TEM, successful labelling had occurred remaining disperse in nature. However as seen in 
Figure 5.21, success was varied. Several NPs showed levels of aggregation; and whilst some 
achieved a “patchy” formation others failed to undergo successful conjugation of any type. PEG 
disassociation or non-binding also occurred, evident in the mottled background effect created 
by these lone, aggregate molecules present in Figure 5.20 and Figure 5.21 TEM images. 
 
100 nm 5 nm 
5 nm 
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Figure 5.20: TEM images of singular 2-NT-PEG-BP NPs displaying a brush-like conformation, from 
magnification levels 100 – 5 nm. Larger annotations of scale bars added for clarity. 
 
 
Figure 5.21: TEM images displaying occurrences of unsuccessful carbodiimide chemistry. Highlighted 
by the orange arrow is a PEG-only labelled NP. Larger annotations of scale bars added for clarity. 
 
 
As seen in the UV/Vis spectra in Figure 5.18, little overall aggregation had occurred within the 
bulk of the colloid – this highlights the propensity of aggregation occurring during TEM 
preparation.  
100 nm 20 nm 
20 nm 5 nm 
100 nm 100 nm 
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5.5 Discussion and Conclusions 
The nature of gold colloid production on a small scale resulted in a prominence of 
polydispersity, with a low level of batch reproducibility. Consistency in SERS requires 
uniformity in AuNP size with monodispersity.
109,115
 As such, to ensure reproducible 
experiments in SERS commercially available AuNPs were obtained. The batch specific 
properties supplied on a data sheet were cross checked using TEM imaging and UV/Vis to 
ensure validity. 
Persistence in the production of the peanut-shaped AuNPs could have been made, however 
consistency in synthesis was lacking and difficult to reproduce due to the need to temper the 
two nucleation points. This may be an interesting avenue to pursue for future work. 
The selection of 80 nm AuNPs falls within the remit of biocompatibility, with a higher known 
success rate of RR binding to the colloidal surface and hence extrinsic enhancement. RRs 2-
NT and 4-MBA are two of the most commonly used as RRs due to the thiolated binding 
mechanism and highly Raman active benzene ring within the molecules. 4-ATP, more 
commonly known as paracetamol, is less widely used, and generally selected as a Raman 
standard.
106
 The difference in binding mechanisms and angles between the acetamido nitrogen 
of 4-ATP, and -thiols of 4-MBA and 2-NT is a point of interest moving forwards in terms of 
the signal intensity garnered from each. 
The actively targeting AuNPs are next considered. To be effective, NPs must avoid clearance 
from the body through the liver, achieving long circulation times with passive, EPR effect and 
active targeting mechanisms enabling tumour retention. The necessary steps were taken to 
considerate the functionalisation design: use of the 2-NT Raman reporter as a carbodiimide 
chemistry inert molecule; the length of PEG chain for optimal brush-like coverage; and the 
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tethering of the actively targeting alendronate molecule at the distal end of the PEG to reduce 
steric hindrance.  
An increase in the chain length of the PEG, plus an increase in the ratio of spacer Raman 
reporters on the colloid surface, may provide a brush-like formation in the first, non-targeting 
functionalisation step. Other BPs with a greater HAP binding affinity, such as risedronate and 
zolendronic acid, could also be tested in place of the alendronate molecule. This brings up the 
possibility of using a different PEG binding mechanism other than the amine, which is known 
to be the main binding site to the HAP. 
The ability to test the RR-AuNPs at depth required the manufacture of optically representative 
breast tissue phantoms, the remit behind the material selection and consideration of the 
required shape for transferability of experimental results into a clinical setting is explored in the 
next Chapter. 
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6. Optical Phantom Construction 
6.1 Introduction 
The use of optical and morphologically representative “tissue-mimicking” phantoms was first 
experimentally proposed in the 1980s, detailing the trans-illumination of the phantoms with 
infra-red light as a potential new method for breast cancer diagnosis.
242,243
 Henceforth, key 
factors enabling the use of optical phantoms, other than crucially representing the scattering 
and absorption factors of the desired tissue type over clinically useful wavelengths, include the 
stability, homogeneity and reproducibility in phantom formation.
243
 
Within this chapter, Section 6.2 considers the optical matching properties of various phantom 
materials relating to breast tissue at an 830 nm wavelength. The fabrication of 
polydimethylsiloxane (PDMS) phantoms is detailed in Sections 6.3 and 6.4. Section 7.4 is 
broken down into two key areas: 6.4.1 describing optically representative breast phantoms of 
a semi-infinite form, and 6.4.2 which considers optically and morphologically representative 
breast phantoms; both utilising additive manufacturing in mould creation. The latter sub-
section considers the transferability of the deep Raman technique into a hospital setting, in 
combination with mammography. This required a notable change of the optical phantoms in 
becoming representative of a breast in a compressed state.  
6.2 Postmenopausal Breast Tissue Optical Property Matching 
Graphs pertaining the results from the breast optical properties studies of pre- and post-
menopausal women have been plotted in Figure 6.1 and Figure 6.2. The vertical, dark grey 
dotted line marks the 830 nm wavelength selected for experimental use in this study; the 
vertical, light grey dotted line marks the collection wavelength of the benzene ring, 
predominant across all RR-AuNPs. 
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Appreciable differences in the optical properties of breast tissue during the phases of the 
menstrual cycle, due to the physiological changes in haemoglobin concentration (oxy- and 
deoxy-), and oxygen and water saturation, have been documented.
244–247
 This increased 
variation is highlighted by the standard deviation values for pre-menopausal women in the 
studies by Cerussi et al and Shah et al.
245,248
  
In relation to the epidemiology of this thesis, predominantly women over 45 years of years 
undergoing or post-menopausal, these cyclical factors can be disregarded. A slowing of 
hormonal and glandular activity in menopausal breast tissue leads to a reduction in vascular 
requirements. A lower blood volume effectively reduces the absorption and reduced 
scattering coefficients, by approximately 230 – 300 % and 16 – 22% respectively.245 
Pre- and post-menopausal µs’ trendlines – indicative of Cerussi et al, Shah et al and Thomsen 
& Tatmen (considering the glandular tissue values for pre-menopausal, and adipose tissue for 
post-menopausal) – intersect 830 nm at 9.702cm-1 and 8.852 cm-1 respectively.  
From Figure 6.2, averaged haemoglobin and adipose values derived from the Jacques review 
paper
147
 were factored by ~4.6 times to be relative to the plotted results, forming the 
absorption trendline.  
At 830 nm for post-menopausal breast tissue, the mean reduced scattering coefficient value 
of ~8.8 cm
-1
, and the average absorption coefficient of approximately 0.056 cm
-1
, were 
selected for use. 
6.3 Optical Phantom Fabrication Techniques 
In the creation of turbid phantoms for spectroscopic diagnosis, both µs’ and µa must be taken 
into consideration.
249
 Materials historically used for optical phantoms in a biomedical setting 
include intralipid, agarose, and animal substitutes, such as porcine fat and muscle. Whilst the 
porcine tissues can be layered, the liquid phantom is unable to create inhomogeneous layers 
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of realistic complexity within itself. Though the optical density of diluted Intralipid is closely 
related to that of tissue, the scattering anisotropy value of g = 0.8 is decreased from that of 
tissue (g = ≥0.9).250 Another drawback is the unstable nature of these materials, having a 
short working life-span – for intralipid and agarose this can be no more than two months, 
whilst porcine tissue is around only three days, with adequate refrigeration between 
measurements. Requiring substitutions, repeatable measurements of the initial phantoms 
cannot take place over a long-time period. 
Solid materials, such as polytetrafluoroethylene (PTFE) and polyurethane (PU), hold long term 
optical stability and a greater freedom in morphological representation. PTFE and PU supplied 
as blocks, sheets or rods, can be machined to size. Castable liquids, such as 
polydimethylsiloxane (PDMS), give an extra element of flexibility, with the stability of a 10-year 
shelf life. The optical nature of the solid polymers is rudimentary, however, much like the 
agarose and intralipid phantoms, scattering and absorbing agents can be added to the PDMS 
to vary the optical properties. The refractive index of PDMS, 1.40 – 1.42, which sits within 
the mammalian soft tissue range, between 1.35 – 1.48.251  
Titanium dioxide (TiO2) and aluminium dioxide (Al3O2) are the two most common scattering 
agents used for optical phantoms, whilst an array of inks, such as India or Nigrosin, can be used 
to create further absorption within the PDMS material if required.
249,252
 The anisotropy of TiO2 
of g = 0.93 is more characteristically aligned with the scattering profile of tissue.
253
 
The solid, reproducible phantom material PDMS with scattering agent TiO2 was investigated. 
The reduced scattering and absorption coefficients of these materials, in comparison with post-
menopausal breast tissue and Caucasian skin tissue, is given in Table 6.1. The optical values 
for pork fat, muscle and dermis are also given, as a representative of breast adipose, glandular 
and skin tissue, respectively. PTFE was also measured as a possible alternate solid phantom. 
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Material 
Reduced Scattering 
Coefficient (µs’) cm
-1
 
Absorption Coefficient (µa) 
cm
-1
 
Human Breast tissue 8.8 0.056 
Human Skin tissue 
254
 15.2 0.38 
Pork Muscle
255
 2.7 0.11 
Pork Adipose
256,257
 4.5 0.8 
Pork Dermis 
258
 10.8 0.3 
PTFE 
259
 161 >0.01 
PDMS 
260
 ~0.01 ~0.01 
 
Table 6.1: The reduced scattering (𝝁𝒔′) and absorption (𝝁𝒂) coefficients of human tissues, comparative 
to the phantom materials of porcine tissue, PTFE and PDMS. 
 
The values for the PDMS are negligible as the material possesses no inherent scattering or 
absorption properties.
260
  
In determining the thickness limitation of the optical phantoms, the SESORS study by Stone et 
al. was considered: the group were able to gain a transmission signal of Raman reporter AuNPs 
at a depth of ~47 mm.
12
 However, to determine the SESORS technique within turbid 
phantoms as a proof of concept, phantoms of a reduced thickness, between 23 – 33 mm, 
was selected. 
6.4 PDMS with Titanium Dioxide Phantoms 
The suitable scattering and absorption coefficients to optically match the pre-menopausal 
breast tissue properties, as defined in Section 6.2, were selected. Although molecular densities 
change person to person, an average blood and fat content value was used to represent the 
absorption coefficients, as in Figure 6.2.
147
 In terms of a quasi-skin layer, melanin content varies 
with ethnicity – for this study, the focus is on developed world groups, represented mainly as 
Caucasian.  
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In creating the quasi-skin layer, a study by Pope et al. determined the breast skin thickness of 
the superior (0.7 – 2.3 mm), inferior (0.7 – 2.7 mm), medial (0.6 – 2.4 mm) and lateral (0.5 
– 2.1 mm) quadrants.261 This led to the average across all quadrants of 1.5 mm. Hence, this 
determined the constant thickness required for the quasi-skin layer. 
The TiO2/PDMS phantoms were produced in the same way. The preparation was modified 
from the studies by de Bruin et al and Iping Petterson et al, following the latter in the use of 
rutile TiO2, Sigma Aldrich (Missouri, USA), to provide uniform scattering at a wavelength of 
830 nm.
262,263
 The volume of PDMS, and hence quantity of TiO2 to provide the required 
reduced scattering coefficient value, was calculated to the total required mould volume. Table 
6.2 describes the required ratios, adjusted to an 830 nm wavelength from the study by 
Greening et al.
264
 
Phantom Type 
PDMS Ratio (mL) 
(10:1 base:curing agent) 
TiO2 Quantity (g) 
Breast tissue 56 : 5.6 48 mg/mL = 2.957 
Skin 9 : 0.9 74 mg/mL = 0.731 
 
Table 6.2: The ratio of PDMS base to curing agent required to fill the semi-infinite tray mould, alongside 
the respective quantities of TiO2 required to fulfil the optical scattering properties of the post-
menopausal breast and skin tissue. 
 
According to the defined ratios, the TiO2 was added to the PDMS curing agent, Dow Corning 
(Wales, UK), and sonicated to ensure an even particulate distribution. The PDMS base was 
then added to the mixture and stirred for 10 minutes until homogeneous. After placing under 
vacuum to remove bubbles, the de-gassed TiO2/PDMS liquid was poured into the moulds, 
and cured in an oven at ~85°C for one hour. Rapid cross-linking of the PDMS through curing 
minimises the “fall-out” of TiO2, improving the optical homogeneity across the whole phantom 
section.
252
  Multiple phantoms were cast from the same batch of breast tissue/skin matching 
TiO2/PDMS to reduce inter-sample variation.
249
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6.4.1 Semi-Infinite Breast & Skin Phantoms 
The desired block phantom proportions were required to consist of a semi-infinite-geometry. 
The longitudinal dimensions of the phantom must be representative of a large volume medium 
and hence ≥45 mm, reducing the lateral dissipation of photons from the system.265–267 
Transferability of experimental measurements to a clinically viable, in vivo setting is made 
feasible when measuring semi-infinite phantoms with an optical axis thickness greater than 20 
mm.
265,268
  
As such, a tray with four mould insertions was 3D printed. Additive manufacturing, or 3D 
printing, of models designed in Autodesk Inventor were completed using the Form 2, 
Formlabs (Massachusetts, USA) and the MakerBot Replicator+, MakerBot (New York, USA). 
The lateral dimensions of each mould within the tray was set at 50 x 45 x 10 mm. 1.5 mm 
depth skin phantoms, a combination of 10 and 5 mm thickness breast phantoms were cast. 
The combination of these layers allows the formation of semi-infinite phantoms, smallest 
thickness of 23 mm (1.5 mm skin | 10 mm breast | 10 mm breast | 1.5 mm skin), increasing 
by a depth diameter of 5 mm. The 3D printed tray mould and a 33 mm phantom combination 
is seen in Figure 6.3.   
Of the breast tissue phantoms, a single hole was driven in at half phantom depth using a cork 
borer, ⌀5 mm, creating a centrally positioned chamber for an AuNP containing NMR tube 
inclusion. Further breast phantom pieces remained whole, allowing layering and depth 
variation possibilities to be explored. 
 124 
 
The use of silicone releasing agent spray ensured mould reusability, granting consistency in 
both breast tissue and skin phantom production. 
 
 
6.4.2 Morphologically Representative Whole Breast Phantoms 
As with endoscopic Raman fibre optic probes, as discussed in Chapter 3, Section 3.3.3, 
incorporation of new techniques within existing ones allows the diagnostics process to be 
efficiently streamlined, eliminating patient wait times between tests and hence delaying disease 
progression. Post-menopausal patients susceptible to breast cancer undergo mammographic 
imaging via referral, or through triennial screening. Capitalising on this current diagnostic 
pathway would create minimal disruption to current procedure. Also, with the breast in a 
compressed state, tissue penetration depth required when using TRS is minimised, with the 
possibility of spot compression further reducing breast thickness and raising the ease of Raman 
photon collection. 
 
 
Figure 6.3:  Left image: 3D printed mould tray, 50 x 40 x 10 mm section dimensions, to be cast. 
The mould is seen here post additive manufacturing, yet to be removed from the base plate within 
the Form2 3D printer. Right image: The completed breast tissue and skin block phantoms, arranged 
with the inclusion space in the middle of the phantom (11.5 mm depth) at a thickness of 33 mm. 
33 mm 
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6.4.2.1 Exploration of Breasts in a Compressed State 
 
Figure 6.4: Standard, two-view mammogram images of both left and right breasts - craniocaudal, 
top level, and mediolateral oblique, bottom level - of three patients under a screening program, 
above 40 years of age. The dashed yellow line marks the margin, and hence general shape, of the 
breasts under compression of a diagnostic quality. 
269
 
 
 
Modelling morphologically representative compressed breast moulds required image analysis 
of mammograms, taking into consideration differences in breast volume and variation in 
pressure applied across the compression paddle. Gaining this understanding of breast shape 
under mammographic compression was an important first step prior to mould making.  
The general, guideline shape can be seen in both craniocaudal and mediolateral oblique 
mammographic images of  
Figure 6.4. To produce a radiographic exposure with consistency in contrast, the compression 
paddle applied must create an even thickness across the whole of the breast, from chest wall 
to nipple. Following this knowledge and the guideline shape, whilst taking into consideration 
the 177.8 mm NMR tubes requiring stable inclusions, a flat sided, elongated, “D” shape was 
chosen. The 3D model and phantom casting process is seen in Figure 6.5. 
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6.4.2.2 Formation of Breast Phantoms 
 
Figure 6.5: Left image: The 11 mm half breast mould design in Autodesk Inventor; Right image: 
Casting progress of one half of the 22 mm breast tissue phantom. The two rows of holes positioned 
at the back of the mould are covered using PTFE tape to avoid leaks. Two ø 5 mm PTFE rods are 
pushed through and affixed into position at a depth of 60 mm into the phantom.  
 
 
Breast tissue phantoms sized 25 mm, 27.5 mm and 30 mm were selected. 3D models of the 
breast moulds were created using Autodesk at three, half sizes: 11 mm, 12.25 mm, and 13.5 
mm. This allowed the two halves of the phantom to be made individually in the reusable 
moulds, avoiding as much TiO2 planar fall-out as possible. Hole positioning using ø 5 mm PTFE 
rods was selected prior to casting, forgoing the need to bore inclusions post-cure. Due to the 
thin walled nature of the moulds, “High Temperature” resin was used to minimise the effects 
of heat shrinkage when placed within the curing oven. 
6.4.2.3 Quasi-Skin 
An encompassing quasi-skin layer was produced, representative of the optical properties of 
skin and the morphological nature of the breast. Large tray moulds, similar to that of the study 
by Saager et al, were 3D printed at a 1.5 mm fillable depth, as an average breast skin 
thickness.
270
 An excess of quasi-skin was cast to ensure an even, un-stretched layer over the 
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tissue phantom. A bidirectional spirit level was used, as seen in Figure 6.6, as the nature of a 
thin TiO2/PDMS layer requires precise, even curing. 
 
Figure 6.6: The bidirectional spirit level placed within the oven; a close-up of the centred bubbles. 
 
 
The quasi-skin was required to wrap round the curved features of the breast phantom as 
seamlessly as possible. An area of the quasi-skin was required to be removed. This was 
calculated by subtracting the filleted surface area of the breast phantom from the assumed 
cuboidal area, detailed in Figure 6.7.  
Figure 6.7: Quasi-skin template sector removal maths. The filleted surface area considers the skin 
thickness of 1.5 mm.  
 
 
The 68.702 mm
2
 area for removal was distributed over seven sectors, placed evenly across 
the fillet in 22.5° segments, equalling a total area of 9.815 mm
2
 per sector. The sector shape 
8.639 mm 
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geometry was calculated in three steps: finding the individual length of each sector, the angle 
of the sector and consequently the sector arc length. 
To create a smooth surface layer, the sector length was required to begin half way along the 
length of the curve. As such, the half curve length was calculated: 
 
𝐶𝑢𝑟𝑣𝑒 𝐿𝑒𝑛𝑔𝑡ℎ =  (
2 𝜋 𝑟
4
) 
                  (
2 𝜋 11
4
) = 17.278 𝑚𝑚 
              
17.278 
2
= 8.639 𝑚𝑚 
(26) 
The angle of the sector could then be derived from the area and length: 
 
 𝑆𝑒𝑐𝑡𝑜𝑟 𝐴𝑛𝑔𝑙𝑒 =  
𝑆𝑒𝑐𝑡𝑜𝑟 𝐴𝑟𝑒𝑎
𝜋 𝑟2
 
9.815
𝜋 8.6392
=  7.534° 
(27) 
 
Hence, the arc length could be calculated: 
 
               𝑆𝑒𝑐𝑡𝑜𝑟 𝐴𝑟𝑐 𝐿𝑒𝑛𝑔𝑡ℎ =  
𝑆𝑒𝑐𝑡𝑜𝑟 𝐴𝑛𝑔𝑙𝑒
180
 ×  𝜋 𝑟 
7.534
180
 ×  𝜋 8.6395 =  1.136 𝑚𝑚 
(28) 
 
The full template design could therefore be produced using the 2D plotting software in 
Autodesk, see Appendix for all three templates. The annotated template is seen in Figure 6.8. 
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Figure 6.8: Final template for 25 mm breast phantom half quasi-skin. The dotted lines highlight the 
cut-out segments, with the shaded area denoting areas to be removed, including a 5 mm area of 
provision.  
 
 
Once precisely cut to shape, the quasi-skin was affixed to the tissue, initially with double-sided 
tape and then more robustly with a thin layer of PDMS. This process was repeated for the 
12.25 mm and 13.5 mm breast phantoms halves. The final 25 mm breast phantom can be 
seen in Figure 6.9. 
 
 
 
 
Figure 6.9: Two views of the completed 25 mm optical breast phantom, displaying the continuous 
nature of the quasi-skin on the surface. 
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6.5 Scattering and Absorbance Plots 
The scaling of light scattering in terms of phantom thickness was measured in relation to pork 
fat and muscle tissue, as a commonly used optical phantom representative of breast tissue.  
Though mice are traditionally used as disease models, for toxicological and pathological studies 
porcine tissues are being chosen as an alternative over dog or monkey due to their similar 
anatomical functionalities to humans.
269,285,286
 
For consistent characterisation and comparison across the materials, semi-infinite layers were 
produced in sections of 10 mm thickness, with an experimental standard of 1.5 mm quasi-skin 
also measured.  
The Transmission Raman set-up, detailed in Section 7.2, and a power meter PM100D, 
Thorlabs (New Jersey, USA), with a 400 – 1700 nm, 500 mW, silicone photodiode power 
sensor, S121C, Thorlabs (New Jersey, USA) was selected for the characterisation of the 
phantom materials. At each thickness, several power meter measurements were recorded (6 
± 3) and averaged up to a 40 mm thickness. This value was divided by the laser power at the 
sample illumination point (300 mW) to calculate the logarithmic value (𝐼/𝐼𝑂) for each phantom. 
The results for the TiO2/PDMS breast and skin phantoms against PTFE, and pork adipose and 
muscle tissue is presented in  
Figure 6.10. 
The grey shaded area behind each of the materials denotes the highest and lowest intensity 
measurements at each thickness point. Variability between measurements was considerably 
higher for all pork tissue samples, with the PTFE and TiO2/PDMS phantoms remaining largely 
consistent throughout testing. However, due to the variability of measurements of highly 
scattering materials the quantity of light detected by the power meter either great, as with the 
1.5 mm skin phantom, or very little, with the breast phantom at 40 mm. This leads to 
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inconsistencies. Another factor leading to variability is the nature of the material. Unlike the 
rigid polymer structure of PTFE, pork tissues are inherently disorganised, leading to a wide-
ranging measurement catchment. 
 
Figure 6.10: A logarithmic intensity scale graph of the breast and skin phantoms, ranging in thickness 
from 1.5 to 40 mm, against PTFE, and a combination of pork adipose and muscle. The shaded grey 
areas map the highest and lowest intensity points for each of the materials power meter 
measurements. 
 
 
At a 10 mm thickness, the breast tissue phantom closely optically matches density of the pork 
muscle. As the thickness increases to 40 mm, the values trend towards the pork adipose 
measurement. This is representative of post-menopausal breasts at variable sizes – with an 
overall increase in breast thickness, the ratio of glandular to adipose tissue increases, trending 
towards “fattier” breasts. The skin phantom values are of a greater optical density than either 
the pork fat or muscle, as expected with the highly scattering characteristics. The absorbance 
of the PDMS at increasing mg/g concentrations of TiO2 was also assessed using the UV/Vis 
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Spectrophotometer, details of which can be found in Section 5.2. The results are displayed in 
Figure 6.11. 
 
Figure 6.11: Absorbance spectra of Sylgard with increasing quantities (mg/g) of TiO2 within the 
PDMS. The inherent absorbance of plain PDMS is minimal at around 0.001, with an absorption 
peak at 908 nm. The scattering nature of the TiO2 causes the absorbance intensity to increase. 
 
 
The absorbance of plain PDMS (Sylgard 184) is minimal, extending above 0.01 AU at two 
separate points – a peak at 908 nm and a smaller “extended” peak area across 1008 – 1030 
nm. These inherent absorbance peaks remain with the addition of TiO2 (mg/g) to the PDMS, 
with an overall trend of an increasing absorbance value due to the highly scattering nature of 
the material. 
6.6 Discussion and Conclusions 
An understanding of the inherent material properties of the PDMS and how the concentration 
of TiO2 determines the characterisation of the phantom for both post-menopausal breast 
tissue and skin tissue optical properties were explored. The PDMS material desirable qualities 
of higher optical stability and prolonged shelf-life, comparative to liquid phantoms, dictated its 
use as the scattering agent vehicle. 
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The relation of the phantom logarithmic intensities in comparison to porcine adipose and 
muscle tissue values confirmed the desired optical properties had been met for each. The skin 
phantom displayed the desired highly scattering properties, whilst the breast phantom had a 
low level of absorption and scattering matching closely to the values of the pork adipose tissue. 
This denoted optical property matching comparable to that of post-menopausal breast tissue. 
 
Figure 6.12: Double integrating sphere for simultaneous transmittance and reflectance 
measurement: (1) incident beam, (2,7) entrance port, (3) exit port, (4) diffuse reflected photons, (5) 
sample, (6) transmitted photons, (8) integrating sphere.
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Calculation of the absolute absorption and reduced scattering coefficient values of the 
phantoms can be made using of a single or double, visualised in Figure 6.12, integrating sphere, 
determining the total transmittance and reflectance of a sample. 
This technique requires the use of a microtome, as the sample thickness must be reduced to 
one MFP length, or 0.1 mm. Structural integrity of the material post-microtome is a major 
area of concern, with possible weak or breakage points being incorporated into the sample. 
Furthermore, the mathematical modelling of the phantom optical properties requires the use 
of the inverse adding–doubling algorithm within a robust Monte Carlo simulation.107 This level 
of optical density specificity was beyond the scope of this thesis. Unlike the sourced values of 
µ𝑎 and µ𝑠′, there is limited transferability of published results from single/double integrating 
sphere studies.  
To gain smoother depth transition possibilities, the dimensions of semi-infinite phantom 
sections could be reduced to a 2 mm thickness. This however brings inconsistencies into 
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phantom reproducibility, which is more easily avoidable with the manufacture of ≥5 mm 
sections. Additional layers of subcutaneous adipose tissue between the skin and breast tissue 
would add another dimension of realism to the phantom. The adoption of a spin-coating 
technique, as used by Lurie et al in the creation of bladder phantoms, could be adopted to 
circumvent pouring discrepancies and establish additional tissue (glandular/adipose) layering.
272
 
Moreover, future work into manufacturing phantoms with tumour or microcalcification 
occlusions present, as with 3D anatomical training models, could also be investigated. This 
level of phantom manufacture did not fall within the remit of possibility for this thesis. 
Additional absorption properties derived from the inclusion of India Ink within the phantom 
was not explored within this thesis. Undoubtedly this is an area which could be improved 
upon. Furthermore, changing the absorption properties of the skin layer to represent distinct 
levels of pigmentation would increase phantom applicability across different races.  
The effect of compression upon the breast could not be mechanically represented. This is an 
area of interest as compression forces may vary comparatively to stationary optical density 
values. This has been previously studied using freeze-thawed polyvinyl alcohol phantoms for 
realistic simulation of compression, however repeatability issues occurred with prolonged 
storage.
273
 
The use of PDMS/TiO2 phantoms within the Raman/SERS field is minimal, with turbid 
phantoms of this nature more widely used in the realms of X-radiation dosimetry 
characterisation
249,274
, diagnostic imaging (both x-ray and ultrasound) studies
150,231,243,252,270
, and 
optical coherence tomography (OCT)
262,272,275
. The incorporation of optical biomedical 
techniques within the current diagnostic remit is essential to ease clinical transferability. The 
production of morphologically representative phantoms, presented as within the imaging 
modality setting, is therefore key. With the foundations for the depth analysis of RR-AuNPs 
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set, the experimental design and set-up for the two phantom types is pursued within the 
following Chapter.  
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7. SESORS of Breast Phantoms: 
Experimental Design 
7.1 Introduction 
This chapter explores the incorporation of the reporter labelled AuNPs within the turbid breast 
phantoms at defined inclusion positions. Point measurements of singular inclusions forms the 
depth intensity profile for each of the Raman reporters, whilst Raman mapping with several 
inclusions determines the ability to distinguish the depth position of the AuNPs in phantoms of 
increasing thickness.  The experimental design and data analysis of such is investigated in 
separate Chapters – Chapter 8 and Chapter 9 respectively. 
Several components and design constraints needed to be met prior to experimentation. 
Section 7.2 details the deep Raman Transmission set-up. Section 7.3 covers the hardware 
(7.3.1), software (7.3.3) and electrical (7.3.2) elements required for the design and 
development of an automated stage, permitting motorised and semi-autonomous 
transmission Raman mapping. Section 7.4 explores the theory and implementation of a 
dielectric bandpass filter, or “photon diode”, incorporated into the experiments using purpose-
designed and 3D printed instrument holders. The concentration of NPs (NPs/mL) for 
experimental use was adjusted and monitored in relation to previous biocompatibility dose 
studies, ensuring the viability of in vivo transferability is upheld, explored in Section 7.5. The 
summarisation of all sections is followed up in Section 7.6. 
7.2 Deep Raman Spectroscopy – Transmission Set-Up 
The system used for transmission Raman spectroscopy of large, turbid samples consisted of 
optics from Thorlabs (Newton, New Jersey, USA), a spectrometer from Kaiser Optical 
Systems (Ann Arbor, Michigan, USA), and a CCD detector array from Andor (Belfast, UK).  
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Unlike the micro-Raman, the initial optical set-up is completely open, allowing adjustments 
and versatility in sample orientation and measurement. This initial zone is depicted in Figure 
7.1. 
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A monochromatic, 830 nm laser (Innovative Photonic Solutions), with ~300 mW sample 
illumination power, is used. To supress spectral deviation, laser line filters (FL830-10, 
Thorlabs) ensures a wavelength centred illumination source, collimated to 25 mm. 
Focal lenses direct the light through the sample and to the holographic notch filter removing 
Rayleigh scattering. The inelastically scattered light is focused to a fibre optic collection bundle, 
configured in a “round to linear” formation. This increases the coupling efficiency to the 
spectrometer allowing a high throughput of light, retaining resolution whilst gaining sensitivity 
and SNR.  
The spectrometer and CCD set-up is depicted in Figure 7.2. The linear collection fibre bundle 
is orientated to match alignment with the 100 µm entrance slit, positioned after a second 
holographic notch filter, removing any stray elastically scattered light which may have entered 
the system. 
 
Figure 7.2: Kaiser Optical Systems HoloSpec ƒ/1.8i Spectrometer and Andor iDus 420 CCD – the 
collected light passes through the holographic notch filter, removing Rayleigh scattering; an entrance 
slit collimates the beam; a holographic grating disperses the Raman signal directly onto the CCD 
array. 
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A transmissive holographic grating is used to efficiently disperse the wavelengths of light. 
Spectrometer efficiency is very high. Comprised of a low f-number (1.8), with high etendue, 
a large fraction of the collected light can be measured. The CCD array is comprised of 1024 
x 256 pixels, sized 26 x 26 µm, and is thermoelectrically cooled to -75°C. Deep deletion 
permits a high quantum efficiency, whereby the likelihood of photon to photoelectron 
production is at a peak of 95%. 
Prior to single-point measurements or mapping, the system is calibrated using the characteristic 
spectral peaks of pure aspirin (acetylsalicylic acid). The intensity of the laser at both the 
immediate illumination point and sample illumination point was collected using a power meter, 
PM100D, Thorlabs (New Jersey, USA), with a 400 – 1700 nm, 500 mW, silicone photodiode 
power sensor, S121C, Thorlabs (New Jersey, USA). The data was logged for quality assurance 
purposes.  
An infrared conversion viewer, IRV2, Laser2000 (Cambridgeshire, UK), was used for 
necessary optical realignment and through the deep Raman experiments to ensure laser 
position upon the turbid samples. 
7.3 Stage Set-Up and Automation 
7.3.1 Hardware – Optomechanical Stage Set-Up 
To map the AuNPs positioned within the phantoms required the design of an x,y movement 
motorised stage (Standa, Lithuania)  with an adaptable sample holder attachment for versatility. 
Prior to purchase, the required optomechanical components (Thorlabs, New Jersey, USA) 
were mapped out using SolidWorks, as in Figure 7.3, to ensure workability within the optical 
constraints of the deep Raman set-up. 
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Figure 7.3: Solidworks curated, digitally planned stage design schematic of the motorised stage 
(Standa, Lithuania), in light grey, configured to an x,z movement range utilising angled brackets 
(Thorlabs, New Jersey, USA); other optomechanical components (Thorlabs) were used in the 
creation of the adaptable sample platform. The design is laid out as if upon the optical table. 
 
 
After physical stage set-up, the mechanisation of external CCD triggering in response to stage 
movement was required. This would allow automated Raman mapping, requiring only the 
computerised set-up prior to Raman measurement.  
7.3.2 Electrical Hardware – 5V Pulse Amplifier 
Getting the stage to “speak” to the CCD required some electronics and circuitry building. 
Using a multimeter, the voltage of the initial pulse from the stage registered at 3.29V. To trigger 
a spectral capture response, the CCD required a pulse of ~5V. Hence, an n-p-n transistor 
diode, consisting of silicon doped with boron/aluminium (p-type) sandwiched between 
arsenic/phosphorus doped silicon (n-type) was used. Triggering the gate with the initial stage 
pulse enabled the higher potential difference (4.84 V) applied to the terminals of the transistor 
to be applied to the external CCD trigger. The circuit design in principal and actuality is seen 
in Figure 7.4. 
90° Angled 
Brackets 
x,z Configured 
Motorised Stage 
Adjustable Sample 
Platform 
Optical Table 
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When connected to three AA batteries, forming 4.84V, and a 470Ω resistor, creating 
impedance strong enough to protect the transistor and circuitry, a pulse amplification strong 
enough to trigger the CCD was garnered. After initial circuit testing using a breadboard with 
LED output substitutes, the components, cables and battery pack were soldered to a copper 
circuit board. The configuration for the D-sub 9 pin stage connector was soldered to the 
synchronisation output (8) and ground (9) pins. A 3D printed box housing the circuit and 
battery pack was designed and manufactured, encapsulating the circuitry with the female SMB 
and D-sub 9 pin able to freely connect to the CCD and motorised stage, respectively. 
  
Figure 7.4: Top image: circuit design of the 5V pulse amplifier. The npn transistor connects to 4.84V 
from 3 AA batteries, with a resistor, R, of 470Ω was used for impedance. Bottom image: the 
completed pulse amplifier circuit within the 3D printed box with a hinge and magnetic closing 
mechanism. The electronic components were soldered onto a copper circuit board. A battery pack 
was used to keep the AA batteries together. Once the connector cables were soldered, a dab of 
hot glue was applied for longevity. 
D-sub 9 pin 
(Stage) 
Female SMB 
(CCD) 
Hinge and Magnet 
Mechanism  
3D Printed Case 
Cable 
Grooves 
470Ω Resistor 
NPN Transistor 
4.84V 
CCD 
+ 
STAGE 
Initial Pulse 
R = 470Ω 
C 
E 
B 
npn 
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7.3.3 Software – Andor SOLIS and Matlab Programming 
Mapping of the desired area under specific acquisition measures were parameters required to 
be adjustable for flexible use of the automated stage. Internal programming within the Andor 
SOLIS for Spectroscopy software and an outward Graphical User Interface (GUI) MATLAB 
program were developed to define the measurement and stage movement specifications 
respectively. An example of the two programs can be seen in Figure 7.5.  
  
Figure 7.5: An example of the MATLAB GUI program and internal Andor SOLIS program for kinetic 
mapping from an external start trigger source. 
 
 
The MATLAB program observes the translation range limits of the motorised stage. When the 
stage is positioned at the uppermost distal point of the desired map area, the button “Set 
Corner 1” is pressed. The lowermost point in diagonal relation is manually translated to where 
“Set Corner 2” is pressed, applying the blue line-raster within the GUI map area under the set 
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horizontal and vertical step size. The red circle defines the current position of the stage, with 
the estimated mapping time length and number of scanning points detailed below. 
The acquisition parameters, measurement time, number of accumulations and auto-save file 
names, are defined within the main Andor software. The curated internal program defines the 
trigger as an external source [SetTriggerMode(6)] and ensures the acquisition is run under the 
kinetic scan mode [SetAcquisitionMode(3)]. The kinetic scan mode required the pulse amplifier 
start signal to be used to begin the scan, rather than at every scan point. This reduced the 
amount of electrical noise within the system, increasing the sensitivity and hence SNR of the 
collected spectra.  
The number of scanning points, plus one, is entered within the run counter ensuring the whole 
of the map scan points are saved. The “Time of acquisition” within the GUI is adjusted with 
extra 1 second time length to ensure the measurement is complete prior to stage movement.  
7.4 Photon Diode 
7.4.1 Background and Theory 
 
Figure 7.6: Diagrammatic of the dielectric bandpass filter, or photon diode, in transmission against a 
turbid sample. As seen, photons rarely pass back through the unidirectional mirror which retransmits 
most Raman photons to the detector. 
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The use of a dielectric bandpass filter, or photon diode, enables light which has been 
backscattered at an acute angle to the laser source to be reflected back into the system.
276–278
 
This increases the number of interacting light photons and hence the potential for Raman signal 
to be collected. 
A 25-mm photon diode centred at 830 nm with a bandwidth of 3.2 nm, Max Laser Line Filter 
LL01-830-25, Semrock (New York, USA) was placed over the laser beam deposition area on 
the sample. The filter has a transmission at 830 nm of >90%.
265
 If the angle of incidence 
changes, the wavelength of light possible to pass through the filter is shifted, as seen in Figure 
7.7. Keeping the photon diode perpendicular to the optical axis is important in enabling 
maximum laser transmission and off axis backscattered reflection. 
 
Figure 7.7: A graph to show the importance of the photon diode remaining perpendicular to optical 
axis: transmission versus wavelength for normal and oblique incidence, whereby the wavelength 
shifts with a change in angle.
265
 
 
 
Minimal air-gap interface between the phantom and photon diode is another key aspect. The 
majority of laser photon losses occur at the air-sample interface, which increases with highly 
scattering samples.
277
 As such, positioning the photon diode with a minimal air-gap interface 
to the optical phantom reduces unwarranted photon loss, increasing the effectiveness of the 
technique.  
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7.4.2 3D Printed Photon Diode Holders  
As discussed, the key factors in ensuring optimal photon diode use include a constant 
perpendicular angle to the optical axis, and a very minimal air-gap interface. To ensure both 
factors were consistently met for individual point spectra and mapping purposes, photon diode 
holders were designed in Autodesk Inventor and manufactured using the MakerBot and Form 
2 3D printers.  
The point measurement photon diode holder was designed to securely slide onto the base 
component of the motorised stage arm. This was then locked into place on the underside of 
the platform base using two sets of nuts and bolts, as seen in Figure 7.8. The motorised stage 
was configured to an x,y formation, allowing the focal length to be adjusted depending on the 
phantom thickness. 
 
Figure 7.8: Left image: The point-measurement photon diode holder designed in Autodesk 
Inventor. The gully slot measures 4 mm in depth, safely securing the photon diode; Right image: 
The 3D printed holder slid into place on the x,z motorised stage arm and secured with two sets of 
nuts and bolts. 
 
 
As shown in Figure 7.9, levelling of the holder platform was ensured using a bidirectional spirit 
level, and the 90° position of the photon diode checked with a metal rule. This design did not 
require any extra fixings to hold the photon diode at a constant perpendicular angle.  
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Fixings 
 146 
 
 
 
On the other hand, the mapping photon diode holder was required to remain in a fixed 
position within the optical axis, without interference of motorised stage movement. Hence, 
the model was designed to affix atop an optomechanical post using a screw within a counter 
bored hole. This eliminated illumination path interference. The optical post was secured to 
the optical rail between the two focusing lenses, affront the breast phantom. 
 
Figure 7.10: Left image: The mapping photon diode holder designed in Autodesk Inventor. A 
counter bore was designed to accommodate the cap head of the screw into the optical post. The 
25 x 3.5 mm recess encompasses three sides of the photon diode, allowing a minimal air gap 
phantom interface; Right image: The 3D printed holder with photon diode secured to the optical 
post, in line with the illumination path. Extra blu-tack pieces were used to ensure stability. 
 
Figure 7.9: Left image: bidirectional spirit level confirming the stage platform is balanced; Right image: 
the photon diode positioned within the slot – the solid metal rule confirms the 90° angle of the 
photon diode. The x,y motorised stage allows the 60 mm focal length to be adjusted dependent on 
phantom thickness. 
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The Autodesk Inventor design and complete set-up, including the breast phantom with a mid-
centrally located NMR tube, is seen in Figure 7.10 and Figure 7.11.  
Respective 3D printers were used due to the difference in the nature of the additive material. 
The MakerBot printer, used in the creation of the single point measurement PD holder, utilises 
Fused Deposition Modelling (FDM) whereby a heated plastic filament is extruded, building 
upon the previous additive layer. 
 
 
The mechanical properties of this macro layered structure provide a surface by which the 
photon diode can be inserted into a gully and “gripped” by the material, requiring no extra 
supportive features. Comparatively, the Form2 3D printer, for the mapping PD holder, 
operates using vat photopolymerisation. This method creates micro layers of hardened plastic 
via a UV laser projecting upon the photosensitive, liquid polymer resin. This technique 
provides a smooth surface finish to the build, decreasing the drag of the material across the 
 
Figure 7.11: Transmission Raman set-up of the morphologically representative breast phantom 
including the photon diode. Left image: Two metal arms, clamped to hold the phantom in 
position, fixed to the x,z stage allows the full range of movement for photon diode enhanced 
mapping to occur; Right image: A top-down view including an NMR tube within the middle breast 
phantom hole. Each phantom is adjusted to adhere to the 60 mm focal length. 
Adjustable 
60 mm 
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phantom interface. Blu-tack was required against the back of the photon diode, seen in Figure 
7.10, required to maintain the 90° angle between the laser and phantom interface. 
7.4.3 Optical Phantom Power Meter Plots with Photon Diode 
The efficiency of the photon diode against the two TiO2/PDMS phantom types of skin and 
breast tissue, seen in Figure 7.12. 
 
 
 
  
Figure 7.12: A graph to show the logarithmic, power meter intensities of the breast and skin 
phantoms, with and without a photon diode, measured in transmission; and a table to show the 
percentage change of light intensity produced with a photon diode present. The standard laser 
intensity at the sample illumination point, 300 mW, was selected. 
     Light Transmission Increase with Photon Diode (%) 
                        Width (mm) 
Phantom Type 
1.5 10 20 30 40 
Breast Tissue N/A 61.26 80.65 258.61 236.80 
Skin Tissue 152.85 132.68 588.68 1438.60 1778.62 
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As previously discussed, at each thickness four measurements were logged, averaged, and 
divided by the laser power at the illumination point (300 mW) to calculate the logarithmic 
value (𝐼/𝐼𝑂) for each phantom, up to a 40 mm thickness. The boundaries of the grey shaded 
areas at each point represent the maximum and minimum values recorded. Overall, the 
variation in sample measurement decreases for both the skin and breast phantoms with 
photon diode use, with an increase in light transmission by up to 2 orders of magnitude.  
7.5 AuNP Inclusions and Dose Biocompatibility 
The optical phantom design required accessible and dispensable vessels for containment and 
positional flexibility, with the added benefit of storage ease. As such, borosilicate glass NMR 
tubes, ColorSpec NMR tubes (ø5 mm × 177.8 mm), Sigma Aldrich (Missouri, USA), were 
selected for use. 
The photoluminescent nature of the 1 mm combined wall thickness of borosilicate glass, 
alongside quartz (a standard Raman neutral material commonly used), stainless steel (used to 
analyse the drop dried nanoparticles under micro-Raman), and the Raman spectrum of an 
Eppendorf tube, is seen in Figure 7.13.  
Figure 7.13: Photoluminescent and Raman (Eppendorf) spectrum of four sample holder materials – 
stainless steel slide was used in Chapter 6 for the micro-Raman testing of the AuNPs. 
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The ideal material for encasing the NPs for the following experiments would be quartz. 
Despite this, quartz is an impractical material comparative to the economic and replaceable 
nature of borosilicate glass NMR tubes. The pre-processing techniques used to reduce the 
spectral contribution of the NMR tube photoluminescence, increasing the SNR of the AuNPs, 
is discussed in Chapter 9, Section 8.2. 
The ability to garner a Raman signal of the AuNPs at large depths required consideration as to 
the ideal NPs/mL concentration, with nanoparticle dose presenting as the biocompatible 
limiting factor.  
Mouse model toxicology studies of PEGylated AuNPs delivered at an ~4 mg/kg dose 
confirmed little to no adverse growth effects, with accumulation and acute inflammation mainly 
sited within the liver.
176,178
  
 
Figure 7.14: In vitro to in vivo extrapolation and species extrapolation of doses and toxicity of gold 
nanoparticles. Blue and red lines represent model-predicted maximum concentrations of gold 
nanoparticles in the liver and blood, respectively, of humans after intravenous injection (0.001–100 
mg/kg). The dashed arrows point to where liver toxicity (0.01 mg/kg) was observed in rats (blue); 
in vitro cytotoxicity (13 μg/ml) of primary human dermal fibroblasts (purple); and haemolysis (50 
μg/ml) of red blood cells (orange). The solid arrows point to the model-predicted human equivalent 
dose (HED) associated with the reported in vitro cytotoxicity (HED = 1 mg/kg), haemolysis (HED 
= 5 mg/kg) and in vivo toxicity (HED = 0.005 mg/kg). Adapted from
167
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Due to the similarity in liver to body weight ratio, the results from rats and pigs is considered 
to have a greater transferability to humans.  As such, dose models and the related toxicological 
effects adapted from the review by Lin et al have been selected as reference for the study. 
The known toxicological effects from both in vivo and in vitro experimental work of rats and 
human cells, and computational pig models, have been plotted to the human equivalent dose 
(HED), seen in Figure 7.14.
167
 
Hence, it is generally considered that a low, safe AuNP HED model is ~0.01 mg/Kg. The 
average female body weight within the UK, at time of writing, is 70.2 Kg, relating to an AuNP 
dose of 0.702 mg. The concentration of the 80 nm AuNPs is 0.052 mg/mL. After depth testing 
for a sufficient enhanced Raman signal at a low acquisition time (10 seconds), the AuNP 
concentration of 0.156 mg/mL, or a dose of 0.156 mg/g, was found to be ideal. This is 
equivalent to 2.91 x 10
10
 NPs in 1.2 mL, after centrifugal concentration from 3 mL. This 
concentration of AuNPs is representative of the mg/mL dose required within the area the of 
the breast tumour.  
Tumours of an ellipsoid geometry which lie between the T1/T2 classification of early breast 
cancer (≤2.5 cm) have been found to have a volume between 1.257 – 5.12 cm3.279–282 Under 
the assumption that tumour tissue density lies closer to that of muscle (1.057 g/cm
3
)
283
 than 
adipose tissue (0.9 g/cm
3
)
284,285
, the mass of a stage T1/T2 tumour is approximately 1.328 – 
5.412 g. Therefore, 0.207 – 0.844 mg of AuNPs of the 0.702 mg HED would be required 
to accumulate within the tumour. Remaining on the conservative end of tumour volume and 
considering a high percentage of AuNP uptake, the experimental dose selected is sufficiently 
biocompatible. 
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7.6 Summary 
Several features of the experimental design set-up required for depth analysis of the three RR-
AuNPs have been outlined. 
Success with the optomechanical design and automation of the translated x,y motorised stage 
put several skill sets to use – hardware, software and electronic circuitry were all required in 
the completion of the project. Automation of the mapping process allowed a rapid and efficient 
workflow, enabling a diversification and increase in the possible work load one could undertake 
– an unavailable luxury prior to the design and implementation of the pulse amplifier and GUI 
mapping system. This automated design may be taken as a protocol for future mapping 
systems within open optical set-ups. 
The benefit of photon diode use lies within the preservation of laser photons within the 
system, increasing the likelihood of Raman photon creation and hence transmission to the 
collection system and the CCD. The purpose designed 3D printed PD holders were 
manufactured with two key factors in mind – the need for a constant perpendicular angle to 
the optical axis, and a minimal air-gap-interface. The design of the singular point measurements 
successfully meets both criteria. The technicalities introduced with mapping (requirement of a 
fixed position isolated from stage movement; the moving phantom interface whilst mapping; 
staying in-line with the optical axis whilst avoiding unwanted interaction with the stage) 
presented a challenge. The trade off in material properties allowed the interface to smoothly 
traverse but hindered the security and fixed angle of the PD. This was countered with the use 
of fixing agents; however, a more robust design/solution could have been found. 
Another possibility which could have been explored, especially with the morphologically 
representative phantom, would have been the use of a fully encasing uni-directional mirror.
276
 
SESORS of Breast Phantoms: Experimental Design 
153 
 
This approach could eliminate photon losses from the system, apart from at the transmission 
exit point. This would be an interesting idea to pursue in future works. 
Optimising the RR-AuNP concentration (NP/mL) required consideration of a biocompatible, 
low dose model, whilst garnering an enhanced Raman signal at depth. These measures were 
met with a tumour specific dose of 2.91 x 10
10
 NPs in 3 mL, equating to a maximal dose of 
0.012 mg/Kg, remaining within the remit of a low HED model.  
Replaceable RR-AuNP inclusions were implemented with the use of borosilicate glass NMR 
tubes. The photoluminescent contribution to the spectrum of these NMR tubes can be 
eliminated, along with cosmic rays and inherent background noise, using pre- and post-
processing techniques. This improves the SNR, “amplifying” the inherent RR-AuNP signal. The 
techniques applied for this purpose, and the resulting analysis of the experimental findings, are 
discussed in the next Chapter. 
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8. SESORS of Breast Phantoms: 
Results and Analysis 
8.1 Introduction 
Following on from the experimental design set-up from the previous Chapter, the analysis of 
results is discussed here forth.  
Section 8.2 details the pre- and post-processing techniques used across the data, and the 
importance of such methods in the analysis of both point spectra and maps. The first depth 
profiling experimental results using semi-infinite breast phantoms of increasing thickness and a 
consistent AuNP inclusion step size depth is explored in Section 8.3. Section 8.4 follows on 
from this with the use of the morphologically representative breast phantom in a 
mammographically compressed state – the depth position of three 2-NT-AuNP inclusions is 
evaluated. The discussions and conclusions, Section 8.5, assesses the capabilities of un-
targeting reporter NPs, concluding on future works necessary to develop a targeted probe for 
deep Raman applications.  
8.2 Data Analysis: Pre- and Post-Processing Techniques 
All data analysis was completed using MATLAB R2014b, The Mathworks Inc. (Massachussetts, 
USA) with occasional graphs plotted in Excel, Microsoft (New Mexico, USA). All PCA was 
completed using the research group developed MATLAB programming and GUI. 
Single-point micro and deep Raman measurements are pre-processed using subtraction and 
baseline removal techniques, the advantages of which can be seen in Figure 8.1. The phantom 
spectrum undergoes subtraction from the AuNP inclusion measurement, allowing the spectral 
features of the RR-AuNPs within the NMR tube to remain. The photoluminescence garnered 
from the NMR tube, discussed in Chapter 8, Section 7.5, is then removed using the baseline 
subtraction. This technique uses a polynomial fit below the spectral line to remove the 
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background noise and photoluminescence, allowing the underlying RR-AuNP spectral features 
to feature more predominantly. 
 
 
When determining the objective signal to noise ratio (SNR) of a peak intensity of a Raman 
band, the following equation can be used: 
𝑆  
𝑆𝑁𝑅 = 
𝜎𝑦 
    (29) 
 
 
Figure 8.1: 3 mL concentrated 2-NT AuNPs within NMR tube, within 10 mm breast phantom pre-
processing techniques. Top Left: the standard 10 mm breast tissue phantom spectra; Top Right: 10 
mm breast tissue phantom with 2-NT AuNP in NMR tube occlusion; Bottom Left: the breast tissue 
phantom subtracted spectrum – the photoluminescence from NMR tube within the can be seen, 
with the polynomial baseline subtraction represented by the pink dashed line; Bottom Right: 
subtracted and baselined spectrum – the photoluminescent contribution is significantly reduced.  The 
acquisition for each measurement was 2 seconds at 5 accumulations. 
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whereby the average peak height above the baseline, 𝑆 , is divided by the standard deviation 
of the peak height, 𝜎𝑦. The SNR is most accurately calculated by acquiring several iterations 
of the sample spectrum for the average single peak height.
117
 
Maps were pre-processed prior to multivariate analysis using a combination of a set 
wavenumber range, cosmic ray removal, vector normalisation and mean centring.
286
  By 
applying a set wavenumber range, this reduces the size of the data set of further analysis, 
effectively streamlining the spectra to the wavenumber range of interest.  Cosmic ray removal 
is a required technique in reducing the variance of the resulting uncharacteristic spectral spikes 
from the eponymous phenomenon. A 3x3 mask median filter is applied to “smooth” the peaks 
to the averaged neighbouring pixels. A limitation to this technique is the resulting loss of spatial 
resolution. Vector normalisation reduces the effects of sample sourced variation, such as 
photon path length differences or intensity fluctuations. The normalised data is then mean 
centred, calculating the mean intensity of each wavenumber within the sample spectra and 
subtracting the difference away, placing all wavenumbers around the zero point. 
Post-processing in the form of Principal Component Analysis (PCA), a multivariate analysis 
technique, is then performed on the collected maps. PCA improves the SNR of a data set by 
reducing the dimensionality of the interrelated variables into their principal components (PC). 
A such, the first PC is the largest variant change within the data set, the second PC is the next 
largest change in variance, uncorrelated to the previous, and so on.
287
 Each PC has a 
corresponding spectral loading, detailing the spectral origin of the variance, and false colour 
map, which plots the regional differentiation between the corresponding (bio)molecules.
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8.3 Depth Profiling – Semi-Infinite Breast Phantom  
Acquisition parameters for the signle-point transmission Raman measurements were set at the 
parameters of 2 seconds and 5 accumulations, with a sample illumination intensity of 300 mW. 
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Initial point measurements of the 2-NT, 4-ATP and 4-MBA within the 10 mm breast phantom 
NMR tube inclusion are plotted in Figure 8.2. The inherent intensity of each reporter is 
displayed along each individual spectrum. 
 
Figure 8.2: Subtracted and Raman baselined spectra of the three Raman reporter AuNPs, 2-NT 
(top), 4-ATP (mid) and 4-MBA (bot), within the single 10 mm breast tissue phantom block. The 
signal intensities plotted across each spectrum is plotted in relation to the colour bar. The acquisition 
for each measurement was 2 seconds at 5 accumulations. 
 
The key characteristic peaks of each reporter are still present – with the C = O stretch (1710 
cm
-1
) of 4-MBA present to further distinguish it from the 4-ATP spectrum.  
Three phantom thicknesses were considered: 23, 28 and 33 mm. The position of the first 
inclusion was set at 6.5 mm – one 1.5 mm skin phantom layer and the 10 mm inclusion breast 
phantom section – increasing at a step size of 5 mm. The resulting spectra at the three (23 
mm phantom thickness), four (28 mm) and five (33 mm) depth positions are plotted in the 
3D graphs below. The relative peak height value of the characteristic peaks was collected using 
the Measure Peak MATLAB function, see Appendix for the code, and annotated upon each 
plot, with the resulting depth intensity profile line-plotted in black across the spectra.  
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Figure 8.3: Raman spectra of 2-NT (top), 4-ATP (mid) and 4-MBA (bot) AuNPs within 23 mm of 
breast phantom at 5 mm intervals towards the detector. Signal intensity of the spectral peaks is 
plotted in relation to the colour bar. The signal intensity depth profile of characteristic peaks 
determined by the relative peak height is line mapped. 
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At 23 mm, Figure 8.3, the depth intensity profiles for each of the RR-AuNPs vary in 
characteristic peak ratio. The depth profiles of the higher wavenumbers (1380, 1589 and 1587 
cm
-1
) differ for each of the RR-AuNPs – the greatest signal intensity is at full depth for the 2-
NT, mid-depth for 4-ATP and least depth for the 4-MBA. Conversely, the low wavenumber 
peaks (1066, 1081 and 1079 cm
-1
) having comparatively lower overall signal intensity, all gain 
in intensity with depth progression.  
At the 28 mm phantom thickness, Figure 8.4, the lower wavenumber intensity profiles remain 
consistent as before. The greater wavenumber intensity profile, however, forms a elongated 
“U” shape, whereby the signal intensity at the front-mid position (11.5 mm depth) sits at the 
lowest most point. This  signal intensity profile is similar to the findings of Vardaki et al in which 
the transition of Trans-Stilbene (TS) through an Intralipid phantom presented a higher Raman 
intensity at the foremost and distal positions of the TS, with a decreased signal across the 
middle of the phantom.
289
 The position at 21.5 mm garners the greatest signal intensity for the 
2-NT and 4-ATP; the 4-MBA, however, has a loss of intensity at this point, aligning back to 
the standard characteristic peak ratio, as seen in Figure 8.2. 
At a depth of 28 mm, the signal from 4-ATP and 4-MBA decreases dramatically. The increased 
Raman signal achieved from the 2-NT RR-AuNPs allowed depth measurements up to 33 mm, 
hindered by a reduction in SNR. 
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Figure 8.4: Raman spectra of 2-NT (top), 4-ATP (mid) and 4-MBA (bot) AuNPs within 28 mm of 
breast phantom at 5 mm intervals towards the detector. Signal intensity of the spectral peaks is 
plotted in relation to the colour bar. The signal intensity depth profile of characteristic peaks 
determined by the relative peak height is line mapped. 
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Figure 8.5: Raman signal profile of 2-NT AuNPs within 33 mm of breast phantom at 5 mm intervals 
towards the detector. Signal intensity of the spectral peaks is plotted in relation to the colour bar. 
The signal intensity depth profile of characteristic peaks determined by the relative peak height is line 
mapped. 
 
 
The 2-NT signal intensity profiles, Figure 8.5, remains consistent to both the “U” shaped profile 
in the high wavenumber region and development of the lower wavenumber intensity at a 
greater depth within the 33 mm semi-infinite phantom. 
For each of the reporters, the peak of a higher Raman shift (≥1380 cm-1) garned an increased 
overall signal intensity comparative to the lower shifted, characteristic peak. The lower Raman 
shift peaks (1066, 1081 and 1078 cm
-1
) gained signal intensity as the inclusion depth profile 
increased, moving closer towards the detector. 
The relative peak position of the Raman reporter AuNPs in relation to the inherent breast 
phantom signal is seen in Figure 8.6. 
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Figure 8.6: Raman spectra of the inherent phantom signal, with the exploded area of interest also 
containing the subtracted and baselined Raman reporters from within the 10 mm phantom. The 
main characteristic peaks for 2-NT, 4-ATP and 4-MBA are highlighted with an ‘X’ of the 
corresponding colour. 
 
 
The lower Raman shifted characteristic peaks of all reporters, and higher shift peaks for the 4-
ATP and 4-MBA are positioned upon a “blank space” area of the spectrum, having minimal 
influence from the inherent Sylgard phantom Raman peaks. The 2-NT peak at 1380 cm
-1
 lies 
directly on the shoulder of the Sylgard peak at 1410 cm
-1
, casuing a level of intereference by 
increasing the overall intnesity and hence peak height. This, along with the intrinsically larger 
Raman cross-section, leads to the 2-NT signal collection at greater depths comparative to the 
4-ATP and 4-MBA reporters. 
The difference in peak height ratio across all of the reporters is made light when analysing the 
position of the characteristic peaks upon the Sylgard absorption spectrum. Conversion of peak 
values from Raman shift (cm
-1
) to wavelength (nm) from the total wavenumbers (10248) is 
described in Equation (29), using 1066 cm
-1
 as an example: 
 
12048 − 1066 =  10982 
1
10982
 ×  107 = 910.58 𝑛𝑚  
(29) 
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The results for each of the reporter characteristic peaks are plotted in Figure 8.7. 
 
 
The reporter peaks 1066 – 1081 cm-1 lie directly upon the absorption peak of the Sylgard, 
causing the signal intensity ratio comparative to the higher wavenumber peaks to be reduced 
when positioned at the lowest depth profile (6.5 mm). The greater absorption of photons 
creates a brevity of AuNP Raman photon contribution at the wavenumber range between 
800 – 1200 cm-1 and hence a greater Raman signal from the Sylgard. The Raman photon 
contribution increases at a greater depth as the scattered photons are able to interact with the 
reporter AuNPs and be available for collection.  
With the depth profile knowledge relating to each of the Raman reporter peaks and the relative 
intensity of each of them, the 2-NT was selected for depth mapping analysis within the 
morphologically representative breast phantoms. 
 
Figure 8.7: Absorbance spectra of the plain Sylgard with the characteristic peaks of the three Raman 
reporters (2-NT, 4-ATP and 4-MBA) plotted and labelled with the corresponding wavenumber 
upon the graph. The illumination wavelength of 830 nm is highlighted with a red dotted line. 
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8.4 Depth Mapping Analysis – Morphological Breast Phantom 
For each breast phantom, the maps were measured at a sample illumination intensity of 300 
mW under the acquisition parameters of 4.5 seconds with 4 accumulations, totalling 18 
seconds. A step size of 0.9 mm both horizontally and vertically was set.  
A visualisation of the mapped area upon the laser-phantom interface is seen in Figure 8.8. 
 
Figure 8.8: Autodesk Inventor modelled 25 mm breast phantom. The mapped area and central 
crosshair is outlined in black. Left to right/front to back ordering of the NMR tube inclusions are 
highlighted, with the path of illumination also shown (red arrow). 
 
Initially, measurement of the 1066 cm
-1
 and 1380 cm
-1
 relative peak height using the Measure 
Peak MATLAB function was undertaken to provide an intensity depth profile across each of 
the breast phantom thicknesses. The results for the two characeristic peaks are shown in 
Figure 8.9. 
Front Back Mid-Centre 
Illumination 
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Figure 8.9: Two graphs to show the peak area intensity of the 2-NT characteristic peaks at 1380 
cm
-1
 (top graph) and 1066 cm
-1
 (bottom). The generalised area of the three NMR tube positions 
within the breast phantoms, front, mid-centre and back, is highlighted in orange. 
 
 
At a lateral distance of ≥6.4 mm from the first, front-left 2-NT AuNPs, no spectral contribution 
arises from the peak at 1066 cm
-1
. Spectral contribution from the peak at 1380 cm
-1
 is seen 
from the starting position of the map, at a distance of 8.1 mm. This, once again, is due to the 
peak position upon the shoulder of the 1410 cm
-1
 PDMS peak granting perceived 
enhancement. 
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The overall intensity profile shape of both characteristic peaks are in agreeance with the 
previously defined profiles visualised within the semi-infinite phantom point-measurements. 
PCA was utilised across all three depth maps to further analyse the intensity ratio of the 1066 
and 1380 cm
-1
 2-NT peaks at increasing depths. All maps were pre-processed with a set 
wavenumber range, cosmic ray removal and mean centering. 
 
Figure 8.10: 25 mm Breast Phantom, principal component 3 map and loading: The red pixels 
corresponds to the ring symmetric stretch at 1066 cm
-1
 of 2-NT, the blue pixels correspond to the 
ring symmetric stretch at 1380 cm
-1
 and 1620 cm
-1 
of the 2-NT – all three are highlighted in orange. 
The PDMS peak at 1410 cm
-1
 is highlighted in green, with the NMR tube photoluminescent 
contribution in blue. The positioning of the AuNPs are signposted in grey above and below the 
pseudo-colour map. Pre-processing: wavenumber range, median filtering and mean centring. 
 
Figure 8.11: 27.5 mm Breast Phantom, principal component 3 map and loading: The red peaks 
correspond to the ring symmetric stretch at 1380 cm
-1
 and 1620 cm
-1 
of the 2-NT, the blue peak 
corresponds to the ring symmetric stretch at 1066 cm
-1
 of 2-NT – all three are highlighted in orange. 
The PDMS peak at 1410 cm
-1
 is highlighted in green, with the NMR tube photoluminescent 
contribution in blue. The positioning of the AuNPs are signposted in grey above and below the 
pseudo-colour map. Pre-processing: wavenumber range, median filtering and mean centring. 
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Figure 8.12: 30 mm Breast Phantom, principal component 3 map and loading: The red peaks 
correspond to the ring symmetric stretch at 1380 cm
-1
 and 1620 cm
-1 
of the 2-NT, the blue peak 
corresponds to the ring symmetric stretch at 1066 cm
-1
 of 2-NT – all three are highlighted in orange. 
The PDMS peak at 1410 cm
-1
 is highlighted in green, with the NMR tube photoluminescent 
contribution in blue. The positioning of the AuNPs are signposted in grey above and below the 
pseudo-colour map. Pre-processing: wavenumber range, median filtering and mean centring. 
 
 
For each map, the third principal component displayed the 1066:1380 cm
-1
 intensity ratio 
difference, highlighted upon the spectral loadings in orange, along with the 1620 cm
-1
 peak. It 
can be seen that the influence of the Sylgard peak at 1410 cm
-1
, highlighted in green, becomes 
more pronounced with an increase in breast phantom thickness. Conversely, the residual 
photoluminescence of the NMR tube, highlighted in blue, reduces in contribution.  
AuNP positioning, left to right increasing in depth location, is highlighted in grey above and 
below the map axes. The regional differentation change displayed within the psuedo-colour 
maps switches peak dependance with an increase in phantom thickness. Within the 25 mm 
phantom, the 1066 cm
-1 
peak intensity becomes dominant at the distal location. Little 
differentiation, however, can be made between the frontal and mid-centrally located AuNPs 
intensity at 1380 cm
-1
. At 27.5 mm, reliance on both peaks occurs: the 1066 cm
-1 
peak again 
becomes dominant at complete depth, but a decrease in the intensity of the 1380 cm
-1
 
between the frontally and mid-positioned AuNPs is identifiable. The 30 mm phantom is no 
longer 1066 cm
-1
 peak dependent, with the 1380 cm
-1
 peak showing overall dominance. This 
follows the previously outlined depth intensity profiles of both peaks at a large depth. 
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8.5 Discussion and Conclusions 
The depth intensity profiles of the higher wavenumber characteristic peaks from three RR-
AuNP, generated from both the 28mm and 33 mm single-point depth measurements and 
mapping experiments, are in agreeance with the findings from Vardaki at el.
278
   
Incursions to the intensity of the lower wavenumber peaks was due to the inherent absorption 
properties of the PDMS, minimising Raman photon collection until the depth position of the 
RR-AuNPs reached a minimal detector distance. It could be argued that the laser wavelength 
selection, in terms of the relative absorption trendline, could be adjusted from 830 nm to 808 
nm. Changing the wavelength, in accordance with the biological NIR window in Figure 3.8, 
allows the illumination and Raman transmission photons greater access into and from the 
system for collection, respectively. 
Within the morphologically representative breast phantoms, determination of the position of 
the 2-NT AuNPs at depth relied on the ratio of the relative peak height intensities of the 
characteristic peaks (1066 and 1380 cm
-1
). Principal component analysis found that at a greater 
phantom thickness, the perception of RR-AuNP depth relied more heavily on the higher 
wavenumber peak (1380 cm
-1
), unaffected by the absorption profile. Singular RR-AuNP use, 
in combination with mammographic imaging, has been shown as a plausible concept.   
Multiplexed depth analysis within the morphologically representative breast phantom could 
not be perceived, due to the vast difference in intensities between the RR-AuNPs. Introducing 
a ratio of RR-AuNPs dependent on the signal intensity they produced would allow the 
multiplexed visualisation. Possible RR-AuNP configurations could be developed such as 
inclusion positioning combinations, or ternary colloid solutions mixed at selective ratios as 
studied by Jaebum Choo’s group.290,291 This required a repeat of the intensity depth profiles to 
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determine the required RR-AuNP concentration ratios, and further breast phantom 
manufacturing – future work to be covered.  
The development of morphologically and optically representative turbid phantoms is an area 
of research within the Raman community which requires further exploration. The use of 
mouse models is not wholly representative of human tissue in terms of both optical properties 
and the pharmacokinetics of AuNPs. As such, greater consideration into the use of optically 
layered turbid phantoms, with AuNP use adhering to a low dose model, must be made in 
future Raman spectroscopic works where human tissue is unavailable. 
As discussed previously, the concentration of RR-AuNPs selected for experimental study falls 
under the remit of a low dose model. This however, would require the whole dose to 
accumulate within the volume of the tumour – an impossibility due to the vast clearance 
mechanisms within the body and recent findings that a median of 0.7% of the administered 
dose arrives at the desired, solid tumour destination.
308
 Current contrast-based imaging, such 
as iodine for CT or barium in fluoroscopy, relies on the overall highlighting of vasculature or 
tissues to identify the abnormalities lying within the regions. This type of contrast use, despite 
increasing the visibility of disease, is non-specific. With NP use, the ability to target the specific 
disease site owes itself to further therapeutic options, such as drug delivery or photothermal 
ablation.
152,206,309
  
As such, improvement upon the RR-AuNP design could be made in terms of the presence of 
active targeting ligands on the colloid surface. Hence, this was possibility was explored within 
the next Chapter. Additionally, consideration into the relative colloidal heating at these depths 
is explored to determine the utility of the NP probes as diagnostic agents.  
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9. Breast Microcalcification Targeting 
Gold Nanoparticles 
9.1 Introduction 
The affinity of the 2-NT-PEG-alendronate functionalised AuNPs to hydroxyapatite (HAP) is 
quantified within this Chapter.  
In Section 9.2 the structural and biochemical features of the collagen scaffold of explored under 
dry and saturated conditions. The inclusion of the AuNPs within the collagen scaffold is seen 
in Section 9.3. Quantification of the effectiveness of the non-targeting and active-targeting 
AuNPs is explored using micro-Raman mapping and principal component analysis techniques 
within Section 9.4. The use of multivariate analysis is a necessary tool in the determination of 
whether selective binding of the targeted NPs to the hydroxyapatite truly occurs.  
Section 9.5 considers the targeting AuNPs at depth, and their effectiveness as a diagnostic tool 
in relation to the colloidal heating effect. Finally, the discussions and conclusions Section 9.6 
summaries the findings of this study. 
9.2 Collagen Scaffold Impregnated with Hydroxyapatite 
The measuring and analysis of the targeting NPs binding to HAP confirms the success of the 
NP labelling and design. Crystalline hydroxyapatite is soluble, making it difficult to quantify 
binding affinity within a colloidal solution. Hence Hydroxycoll, a HAP infused collagen which 
retains form once saturated, was used. 
The material is produced using homogenised fibrillar collagen blended with 5 µM 
hydroxyapatite crystals, which consequently undergoes lyophilisation to create a scaffold-like 
structure.
292
 The scaffold consists of holes up to 100 µM in diameter, seen in Figure 9.1, 
allowing permeation of the targeted NPs through the structure. 
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Figure 9.1: A scanning electron microscopy (SEM) image showing the pore size and structure of the 
Hydroxycoll material.
293
 
 
 
Initially, single-point Raman spectra of the scaffold, both dry and saturated in DI water, were 
collected. This established the biochemical signature of the material as a bulk and gain 
understanding of how the structure of the collagen changes under the two conditions. Two, 
small 10 x 20 mm sections of the Hydroxycoll was sectioned using a cutting mat and scalpel. 
One remained dry whilst the other was saturated in de-ionised water. Eight Raman 
measurements using the 830nm laser at 100% power for 5 seconds over three accumulations 
were measured and equated into single mean spectra for each series.  
The main peaks of interest, annotated in Figure 9.2, highlight the signal intensity change 
between the HAP phosphate (−𝑃𝑂4
 3−
) and collagen structures as the material transitions from 
a dry to a hydrated state.  
In the dehydrated state, peaks at 667 cm
-1
, 1243cm
-1
, 1343 cm
-1
, 1667 cm
-1
 and the range 
over 1437-145 cm
-1
 relate to the 𝐶–𝑆 stretching of cystine, amide III, −𝐶𝐻2 and −𝐶𝐻3 
symmetic stretch, amide I, and −𝐶𝐻2 deformation within the collagen, respectively. The 
shoulder peak at 920 cm
-1
 is assigned to the 𝐶–𝐶 stretch of the collagen proline ring. Hydrating 
the scaffold causes a significant change in the collagen structure: breaks in cystine and proline 
ring structures increases the concentration of 𝐶–𝑆 and −𝐶𝐻2 within the material. −𝑃𝑂4
 3−
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symmetric stretching peaks at 589 cm
-1
 and 960 cm
-1
 increase in intensity as the HAP becomes 
exposed. 
 
 
The nature of the HAP in relation to carbonate substitution was explored further. The ratio 
between the phosphate (−𝑃𝑂4
  3−
) symmetric stretch peaks at 960 cm
-1
 and 1046 cm
-1
, and 
carbonate (−𝐶𝑂3
  2−
) ions −𝐶𝑂 in-plane stretch at 1070 cm-1 determines the level of B-type 
substitution. This can be clinically applied to distinguish the degree of malignancy – a lesser B-
type substitution, or high carbonate level, is associated with benign lesions.
49,294
  A pure HAP 
crystal within the scaffold was micro-Raman point measured at 100% laser power for three 
seconds, seen in Figure 9.3:.  
 
Figure 9.2: Mean Raman spectra of the HAP impregnated collagen scaffolds under dry (blue) and 
wet (green) conditions. Specific peak assignments have been highlighted for clarity.  
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Figure 9.3: Raman spectrum of a pure HAP crystal within the dry collagen scaffold. The symmetric 
stretching phosphate peaks at 960 cm
-1
 and 1045 cm
-1
, and the in-plane stretching of the −𝑪𝑶 
within the carbonate ions at 1074 cm
-1
 have been labelled. The ratio of between the two groups of 
peaks confirms an elevated level of B-type substitution. 
 
 
Comparative to study by Kerssens et al, the intensity ratio of the carbonate peak to phosphate 
peaks within the HAP spectra mimics a 1.24% / 2.92% substitution level.
49
 This is 
representative of a high B-type substitution level, equivalent to a prolific cancerous lesion, 
making the Hydroxycoll a suitable representative material for breast cancer microcalcifications 
within malignant tissue. 
Next, a dry, 10 x 20 mm Hydroxycoll section was micro-Raman mapped to verify pore size 
and distribution of HAP throughout the collagen matrix. Due to the tiered, interlinking nature 
of the scaffold, surface montages collected of the scaffold, as seen in Figure 9.4, could not 
remain in complete focus. The highlighted area settled in focus across a complete scaffold 
pore, so was selected for Raman mapping. This smaller, highlighted image has been rotated 
to reflect the analysed colour maps below. 
960 cm
-1
 (−𝑃𝑂4
 3− symmetric stretch) 
1045 cm
-1
 (−𝑃𝑂4
 3− symmetric stretch) 
1074 cm
-1
 (−𝐶𝑂 in-plane stretch) 
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 Figure 9.4: A surface montage of the dry Hydroxycoll at 50X magnification – the exploded, rotated, 
section highlights the area selected to be Raman mapped. 
 
 
The mapping parameters consisted of 50X magnification, using the Streamline 830 nm laser 
at a 140 mW sample illumination intensity, with an imaging time of 30 seconds per step at a 5 
µm step size. The resulting maps highlighting the peak area intensity of the collagen at 667 cm
-
1
, and at 960 cm
-1
 for HAP, is displayed in Figure 9.5. 
 
Figure 9.5: Colour maps of peak area intensities to show the distribution of: collagen (left image), 
identified by the selected peak at 667 cm
-1
, 𝑪 − 𝑺 cysteine symmetric stretch; and HAP within the 
collagen structure (right image), identified by the selected peak at 960 cm
-1
, −𝑷𝑶𝟒
   𝟑−
 symmetric 
stretch. Pre-processing: Wavenumber range and median filter for cosmic ray removal. 
 
 
As seen, the HAP distribution was inclusive, but uneven, within the collagen, appearing to 
clump in junction areas of the scaffold. In a saturated state, however, internally bound HAP 
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becomes more available at the surface – a crucial factor to consider when analysing the binding 
patterns of the targeting colloid. 
9.3 Collagen Scaffold Colloid Introduction 
Prior to the introduction of the NPs to the collagen scaffold, NP/mL concentrations of targeting 
and non-targeting NP batches were required to be consistent. Beer-Lambert Law can be used 
to define the absorptivity of known, and unknown, concentrations of colloids.  First, known 
dilutions of bare AuNPs were measured using the UV/Vis spectrometer and plotted as a graph. 
A DI water blank set the zero-zero mark. The known standard concentration of NPs was 2.64 
x 10
-4
 M, hence a half and half dilution with DI water leads to ~1.32 x 10
-4
 M. Dilutions were 
further halved until a 1:16 ratio was reached. 
Figure 9.6: A graph to show the maximum absorbance peak value versus the known concentration 
of a NP dilution series. 
 
 
Beer’s Law is defined by the equation:  
 𝐴 =  𝜀 𝑙 𝑐 (30) 
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whereby 𝐴 is the maximum absorbance defined by the molar absorptivity, 𝜀, the light path 
length in cm, 𝑙, and the concentration of the solution in mol dm-3, 𝑐. To gain the molar 
absorptivity value, part of the equation can be rearranged to: 
 𝜀 =  
𝑐
𝑙
 (31) 
 
Taking the equation of the line in Figure 9.6, the absorbance value can be said to be: 
 𝐴 =  0.5532𝑐 + 0.0125 (32) 
  
where the concentration, c, is now the known value of 0.5532. The cuvette width, path length 
is a constant value of 1.25 cm. Hence, ε was calculated to a value of 4425.6 M-1 cm-1. The 
known maximum absorbance values of the labelled NPs were then calculated using Beer’s 
Law and the values gathered from this initial concentration sampling method. The results are 
plotted in the graph in Figure 9.6. 
Figure 9.7: A graph to show the maximum absorbance peak value versus the known concentration 
of labelled NPs, found using Beer-Lambert Law. 
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It can be seen from the equation of the line in Figure 9.6 that a negligible amount of deviation 
has occurred from the initial results. This is down to several factors: the UV/Vis graph in Figure 
5.18 shows asymmetry between the shape of the labelled and bare NP LSPR peak – variation 
of results is to be expected when measuring modified samples.  
From the results garnered, the labelled NPs were diluted to the known bare NP constant 
molar value of 2.64 x 10
-4
 for consistent experimentation.  
 
 
 
Figure 9.8: Targeted and non-targeted nanoparticle impregnation within collagen scaffold sections: 
(a) 0.5 mL NPs and hydrated 10 x 20 mm collagen sections prepared; (b) – (e) collagen placed and 
rotated in NPs for 5 minutes, progression over time seen; (f) remaining water/colloid – a slight 
difference of colour can be seen between the two solutions. 
Breast Microcalcification Targeting Gold Nanoparticles 
179 
 
The introduction of targeting and non-targeting NPs to the Hydroxycoll began with the 
sectioning of the scaffold into regular 10 x 20 mm pieces. Two pieces were fully saturated, 
lightly drained of excess water and placed individually into 0.5 mL of 2-NT-PEG and 2-NT-
PEG-BP colloids. To gain an even coverage, the scaffold pieces were rotated every minute for 
five minutes, shown in Figure 9.8. The scaffolds were removed from the colloid solution, 
washed three times in excess DI water, and stored in a layer of cling film to preserve saturation. 
The remainder colloid solution was stored in Eppendorf tubes to be later analysed with UV/Vis.  
9.4 Micro-Raman Mapping and Analysis 
The Micro-Raman InVia, as described in Section 5.3 was used for single-point and mapped 
measurements. Single-point acquisition parameters were set at a sample illumination intensity 
of 70 mW, at 2 seconds and 5 acquisitions. The targeting and non-targeting colloid infused 
scaffolds were surface montaged and mapped using the 50x magnification, using the Streamline 
830 nm laser at 140 mW sample illumination power. An imaging time of 30 seconds per step 
at a 5 µm step size was selected. The pre- and post-processing techniques as established in 
Chapter 9, Section 8.2 were used again for this Chapter.  
Initial point spectra of the Hydroxycoll sections saturated with the respective targeting and 
non-targeting nanoparticles were taken, as seen in Figure 9.9. The spectra were normalised 
to the 960 cm
-1
 HAP peak to succinctly compare the spectra, reducing the relative intensities 
from differences in photon depth collection and scattering contributions.  The 2-NT-PEG 
colloid adsorbed section had a minimal 2-NT spectral contribution, with the collagen scaffold 
most prominent. By comparison, the contribution from the 2-NT reporter was greatly 
enhanced on the 2-NT-PEG-BP adsorbed collagen scaffold spectrum, Figure 9.9.  
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Mapping the saturated scaffolds caused several difficulties, as seen in Figure 9.10. The tiered 
nature of the scaffold had previously caused focussing issues; the drying rate of the wet scaffold, 
increased by laser heating during mapping, added an additional factor.  
 
 
 
With a focus drop off, signal intensity similarly fell, requiring a high laser power to compensate. 
However, high laser intensity caused burning artefacts to the scaffold when focussed to a 
cluster of NPs, heating them to very high temperatures. Irregularity in focus and difficulties in 
selecting an appropriate laser power resulted in many unfocused or burnt mapping attempts. 
  
Figure 9.9: Point spectra of the surface of a 10 x 20 mm Hydroxycoll section adsorbed with 0.5 mL 
2-NT-PEG AuNPs (left spectra) and 0.5 mL 2-NT-PEG-BP AuNPs (right spectra), normalised to 
the main HAP peak at 960 cm
-1
 (−𝑷𝑶𝟒
   −𝟑
).  
 
Figure 9.10: Surface montaged area before and after Raman mapping, mapped area highlighted by 
the red boxes. Post-mapping, the scaffold was refocused at the origin – a shift in the y and z axis of 
approximately 20 µm in both directions had occurred. 
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9.4.1 Non-Targeting 2-NT-PEG NPs 
 
 
Figure 9.11 shows the intensity map about the 960 cm
-1
 peak area, −𝑃𝑂4
   −3
, of the 2-NT-
PEG saturated collagen scaffold. Three, averaged spectral areas of interest have also been 
extracted from the map.  
The maps three distinct areas can be categorised into two groups – the first solely highlighting 
the HAP-collagen scaffold structure in spectrum 2; and the second displaying the 2-NT spectral 
 
Figure 9.11: peak area @960 cm
-1
. Highlighted areas #1 and #3 relating to the 2-NT-PEG signal; 
#2 is the pure HAP signal which remains free of 2-NT spectral peaks. Colour changes to annotation 
boxes and numbers on map for clarity only.  The characteristic 2-NT peaks within the PC1 spectrum 
are highlighted in orange, whilst the −𝑷𝑶𝟒
   −𝟑
 peak at 960 cm
-1
 is highlighted in purple. 
1 
2 
3 
1 
2 
3 
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contribution in number 1 and 3. Both areas 1 and 3 contain inherent collagen scaffold spectral 
contribution. These areas show no strong overlap between the −𝑃𝑂4
   −3
 and non-targeting 
AuNPs, made more apparent in the PCA map in Figure 9.12. 
 
Figure 9.12: PCA map and loading confirming non-selective clustering of 2-NT-PEG AuNPs. The 
characteristic 2-NT peaks within the PC1 spectrum are highlighted in orange, whilst the −𝑷𝑶𝟒
   −𝟑
 
peak at 960 cm
-1
 is highlighted in purple. Pre-processing: Wavenumber range, vector normalised, 
mean centred. 
 
 
The clustered nature of the two NP areas can be attributed to aggregation occurring during 
drying. 
9.4.2 Targeting 2-NT-PEG-BP NPs 
By comparison, the alendronate functionalised targeting AuNPs show a strong affinity to the 
−𝑃𝑂4
   −3
 within the collagen scaffold. Visualised by the peak area maps in Figure 9.13, map A 
for the −𝑃𝑂4
 −3
 960 cm
-1
 peak area and, B and C the signature 2-NT peaks at 1066 cm
-1
 and 
1380 cm
-1
 respectively. A section of the complete scaffold pore is well visualised in map A, 
with the cluster of 2-NT signal occurring along the scaffold path highly resembling the clumped 
distribution nature of the HAP, as seen in Figure 9.5. 
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Figure 9.13: Targeting AuNPs on collagen scaffold colour map: (A) peak area at 960 cm
-1
 (B) peak 
area at 1066 cm
-1
 (C) peak area at 1380 cm
-1
. 
 
 
From map A, six distinct areas of interest were extracted, with the area averaged spectra 
displayed in  
Figure 9.14. The 2-NT spectrum is present in each of the interest areas to varying degrees of 
intensity. Section 1 displays the greatest intensity, possibly due to this area having a 
topographically elevated position comparative to the well-defined scaffold pore, gaining a 
smaller z length to the objective and hence greater focus. Section 5, of the greatest HAP 
intensity, has contains a large collagen scaffold spectral contribution in addition to the signature 
2-NT peaks. This confirms the presence of incompletely functionalised targeting AuNPs, 
whereby the functionalised area containing the Raman reporter binds to the HAP, allowing 
the bare gold surface to interact with the collagen scaffold. 
For full confirmation of active targeting with PCA, further maps were explored. 
A 
B C 
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Figure 9.14: Targeting AuNPs on collagen scaffold colour map, peak area 960 cm
-1
. Six distinct areas 
of interest are outlined on the map, with the averaged spectra (1-6) plotted below. The characteristic 
2-NT peaks are highlighted in orange, whilst the −𝑷𝑶𝟒
   𝟑−
 peak at 960 cm
-1
 is highlighted in purple. 
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Figure 9.15 displays the intensity maps of a new pore area, map A for the −𝑃𝑂4
   −3
 960 cm
-1
 
peak area and, B and C the signature 2-NT peaks at 1066 cm
-1
 and 1380 cm
-1
 respectively. 
Once again, the clustered nature of the HAP is visualised, alongside the seemingly targeted 
agreeance of the signature 2-NT peaks. 
 
Figure 9.15: (A) peak area @ 960 cm
-1
 (B) peak area @ 1066 cm
-1
 (C) peak area @ 1380 cm
-1
  
 
 
Once again, areas of interest were extracted with the area averaged spectra displayed in Figure 
9.16. 
A 
B C 
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Figure 9.16: Targeting AuNPs on collagen scaffold colour map, peak area 960 cm
-1
. Six distinct areas 
of interest are outlined on the map, with the averaged spectra (1-6) plotted below. Colour changes 
to boxes and numbers on map only for contrast/clarity. The characteristic 2-NT peaks are highlighted 
in orange, whilst the −𝑷𝑶𝟒
   −𝟑
 peak at 960 cm
-1
 is highlighted in purple. 
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All six averaged spectra confirm a presence of 2-NT. From post-processing, the second 
principal component map and spectra is displayed in Figure 9.17, with the areas of interest 
from Figure 9.16 transposed onto the map.  
 
 
Within the PC2 map, areas of interest 2 and 3, despite the 1060 cm
-1
 and 1380 cm
-1
 peak 
area signal intensity, shows a variance more greatly aligned to the HAP spectrum. As such, this 
initial map was sectioned to include areas 2 and 3 for further analysis. Figure 9.18 and Figure 
9.19 displays the third and twelfth principal component colour maps and spectral loadings of 
the sectioned area, respectively.  
 
Figure 9.17:  The areas of interest from Figure 9.16 have been transposed. On the PC2 spectrum, 
the characteristic 2-NT peaks are highlighted in orange, whilst the −𝑷𝑶𝟒
   −𝟑
 peak at 960 cm
-1
 is 
highlighted in purple. Pre-processing: vector normalisation and mean centring; post-processing: 
principal component analysis.  Grey pixels = cosmic ray 
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In principal component analysis three, the two variable components within Figure 9.18  loading 
are the positive 2-NT spectrum, with the 1060 cm
-1
 and 1380 cm
-1
 peaks clearly defined. The 
negative peaks correspond to the −𝐶𝐻2,−𝐶𝐻3 twisting, wagging, and/or bending modes at 
1308 cm
-1
, and −𝐶𝐻2 deformation at 1425 cm
-1 
within the collagen scaffold. 
The presence of the −𝐶𝐻2,−𝐶𝐻3 vibrational modes is typical to the saturated state of the 
collagen scaffold; however, scaffold enhancement can only be due to the interaction between 
a bare AuNP surface. In relation to the PC3 map, this is specific to area of interest 3, with area 
2 holding a predominantly 2-NT saturated spectral area. 
 
 
Figure 9.18:  Principal component 3: colour map and loading of map resection for areas of interest 
2 and 3. Red pixels correspond to 2-NT, blue pixels correspond to the −𝑪𝑯𝟐, −𝑪𝑯𝟑 twisting, 
wagging, and/or bending at 1308 cm
-1
, and deformation at 1425 cm
-1
 within the collagen scaffold.  
On the PC3 spectrum, the characteristic 2-NT peaks are highlighted in orange, whilst the 
−𝑪𝑯𝟐, −𝑪𝑯𝟑 peaks and are highlighted in purple.  Pre-processing wavenumber range, mean 
centring. Grey pixel = cosmic ray 
2 
3 
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Figure 9.19: Principal component 12: map and loading of map resection for areas of interest 2 and 
3. Red pixels are the 960 cm
-1
 HAP, and the blue pixels correspond to 2-NT. On the PC12 
spectrum, the characteristic 2-NT peaks are highlighted in orange, the −𝑷𝑶𝟒
   −𝟑
 peak at 960 cm
-1
 
is highlighted in purple, and the −𝑷𝑶𝟒
   −𝟑
 peak at 1045 cm
-1
 and −𝑪𝑶 symmetric stretch at 1074 
cm
-1
 highlighted in blue.  Pre-processing wavenumber range, mean centring. Grey pixel = cosmic 
ray. 
 
 
The twelfth principal component, pseudocolour map and spectral loading pictured above in 
Figure 9.19, presents the three main HAP peaks alongside the 2-NT characteristic peaks with 
the spectrum as a whole. The main distinctive HAP peak at 960 cm
-1
 is highlighted in purple, 
with the −𝑃𝑂4
   −3
 peak at 1045 cm
-1
 and −𝐶𝑂 symmetric stretch at 1074 cm-1 highlighted in 
blue. Once again, the 2-NT peaks are displayed in orange, at 1067 cm
-1
 and 1379 cm
-1
. Due 
to the spectral resolution of the InVia of ~2 cm
-1
, this was not considered as a peak shift.  
The presence of both the HAP and 2-NT peaks within the same spectral loading quantitively 
confirms the active targeting of the nanoparticles.  
 
 
 
2 
3 
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Further to micro-Raman mapping, the remaining colloidal solution post collagen scaffold 
introduction was analysed against the starting colloidal concentration.  Using UV/Visible 
measurements and Beer Lambert Law, this determined the relative uptake for each set of 
colloids. 
 
Figure 9.20:  Beer-Lambert Law used to plot maximum absorbance at 546 nm against 
concentration; a bar graph to show the concentration of NPs remaining in solution, shown in the 
photo inset, with the uptake percentage added above each bar. 
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As seen within the insert photo in Figure 9.20, a slight colour difference between the targeting 
and non-targeting colloidal remains could be seen. The absorptivity defined concentration of 
the targeting NPs showed a 7.72% increase in collagen scaffold uptake compared to non-
targeting. The sponge-like nature of the scaffold is a factor to consider in the overall colloidal 
uptake.  
9.5 Colloid Heating 
Measurement of the 2-NT-PEG NPs at depth within the block breast phantoms was 
unsuccessful. The relative number of 2-NT molecules on the colloid surface of the pure RR-
AuNPs in comparison to the successfully functionalised 2-NT-PEG AuNPs is at a ratio of 33:1, 
or 81,855 molecules per AuNP to 2,474 molecules, respectively. As a point of interest, the 
2-NT-PEG AuNPs were synthesised with 58,978 PEG molecules per NP. As such, the dose 
of functionalised NPs required for extrinsic SERS at depth would be far out of the possible 
biocompatible range. 
 
 
Figure 9.21: A graph to show the temperature change, in Celsius, of the functionalised nanoparticles 
(2.91 x 10
10
 NPs) outside of and within different phantom thicknesses. DI water was selected as the 
control. The overall change in temperature for each has been labelled next to the corresponding 
line. 
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Despite this, the diagnostic quality in terms of relative 2-NT-PEG AuNP heating, and hence 
unwarranted heat transfer to surrounding tissue, was considered. Figure 9.21 shows the 
temperate change over two minutes of solely the AuNPs (2.91 x 10
10
 NPs in 1.2 mL), and 
the AuNPs within 10 mm of breast phantom, and 13 mm of breast and skin phantom. DI 
water was selected as the control. To preserve the functionality of the NP probes, the 
measurement outside of the phantom was cut short after a temperature of 30°C was reached. 
The dramatic decrease in 2-NT-PEG AuNP temperature from the 10 to 13 mm phantom is 
due to the MFP of the phantom (0.1 mm) leading to mostly scattering, reducing the light flux 
reaching the extended colloidal position. The change in light intensity (mW) from the laser 
interface (𝐼) to the colloid location (𝐼𝑂) is determined using the following equation: 
 𝐼𝑂 =  𝐼𝑒
−(𝜇𝑠+𝜇𝑎)𝑥 (33) 
 
whereby the intrinsic scattering and absorption coefficients (𝜇𝑠 and 𝜇𝑎) are multiplied by the 
overall change of material thickness in mm (𝑥). The 𝜇𝑠 of the breast and skin phantoms are 
taken from the supplied literature results and calculated, from the known anisotropy of TiO2 
(0.93), to be 8.05 cm
-1
 and 13.91 cm
-1
 respectively. The 𝜇𝑎 of both phantoms is set at 0.05 
cm
-1
. 
Hence, the change in laser intensity from the interface (300 mW) to the colloid position within 
the 10 mm phantom is described as follows: 
 
𝐼𝑐𝑜𝑙𝑙𝑜𝑖𝑑 = 300𝑒
−(8.05+0.05)0.5
 
𝐼𝑐𝑜𝑙𝑙𝑜𝑖𝑑 = 5.23 𝑚𝑊                 
(34) 
 
The light intensity change on the optical axis from interface to collection through the 13 mm 
phantom is detailed in the exploded view in Figure 9.22. 
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Figure 9.22: Exploded view of the 13 mm breast and skin phantom with a 2-NT-PEG AuNP NMR 
tube inclusion. The calculated intensity of light after each phantom layer, and at the colloidal position, 
is depicted above the phantom illustration. The logarithmic light intensity graph across the phantom 
at 0.1 mm intervals, the mean free path of the phantom, is also plotted, with the colloid position 
highlighted with a red dashed line. 
 
 
Overall, a 4.586 mW difference in light intensity between the two phantom thicknesses is 
founded, clarifying the large drop-off in colloidal heating. From an initial illumination of 300 
mW, only 1.4 x 10
-3
 mW transmissions through the phantom to the detector. Extrapolated to 
the 30 mm morphological breast phantom, the intensity is further reduced to 1.45 x 10
-9
 mW. 
9.6 Discussion and Conclusions 
The 2-NT-PEG-Bisphonate labelled AuNPs have been shown the actively target the 
hydroxyapatite biomolecules which present at elevated levels within breast microcalcifications 
signalling malignancy, especially within cases of DCIS. The absence of HAP binding with the 2-
NT-PEG AuNPs leads to the conclusion that the affinity of the 2-NT-PEGNP AuNPs is due to 
the present alendronate moiety. 
The synthesis of the 2-NT-PEG-BP requires adjusting, with an increased ratio of 2-NT : PEG 
molecules required, for the NPs to be considered for SESORS. This would require further 
experimentation of the synthesis recipe to garner an increased RR signal whilst maintaining a 
brush-like PEG formation.  
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A complete remodel of the NP design could increase their effectiveness at depth. For example, 
the use of multi-layered, nanomatryoshka AuNPs would: increase the enhancement 
capabilities of the RR, with the additional remit for multiplexed imaging; allow full surface PEG 
coverage for increased biocompatibility; and introduce a possible photothermal aspect to the 
NP probes.
295,296
 This would vastly improve the functionality of the targeting AuNPs, a 
possibility to be explored within future works. 
Micro-Raman mapping proved difficult in terms of laser power adjustments to reduce the 
evaporation speed of the collagen scaffold and likelihood of AuNP burning. The use of a low 
lines/mm grating to visualise the Stokes scattering would quantification of the level of 
temperature increase reached. This would give verification of the thermo-therapeutic 
capabilities of the targeting AuNPs if used in conjunction with a Raman probe, for example. 
The active targeting molecule alendronate is non-specific to solely breast microcalcifications, 
binding to areas of osteoporosis and metastases within bone. This could be useful in 
ascertaining if the breast tumour has metastasised to the bone, with the nanoparticles providing 
excellent contrast for further x-ray imaging. The multi-faceted capabilities of these AuNPs 
within both Raman and X-ray imaging aligns them as a truly clinically viable, diagnostic probe. 
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10. Discussions, Conclusions and Future 
Work 
The main focus of this thesis has been: 
1. Nanoparticle design for diagnostic use in considering Raman signal, functionality and 
biocompatibility, in the selection of 80 nm gold nanospheres and the use of PEG.  
2. The use of turbid, multi-layered optical phantoms as a tissue representative. 
3. Demonstrating the first use of SESORS in anatomical tissue phantoms for breast 
imaging 
4. SESORS imaging development including protocols for an automated mapping system 
5. Exploring the translation requirements for the transmission Raman spectroscopy 
technique within the current practice of mammography, aiming to streamline the 
diagnostic pathway 
Discussions 
Prior to nanoparticle testing, a careful balance in attaining the maximum Raman signal possible 
within the remit of biocompatibility was required.  
Initially the material, size and shape were considered. The identification of gold as an inert 
material with low cytotoxicity deemed it more favourable than silver, despite a reduced 
localised surface plasmon resonance 𝜆𝑚𝑎𝑥.109,115 AuNP size and shape selection considered 
the LSPR peak position, with a red-shift occurring with the increase of size.
121,122,226
 In focussing 
on the production of a diagnostic tool, the selection of the nanosphere shape, over the 
increased photothermal potential of the nanorods or nanoshells,
141,142,145
 was made. The 
enhanced plasmonic effects produced by larger Au nanospheres makes them preferable for 
biomedical applications, whereby the selected 830 nm illumination wavelength lies within the 
 196 
 
NIR biological window.
146–148
 The adsorption affinity of Raman reporters upon the surface of 
AuNPs ≤50 nm was also noted in the size selection process.110,139,140 Finally, the evaluation of 
the pharmacokinetics of AuNPs (≤8 nm undergoing glomerular filtration and >100 nm 
accumulating within the Kupffer cells of the liver)
176,177,179,180,297–300
 and the favourable enhanced 
permeability and retention effect of NPs between 10 – 100 nm,201,209,210 gold nanospheres 80 
nm in size were selected.  
To create a consistent, analytical SERS probe, the AuNPs employed need a high level of 
uniformity, being monodisperse in nature.
109,115
 The certainty of this within the on-site 
synthesised AuNPs could not be guaranteed and, as such, commercially purchased, citrate-
capped AuNPs were selected for use. 2-NT, 4-MBA and 4-ATP were selected as Raman 
reporters, known to have effective gold-thiolate and acetamido nitrogen binding mechanisms, 
and for previous use within NP biocompatibility studies.
110,120,206,228–230
 The low levels of colloid 
heating at depth confirmed the diagnostic potential of these AuNPs. To further explore 
biocompatibility Polyethylene Glycol, as a known stealth or “cloaking” agent, 200,201 was 
introduced in ratio with the 2-NT RR. This combination was explored to study the effect on 
signal at depth, which was founded to be unobtainable.  
Further development of the 2-NT-PEG AuNPs lead to an additional functionalisation with a 
bisphosphonate, alendronate. Bisphosphonates have a high affinity for the bone mineral 
hydroxyapatite, found to be present within Type II, −𝑃𝑂4
  3−
 B-type substitution breast 
microcalcifications, most commonly associated with neoplasms.
49,50
 Current literature from 
Cole et al has shown the successful binding of PEG-alendronate functionalised AuNPs to 
microcalcifications and bone tumours, which then act as an X-ray contrast agent within 
mammography or CT imaging.
59,231,232
 The current method used in confirming the successful 
functionalisation and selective binding of these PEG-BP AuNPs is through the micro-CT 
imaging of in vitro and in vivo mouse models. 
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The application of the 2-NT, PEG and BP created a biocompatible, actively targeting and 
Raman sensitive AuNP probe – a novel combination. Consideration into the chain length of 
the PEG, resolved at 2000 Da,
232
 and the positioning of the targeting moiety, decided upon 
placement at the distal end of the PEG,
233–235
 was undertaken. TEM imaging confirmed the 
carbodiimide chemistry undertaken to adjoin the alendronate molecule had affected the gold 
surface, although this could not confirm the success of functionalisation. As such, a HAP infused 
collagen scaffold, Hydroxycoll, was obtained through a Material Transfer Agreement, see 
Appendix, and saturated with both the targeting and non-targeting PEGylated NPs. Micro-
Raman maps, post-processed using Principal Component Analysis, quantified and confirmed 
(the absence of the 2-NT-PEG AuNPs in binding to the HAP) the combined presence of the 
2-NT and HAP spectral features with the 2-NT-PEG-BP AuNPs. concluding that the BP 
molecule had undergone successful binding to the PEG distal end. Evaluation of the remaining 
colloidal solution using Beer-Lambert Law further solidified the binding mechanism at work, 
with the remaining concentration of the 2-NT-PEG AuNPs 7.72% greater. This synthesis 
success opens the door to further consideration into the use of RR-PEG-BP functionalised 
AuNPs within a combined transmission Raman spectroscopy – mammographic imaging 
system, especially for patients with dense breast tissue. 
Requiring the NPs to remain within the biocompatible remit and the laser wavelength within 
the NIR range limited the level of SERS enhancement which could have been experimentally 
produced. As such, the transmission depths achieved within this thesis remained biologically 
relevant. In relation to the average compressed breast thickness of ~50 mm in the UK, over 
half of the population would not be sufficiently catered for under the current RR AuNP design 
and laser wavelength. As such, further modifications to both areas would need to be 
undertaken, blue-shifting the laser wavelength further into the centre of the NIR biological 
window and adjusting the NP size to RR ratio. 
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The use of turbid phantoms within Raman applications is a poorly explored area, with 
homogeneous Intralipid often selected for simple phantom work.
250
 Having a short working 
life-span and inability to form realistic complexity, liquid phantoms are fast being replaced with 
stable, solid phantoms of polydimethylsiloxane. These can be cast to the required shape with 
an adjustable quantity of scattering and absorption agents added.
249,252
 With this, an 
introduction of multiple-tissue layers, with varying optical properties, is viable, enhancing the 
realism of the phantoms. One such example of this is the use of spin-coating to simulate the 
epithelial tissue layers of the skin and bladder.
272,275
 Here, the creation of both breast and skin 
tissue phantoms through pour-casting into 3-D printed moulds was explored and tested. As 
discussed previously, the use of double integrating spheres would enable the measurement of 
the absorption and scattering coefficients of the phantom materials. This, however, required 
a sophisticated Monte Carlo photon migration model to provide the coefficients following back 
projection of the integrating sphere measurements on carefully prepared thin samples. In its 
place, care was taken to use protocols found within the literature to adjust the mg/mL 
concentration of titanium dioxide to PDMS, providing an appropriate set of optical properties 
relevant to post-menopausal breast and skin tissue.   
To efficiently analyse the breast phantoms within the transmission Raman set-up, a new 
mapping system was required. The design and implementation of the automated mapping 
system required several skill sets – optomechanical hardware construction, MATLAB and 
Andor software programming knowledge, and npn transistor electronic circuitry building. This 
delivered an efficient and rapid automation protocol. The main advantages of this system 
included an increase in workload capacity, and the production of highly specific and large data 
sets for further analytical “manipulation”. Further and continued use of this automated set-up 
across institutions would cement the protocol as a highly effective solution for mapping 
purposes within numerous, open-optics settings. 
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Conclusions 
The main aims of this thesis were to: confirm the use of turbid, multi-layered optical phantoms 
as viable tissue representatives; design and functionalise diagnostic gold nanoparticles with 
biocompatibility in mind; and demonstrate the potential for the incorporation of a SESORS 
transmission Raman spectroscopy technique within the current mammographic system, 
identifying the labelled AuNPs at varying depths. 
The ability to produce, and reliably replicate, phantoms of both breast and skin tissue was 
founded. The use of high-temperature 3D printed moulds, designed in semi-infinite and 
morphologically representative ways, successfully enabled consistent phantom production. In 
adjusting the concentration of TiO2 to satisfy the reduced scattering optical properties of post-
menopausal breast and skin tissue, multi-layered phantoms could be realised.  
It was concluded that within the remit of a low human equivalent dose, three Raman-reporter 
labelled AuNPs could be distinguished within ≤33 mm turbid phantoms. Under 
mammographic compression the average of breast thickness of women in the UK is ~50 mm, 
however this is further reduced with the use of spot compression on areas of interest.
87
 As 
such, this proof-of-concept phantom size is within the range of applicability, although an 
increased thickness would translate to a larger portion of the population. The Raman signal 
intensities obtained from the 4-MBA and 4-ATP were markedly lower than that of the 2-NT, 
owing to its affinity to and compact orientation upon the AuNP surface. The relative depth 
signal profile of each NP probe within the sample was also established, and found to be in 
agreement with the findings from Vardaki at el.
278
 Spectral interferences obtained from the 
inherent absorption and characteristic Raman peaks of the phantom material affected the RR 
peak height ratios between the high and low wavenumbers. As such, system adjustments 
concerning the preferable laser wavelength, working around the inherent material properties 
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whilst ensuring the illumination and collection photon remain within the NIR window, must 
be made. 
The functionalised 2-NT-PEG-BP AuNPs were confirmed to be actively targeting, with the 
present alendronate moiety having a high affinity to the HAP present within the Hydroxycoll 
collagen scaffold. This clearly demonstrates the successful creation of an AuNP probe with 
novel functionalisation. The multi-faceted capabilities of the 2-NT-PEG-BP AuNPs for both 
Raman and X-ray imaging, albeit requiring further exploration in design and biocompatibility, 
aligns them as a potentially clinically viable, diagnostic probe. Clearly the application of such a 
nanoparticle requires much greater safety analysis, considered in the Future Work sub-section 
of this chapter. 
The integration of new techniques within the clinical setting requires a high level of diagnostic 
accuracy. A critical appraisal of current diagnostic techniques versus SESORS is as follows: 
- MRI is a sought-after technique, providing highly sensitive images for diagnosis, 
although it comes at a large cost with extended waiting times. The use of gadolinium contrast 
is successful in increasing hydrogen relaxation times, providing enhanced clarity of lesions, 
however the agent is inherently toxic causing kidney tissue scarring. 
- Mammography provides the gold standard of imaging; it is however an inaccurate 
technique for patients with dense breasts, lacks specificity in defining microcalcifications, and 
requires ionising x-radiation. However, the use of Digital Breast Tomosynthesis is improving 
the sensitivity of cancer diagnosis. 
- Ultrasound is a non-ionising technique, providing rapid imaging for patients with dense 
breasts, with new advances into the use of higher frequency probes (~60 MHz) to detect 
microcalcifications which cannot be visualised within the standard frequency range. Biopsy, 
Discussions, Conclusions and Future Work 
201 
 
taken under local or general anaesthetic, is still required to definitively determine the type of 
microcalcification, HAP or calcium oxalate prevalent. 
- Histopathology as the gold standard for micro-level tissue interpretation is gaining 
inter-practitioner accuracy, yet the required biopsies necessitate anaesthesia with possible 
repeat procedures essential if x-ray imaged microcalcifications are not represented within the 
specimen. 
SESORS, working with extrinsic SERS AuNPs has a consistent characteristic Raman spectrum, 
uninfluenced by the biochemical signatures of the surrounding tissues, with multiplexed 
imaging capabilities using non-ionising spectroscopy. This however, is reliant on several 
concerns. The surface chemistry of the gold-Raman reporter bond must be impervious, and 
fully label the complete AuNP surface. At a in vivo level, the EPR effect must alone accumulate 
a high concentration of low dosed AuNPs within the malignant tissues, relying on minimal 
Mononuclear Phagocyte System clearance. Further biocompatibility using PEG and active 
targeting functionalisation requires more in-depth study to determine the success of signal 
recovery at depth. 
This work has highlighted the need to focus on employing techniques which can be easily 
translated to the current diagnostic workflow. By employing transmission Raman and designing 
the breast phantom as if under mammographic compression, this enables detailed testing and 
device development to assist the easier translation of the technique as an adjunct for 
mammography. Incorporation of novel spectroscopic techniques within clinical diagnostic 
methods, as opposed to replacing them, propagates the likely acceptance into clinical practice. 
Furthermore, this would lessen the impact on current diagnostic pathways, reducing patient 
result wait times between several techniques and hence shortening disease development.
64
 
Other considerations crucial to evaluate for the translation of new techniques to future, 
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clinically minded work include: health economics (Is the expense of the technique 
unaffordable? Would it be manageable or cost effective on a specific clinical pathway, such as 
familial breast cancer patients?); diagnostic accuracy (Does the SESORS technique provide 
highly sensitive and specific results, and is a skilled professional required to translate them?); 
and, in the actuation of the technique, medical device ergonomics and safety, for both 
practitioner and patient. 
Future Work 
The work of this thesis is a step on the pathway to the use of gold nanoparticles in medical 
diagnostics, with particular focus on SESORS. The next steps that should be considered to 
develop, test and translate this approach would be as follows. 
Nanoparticle Development 
The configuration of the AuNPs into novel designs such as those found in a multi-layered 
nanomatryoshka should be considered.
295,296
 This would create the possibility of a more 
theranostically minded probe, applicable as both a diagnostic (inner AuNP) and photo-thermal 
therapeutic (Au shell) probe. Ultimately, this would eliminate the concerns surrounding the 
ratio between Raman-reporter:PEG molecules, increasing Raman signal intensity and the 
brush-like PEG conformation for biocompatibility simultaneously. Furthermore, the encasing 
of RR would allow the exploration of multiplexed imaging of cytotoxic reporters, such as 
malachite green isothiocyanate or crystal violet, as known reporter molecules with large 
Raman cross-sections. This may bring about the possibility for multiplexed depth analysis.  
The exploration of colloid heating could then be analysed with the thermo-therapeutic 
capabilities in mind. Within the micro-Raman system, the addition of a notch filter could enable 
the measurement of both the Stokes and anti-Stokes lines, enabling direct quantification of the 
temperature increase at the NP surface level. 
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Returning to the current AuNP designs, the dose model used within this thesis was based 
upon the low Human Equivalent Dose from studies using rat and pig animal models.
166,167,176
 
As such, the biocompatible nature of the functionalised AuNPs could be further explored. For 
example, introducing the AuNPs within a metastatic breast cell 3D model, using the 
Hydroxycoll collagen scaffold as a support network. This would be the first step towards 
determining the pharmacokinetics of the AuNPs within malignant breast tissue, and hence the 
relative levels of biocompatibility. 
Looking further forward, the clinical translation of gold nanoparticles requires an experimental 
testing and trail-based pathway, such as the one seen in Figure 10.1. 
 
Figure 10.1: A proposed guideline strategy for nanoparticle delivery research.
308
 
 
In developing and adjusting the delivery efficiency of a NP, the use of mouse models is 
paramount in determining the circulation half-life and biocompatibility of the design. As 
previously discussed, the use of swine for the large animal model is considered more applicable 
for the transferability of NPs to a Human Equivalent Dose, and as such would be considered 
alongside dogs, rabbits and monkeys. 
Progressing to the clinical testing phase, consideration of patient suitability for the trial is of the 
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utmost importance. Initially, patients selected for trial must fit under the “inclusion criteria” 
based on life expectancy, including for other medical conditions, previous treatment received 
and general health.
319
 Patients with advanced cancers are recommended for trials involving 
new therapies or techniques, for example immunotherapy (the treatment of disease by 
inducing/enhancing/suppressing an immune response), due to the experimental nature of the 
therapy.
319-321
 FDA approval (US) – nanomedicines (liposomes and polymer micelles) and 
magnetic NPs for imaging in clinical phases; estimated 5% approval rate for oncology drugs, 
costing $1 billion total cost to make it through all 4 Phases.
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Finally, the next steps in realistic phantom design for further development of the approach 
could be improved upon using the spin-coating technique in creating discrete layers of dermis, 
epidermis, adipose and glandular tissues.
272,275
 Furthermore, the addition of static occlusions 
within the phantoms, such as HAP with varying levels of carbonate substitution for a range of 
microcalcifications, could also be explored.  
Phantom Development 
The breast phantom within this study was adjusted to represent Caucasian, post-menopausal 
breast tissue. Altering the absorption properties of the skin layer, representing distinct levels of 
pigmentation, and scattering properties of the breast tissue, to be applicable for pre-
menopausal breast tissue, would increase phantom applicability across different races and 
patient demographics. 
Testing of other clinically transferrable Raman techniques could also be explored, such as with 
the needle probe method.
159,160
 Although a comparatively invasive technique in comparison 
to transmission Raman spectroscopy, this method would provide highly sensitive results in 
determining the presence of the targeted AuNPs. A change in phantom material selection, or 
silicone base to curing agent ratio, would lead to the close resemblance of the natural feel and 
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haptic feedback of breast. This would cover the optical, morphological and tactile properties 
of the breast to produce hyper realistic phantoms. Additionally, the needle probe has the 
capability of harnessing the photo-thermal potential of the nanospheres, attainable with a close 
illumination-to-AuNP working distance. 
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Quasi-Skin Templates 
Produced to scale on a full A3 page. 
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MATLAB Code 
Standa Stage Automation with Andor CCD Trigger 
function varargout = GUI_Louise_motor_and_camera_V13(varargin) 
% GUI_LOUISE_MOTOR_AND_CAMERA_V13 MATLAB code for 
GUI_Louise_motor_and_camera_V13.fig 
%      GUI_LOUISE_MOTOR_AND_CAMERA_V13, by itself, creates a new 
GUI_LOUISE_MOTOR_AND_CAMERA_V13 or raises the existing 
%      singleton*. 
% 
%      H = GUI_LOUISE_MOTOR_AND_CAMERA_V13 returns the handle to a new 
GUI_LOUISE_MOTOR_AND_CAMERA_V13 or the handle to 
%      the existing singleton*. 
% 
%      
GUI_LOUISE_MOTOR_AND_CAMERA_V13('CALLBACK',hObject,eventData,handles,.
..) calls the local 
%      function named CALLBACK in GUI_LOUISE_MOTOR_AND_CAMERA_V13.M 
with the given input arguments. 
% 
%      GUI_LOUISE_MOTOR_AND_CAMERA_V13('Property','Value',...) creates 
a new GUI_LOUISE_MOTOR_AND_CAMERA_V13 or raises the 
%      existing singleton*.  Starting from the left, property value 
pairs are 
%      applied to the GUI before 
GUI_Louise_motor_and_camera_V13_OpeningFcn gets called.  An 
%      unrecognized property name or invalid value makes property 
application 
%      stop.  All inputs are passed to 
GUI_Louise_motor_and_camera_V13_OpeningFcn via varargin. 
% 
%      *See GUI Options on GUIDE's Tools menu.  Choose "GUI allows 
only one 
%      instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
  
% Edit the above text to modify the response to help 
GUI_Louise_motor_and_camera_V13 
  
% Last Modified by GUIDE v2.5 30-Mar-2016 14:11:25 
  
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', 
@GUI_Louise_motor_and_camera_V13_OpeningFcn, ... 
                   'gui_OutputFcn',  
@GUI_Louise_motor_and_camera_V13_OutputFcn, ... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 
    gui_State.gui_Callback = str2func(varargin{1}); 
end 
  
if nargout 
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    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
  
  
% --- Executes just before GUI_Louise_motor_and_camera_V13 is made 
visible. 
function GUI_Louise_motor_and_camera_V13_OpeningFcn(hObject, 
eventdata, handles, varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   command line arguments to GUI_Louise_motor_and_camera_V13 
(see VARARGIN) 
  
    % Choose default command line output for 
GUI_Louise_motor_and_camera_V13 
    handles.output = hObject; 
  
  
    handles = initGUI(handles); 
    handles = loadConfig(handles); 
     
    enableGUI(handles , 'idle'); 
  
    handles = initMotors(handles); 
    if handles.MotorsOK == 0; 
        set(handles.txMotorStatus , 'ForegroundColor' , 'r' , 'String' 
, 'Motors not detected'); 
    end 
  
  
  
    % Update handles structure 
    guidata(hObject, handles); 
  
% UIWAIT makes GUI_Louise_motor_and_camera_V13 wait for user response 
(see UIRESUME) 
% uiwait(handles.GUI_Motor_and_camera); 
  
  
% --- Outputs from this function are returned to the command line. 
function varargout = 
GUI_Louise_motor_and_camera_V13_OutputFcn(hObject, eventdata, handles)  
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Get default command line output from handles structure 
varargout{1} = handles.output; 
  
  
  
  
function handles = initGUI(handles) 
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    xlabel(handles.axesMain , '[mm]'); 
    ylabel(handles.axesMain , '[mm]'); 
%     set(handles.axesMain , 'XTick' , [] , 'YTick' , [] ); 
  
    handles.Corners.TopLeft     = []; 
    handles.Corners.BottomRight = []; 
  
    handles.hLinePath = []; 
    handles.hCurrentPoint = []; 
    handles.ScansDone = []; 
     
    handles.hScanTimer = []; 
     
    handles.lastSavePath = []; 
     
    % Prepare progress bar 
    axis(handles.axesProgress , [0 1 0 1]); 
    box(handles.axesProgress , 'off'); 
    set(handles.axesProgress , 'XColor' , 'w'  , 'YColor' , 'w') 
     
    handles.hProgressBar = rectangle('Parent' , handles.axesProgress , 
... 
        'Position' , [0 , 0 , 0.01 , 1] , 'FaceColor' , 'g' , 
'EdgeColor' , 'none'); 
     
     
     
     
function FileNotFound(FileName) 
  
    msgbox(['File not found : ' FileName] , 'modal') 
  
     
function handles = initMotors(handles) 
  
    scriptPath = fileparts(mfilename('fullpath')); 
    NecessaryFiles = {'ximc.h' , 'ximc.h' , 'libximc.dll' , 
'xiwrapper.dll' , 'libximc_thunk_pcwin64.dll' , 'ximcm.m'}; 
     
    handles.MotorsOK = 0; 
    handles.DEBUGMODE = true;   % If something goes wrong, continue as 
simulation 
     
    set(handles.txMotorStatus , 'ForegroundColor' , [204,204,0]/255 , 
'String' , 'Initializing motors...'); 
  
     
    % Check for necessary files 
    for k = 1 : length(NecessaryFiles) 
        if ~exist([scriptPath , '\' , NecessaryFiles{k}] , 'file') 
            FileNotFound(NecessaryFiles{k}) 
            return 
        end 
    end 
     
     
     
    % Load library 
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    [~,maxArraySize]=computer; 
    is64bit = maxArraySize > 2^31; 
    if not(libisloaded('libximc')) 
        disp('Loading library') 
            if ispc 
                if (is64bit) 
                        [notfound,warnings] = 
loadlibrary('libximc.dll', @ximcm); 
                else 
                        [notfound, warnings] = 
loadlibrary('libximc.dll', 'ximcm.h', 'addheader', 'ximc.h'); 
                end 
            elseif ismac 
                [notfound, warnings] = 
loadlibrary('libximc.framework/libximc', 'ximcm.h', 'mfilename', 
'ximcm.m', 'includepath', 
'libximc.framework/Versions/Current/Headers', 'addheader', 'ximc.h'); 
            elseif isunix 
                [notfound, warnings] = loadlibrary('libximc.so', 
'ximcm.h', 'addheader', 'ximc.h'); 
            end 
    end 
     
     
    % List all functions 
    % F = libfunctions('libximc','-full'); 
    % libfunctionsview('libximc'); 
  
    % Find devices (two motors) 
    device_names = ximc_enumerate_devices_wrap(0); 
    devices_count = size(device_names,2); 
    if devices_count == 0 
        waitfor(msgbox('No devices found - simulating movement' , 
'modal')); 
        return 
    end 
  
    if length(device_names) < 2 
        waitfor(msgbox('I could not find 2 motors connected to the 
computer!' , 'modal')) 
        return 
    elseif length(device_names) > 2 
        waitfor(msgbox('There is more than 2 motors connected to the 
computer!' , 'modal')) 
        return 
    end 
  
    handles.device_idUP = calllib('libximc','open_device', 
device_names{1,1}); 
    handles.device_idLR = calllib('libximc','open_device', 
device_names{1,2}); 
  
  
    handles.MotorState_UP = ximc_get_status(handles.device_idUP); 
    handles.MotorStat_LR  = ximc_get_status(handles.device_idLR); 
  
     
     
     
  
    % Get options for SYNCH OUT 
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    % t = struct('SyncOutFlags', 0, 'SyncOutPulseSteps', 0, 
'SyncOutPeriod', 0, 'Accuracy', 0); 
    % t_ptr = libpointer('sync_out_settings_calb_t', t); 
    sync_settings = struct('SyncOutFlags', 0, 'SyncOutPulseSteps', 0, 
'SyncOutPeriod', 0, 'Accuracy', 0, 'uAccuracy', 0); 
    [result, sync_settings] = 
calllib('libximc','get_sync_out_settings', handles.device_idUP, 
sync_settings); 
     
     
    % Specify options for SYNCH OUT and send to device 
    sync_settings.SyncOutFlags  = bin2dec('00101001');  % Synch 
enabled, on stop, motor steps/encoder pulses instead of milliseconds 
    sync_settings.SyncOutPeriod = 100;  % ms 
    sync_settings.Accuracy = 0;  % distance to the target position. As 
soon as the distance to 
                                 % target on approach is less than or 
equal to this distance  
                                 % a synchronizing pulse will be 
generated if "on stop" option is used. 
  
    result(1) = calllib('libximc','set_sync_out_settings', 
handles.device_idUP, sync_settings); 
    result(2) = calllib('libximc','set_sync_out_settings', 
handles.device_idLR, sync_settings); 
  
    if ~all(result == 0) 
        popupErrorMessage('Error writing motor setup'); 
        return 
    end 
  
     
    % External IO mode flags 
    % What I want: 00100001 (Enabled + synch when motor stop + 
duration in ms) 
    % SYNCOUT_ENABLED   0X01  // 00000001  // Synchronization out pin 
follows the synchronization logic, if set. 
    % SYNCOUT_STATE     0X02  // 00000010  // When output state is 
fixed by negative SYNCOUT_ENABLED flag, the pin state is in accordance 
with this flag state. 
    % SYNCOUT_INVERT    0X04  // 00000100  // Low level is active, if 
set, and high level is active otherwise 
    % SYNCOUT_IN_STEPS  0X08  // 00001000  // Use motor steps/encoder 
pulses instead of milliseconds for output pulse generation if the flag 
is set 
    % SYNCOUT_ONSTART   0X10  // 00010000  // Generate synchronization 
pulse when movement starts. 
    % SYNCOUT_ONSTOP    0X20  // 00100000  // Generate synchronization 
pulse when movement stops. 
    % SYNCOUT_ONPERIOD  0X40  // 01000000  // Generate synchronization 
pulse every SyncOutPeriod encoder pulses 
    % hexToBinaryVector('0x20') 
  
  
    % structs.sync_out_settings_t.members=struct('SyncOutFlags', 
'uint32', 'SyncOutPulseSteps', 'uint32', 'SyncOutPeriod', 'uint32', 
'Accuracy', 'uint32', 'uAccuracy', 'uint32'); 
    % sync_out_settings_t       Struct Reference 
    % unsigned int SyncOutFlags 
    % Flags of synchronization output. 
    %  
    % unsigned int SyncOutPulseSteps 
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    % This value specifies duration of output pulse. 
    %  
    % unsigned int SyncOutPeriod 
    % This value specifies number of encoder pulses or steps between 
two output synchronization pulses when SYNCOUT ONPERIOD is set. 
    %  
    % unsigned int Accuracy 
    % This is the neighborhood around the target coordinates, which is 
getting hit in the target position and the momentum 
    % generated by the stop 
    %  
    % unsigned int uAccuracy 
    % This is the neighborhood around the target coordinates in micro 
steps (only used with stepper motor) 
  
     
    handles.MotorsOK = 1; 
    handles.DEBUGMODE = false; 
     
    set(handles.txMotorStatus , 'ForegroundColor' , 'g' , 'String' , 
'Motors detected'); 
     
     
     
     
  
  
% --- Executes on button press in btSetCorner1. 
function btSetCorner1_Callback(hObject, eventdata, handles) 
% hObject    handle to btSetCorner1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
    if handles.DEBUGMODE  
        handles.Corners.TopLeft = step2mm([0 , 0]); 
        updateROIstatus(handles); 
         
    elseif handles.MotorsOK == 1 
        state_UP = ximc_get_status(handles.device_idUP); 
        state_LR = ximc_get_status(handles.device_idLR); 
  
        handles.Corners.TopLeft = step2mm([state_UP.CurPosition , 
state_LR.CurPosition]); 
    end 
  
    updateROIstatus(handles); 
    handles = parseInput(handles); 
    guidata(hObject , handles); 
  
     
     
% --- Executes on button press in btSetCorner2. 
function btSetCorner2_Callback(hObject, eventdata, handles) 
% hObject    handle to btSetCorner2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
     
    if handles.DEBUGMODE  
        handles.Corners.BottomRight = step2mm([-4700 , 0]); 
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        updateROIstatus(handles); 
  
    elseif handles.MotorsOK == 1 
        state_UP = ximc_get_status(handles.device_idUP); 
        state_LR = ximc_get_status(handles.device_idLR); 
  
        handles.Corners.BottomRight = step2mm([state_UP.CurPosition , 
state_LR.CurPosition]); 
    end 
     
     
    updateROIstatus(handles); 
    handles = parseInput(handles); 
    guidata(hObject , handles); 
  
         
     
function updateROIstatus(handles) 
    % Lights up the ROI indication in the status bar 
     
    if isempty(handles.Corners.TopLeft) && 
isempty(handles.Corners.BottomRight) 
        set(handles.txROIInitialized , 'ForegroundColor' , 'r' , 
'String' , 'ROI not initialized');     
    elseif xor(isempty(handles.Corners.TopLeft) , 
isempty(handles.Corners.BottomRight)) 
        set(handles.txROIInitialized , 'ForegroundColor' , 
[204,204,0]/255 , 'String' , 'One corner initialized'); 
    else 
        set(handles.txROIInitialized , 'ForegroundColor' , 'g' , 
'String' , 'ROI initialized');     
    end 
         
     
     
function x = step2mm(x) 
    % Transforms motor steps in mm 
    % 53942 steps = 100 mm 
  
    x = x / 53942 * 100; 
     
     
function x = mm2step(x)     
    % Transforms mm in motor steps  
    % 53942 steps = 100 mm 
  
    x = round(x * 53942 /100) ; 
  
  
  
     
function [handles , Nscans] = buildPath(handles) 
     
    Nscans = []; 
  
    [handles , inputOK] = checkInput(handles); 
    if inputOK ~= 1;   return;    end 
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    % Builds the motor paths from the input data 
    % Startij point 
    xpos0 = handles.Corners.TopLeft(1); 
    ypos0 = handles.Corners.TopLeft(2); 
     
    % Ending point 
    xlim = handles.Corners.BottomRight(1); 
    ylim = handles.Corners.BottomRight(2); 
     
    % Check if user indicated a single line 
    if xpos0 == xlim 
        button = questdlg('Are you trying to scan a single vertical 
line?','Single line scan alert','Yes','No','Cancel','Yes') ; 
        if strcmpi(button , 'No') || strcmpi(button , 'Cancel') 
            setappdata(handles.GUI_Motor_and_camera , 'MotorPath' , 
[]); 
            setappdata(handles.GUI_Motor_and_camera , 'ScansDone' , 
[]); 
            return 
        end 
         
        handles.StepSizeHorizontal = 0; 
        set(handles.txHorizontalStep , 'String' , '0'); 
         
    elseif ypos0 == ylim 
        button = questdlg('Are you trying to scan a single horizontal 
line?','Single line scan alert','Yes','No','Cancel','Yes') ; 
        if strcmpi(button , 'No') || strcmpi(button , 'Cancel') 
            setappdata(handles.GUI_Motor_and_camera , 'MotorPath' , 
[]); 
            setappdata(handles.GUI_Motor_and_camera , 'ScansDone' , 
[]); 
            return 
        end 
         
        handles.StepSizeVertical = 0; 
        set(handles.txVerticalStep , 'String' , '0'); 
    else 
         
    end 
     
    % Steps 
    xstep = handles.StepSizeHorizontal; 
    ystep = handles.StepSizeVertical; 
  
     
    % Check if steps make sense 
    if (xstep == 0  &&  xpos0 ~= xlim)  ||  (ystep == 0  &&  ypos0 ~= 
ylim)  
        msgbox('You indicated a zero-size step, which is only valid 
for single line scans!','Wrong step size'); 
        setappdata(handles.GUI_Motor_and_camera , 'MotorPath' , []); 
        setappdata(handles.GUI_Motor_and_camera , 'ScansDone' , []); 
        return 
    end 
     
     
    % X and Y coordinates of all points 
    if xlim < xpos0 
        xstep = -xstep; 
    end 
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    if ylim < ypos0 
        ystep = -ystep; 
    end 
     
     
    X  = (xpos0 : xstep : xlim + xstep)'; 
    Y  = (ypos0 : ystep : ylim + ystep)'; 
     
    if isempty(X);   X = xpos0;   end 
    if isempty(Y);   Y = ypos0;   end 
     
    LX = length(X); 
    LY = length(Y); 
    Nscans = LX * LY; 
     
    % Assemble motor path 
    MotorPath = zeros(Nscans , 2); 
    for k = 1 : length(Y) 
        if mod(k,2) == 1 
            MotorPath((k-1)*LX+1 : k*LX , :) = [X , repmat(Y(k) , LX , 
1)]; 
        else 
            MotorPath((k-1)*LX+1 : k*LX , :) = [flipud(X) , 
repmat(Y(k) , LX , 1)]; 
        end 
    end 
     
     
     
    % Repeat acquisitions at each step if necessary 
    if handles.AcquisitionsPerStep > 1 
        X = MotorPath(: , 1)'; 
        Y = MotorPath(: , 2)'; 
         
        X = repmat(X , handles.AcquisitionsPerStep , 1); 
        Y = repmat(Y , handles.AcquisitionsPerStep , 1); 
        X = X(:); 
        Y = Y(:); 
        MotorPath = [X , Y]; 
    end 
  
    Nscans = size(MotorPath , 1); 
    setappdata(handles.GUI_Motor_and_camera , 'MotorPath' , 
MotorPath); 
    ScansDone = zeros(Nscans , 1); 
    setappdata(handles.GUI_Motor_and_camera , 'ScansDone' , 
ScansDone); 
  
    handles = updateGraph(handles) ; 
     
     
     
     
function handles = updateGraph(handles)     
     
    ScansDone = getappdata(handles.GUI_Motor_and_camera , 
'ScansDone'); 
    currentPoint = find(ScansDone , 1 , 'last'); 
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    MotorPath = getappdata(handles.GUI_Motor_and_camera , 
'MotorPath'); 
     
    if isempty(currentPoint);  currentPoint = 1;   end 
     
    if isempty(handles.hLinePath) 
        handles.hLinePath = plot(handles.axesMain, MotorPath(:,1) , 
MotorPath(:,2) , 'b-'); 
        hold(handles.axesMain , 'on'); 
        handles.hCurrentPoint = plot(handles.axesMain , 
MotorPath(currentPoint,1) ,... 
                                                        
MotorPath(currentPoint,2) , 'ro'); 
        grid(handles.axesMain , 'on'); 
    else 
        set(handles.hLinePath , 'XData' , MotorPath(:,1) , ... 
                                'YData' , MotorPath(:,2)) 
        set(handles.hCurrentPoint , 'XData' , 
MotorPath(currentPoint,1) , ... 
                                    'YData' , 
MotorPath(currentPoint,2)) 
    end 
     
    xstep = handles.StepSizeHorizontal; 
    ystep = handles.StepSizeVertical; 
     
    % change step size just for drawing 
    if xstep == 0; xstep = 1; end ;    if ystep == 0; ystep = 1; end 
     
    axis(handles.axesMain, [min(MotorPath(:,1)) - xstep*2 , ... 
                            max(MotorPath(:,1)) + xstep*2 , ... 
                            min(MotorPath(:,2)) - ystep*2 , ... 
                            max(MotorPath(:,2)) + ystep*2]); 
         
    xlabel(handles.axesMain , '[mm]'); 
    ylabel(handles.axesMain , '[mm]'); 
  
     
     
  
function txHorizontalStep_Callback(hObject, eventdata, handles) 
% hObject    handle to txHorizontalStep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of txHorizontalStep as 
text 
%        str2double(get(hObject,'String')) returns contents of 
txHorizontalStep as a double 
    handles = parseInput(handles); 
    guidata(hObject , handles); 
  
  
% --- Executes during object creation, after setting all properties. 
function txHorizontalStep_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to txHorizontalStep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
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% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
  
  
function txVerticalStep_Callback(hObject, eventdata, handles) 
% hObject    handle to txVerticalStep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of txVerticalStep as 
text 
%        str2double(get(hObject,'String')) returns contents of 
txVerticalStep as a double 
    handles = parseInput(handles); 
    guidata(hObject , handles); 
  
  
% --- Executes during object creation, after setting all properties. 
function txVerticalStep_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to txVerticalStep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
  
  
function txAcquisitionTime_Callback(hObject, eventdata, handles) 
% hObject    handle to txAcquisitionTime (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of txAcquisitionTime 
as text 
%        str2double(get(hObject,'String')) returns contents of 
txAcquisitionTime as a double 
    handles = parseInput(handles); 
    guidata(hObject , handles); 
  
     
  
% --- Executes during object creation, after setting all properties. 
function txAcquisitionTime_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to txAcquisitionTime (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
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%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
  
% --- Executes on selection change in comboAcquisitionUnit. 
function comboAcquisitionUnit_Callback(hObject, eventdata, handles) 
% hObject    handle to comboAcquisitionUnit (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: contents = cellstr(get(hObject,'String')) returns 
comboAcquisitionUnit contents as cell array 
%        contents{get(hObject,'Value')} returns selected item from 
comboAcquisitionUnit 
     
    handles = parseInput(handles); 
    guidata(hObject , handles); 
     
  
% --- Executes during object creation, after setting all properties. 
function comboAcquisitionUnit_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to comboAcquisitionUnit (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: popupmenu controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
  
  
function [handles , inputOK]= checkInput(handles) 
  
  
    if isempty(handles.Corners.TopLeft) || 
isempty(handles.Corners.BottomRight) 
        inputOK = 'Please define a ROI'; 
        return 
    end 
     
    
    inputOK = 1; 
     
     
     
  
function handles = parseInput(handles) 
     
  
     
    handles.StepSizeHorizontal  = 
str2double(get(handles.txHorizontalStep , 'String')); 
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    handles.StepSizeVertical    = 
str2double(get(handles.txVerticalStep , 'String')); 
    handles.AcquisitionsPerStep = 
str2double(get(handles.txAcquisitionsPerStep , 'String')); 
    handles.AcquisitionTime     = 
str2double(get(handles.txAcquisitionTime , 'String')); 
     
    % Time in seconds 
    if get(handles.comboAcquisitionUnit , 'Value') == 2; 
        handles.AcquisitionTime = handles.AcquisitionTime * 60; 
    end 
  
    [handles , Nscans] = buildPath(handles); 
  
    setTimeRemaining(0 , Nscans , handles.AcquisitionTime, 
handles.txEstimatedTime); 
  
  
     
function popupErrorMessage(message) 
  
    waitfor(msgbox(message , 'modal')) 
        
     
     
function enableGUI(handles , option) 
  
switch option 
    case 'running' 
        set(handles.btSetCorner1 , 'Enable' , 'off'); 
        set(handles.btSetCorner2 , 'Enable' , 'off'); 
  
        set(handles.txHorizontalStep , 'Enable' , 'off'); 
        set(handles.txVerticalStep , 'Enable' , 'off'); 
        set(handles.txAcquisitionTime , 'Enable' , 'off'); 
        set(handles.txAcquisitionsPerStep , 'Enable' , 'off'); 
        set(handles.comboAcquisitionUnit , 'Enable' , 'off'); 
         
        set(handles.btStart , 'Enable' , 'off'); 
        set(handles.btGoToStep , 'Enable' , 'off');         
        set(handles.btReset , 'Enable' , 'off'); 
        set(handles.btStop , 'Enable' , 'on'); 
         
    case 'paused' 
        set(handles.btSetCorner1 , 'Enable' , 'off'); 
        set(handles.btSetCorner2 , 'Enable' , 'off'); 
  
        set(handles.txHorizontalStep , 'Enable' , 'off'); 
        set(handles.txVerticalStep , 'Enable' , 'off'); 
        set(handles.txAcquisitionTime , 'Enable' , 'off'); 
        set(handles.txAcquisitionsPerStep , 'Enable' , 'off'); 
        set(handles.comboAcquisitionUnit , 'Enable' , 'off'); 
         
        set(handles.btStart , 'Enable' , 'on'); 
        set(handles.btGoToStep , 'Enable' , 'on');         
        set(handles.btReset , 'Enable' , 'on'); 
        set(handles.btStop , 'Enable' , 'off'); 
         
    case 'idle' 
        set(handles.btSetCorner1 , 'Enable' , 'on'); 
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        set(handles.btSetCorner2 , 'Enable' , 'on'); 
  
        set(handles.txHorizontalStep , 'Enable' , 'on'); 
        set(handles.txVerticalStep , 'Enable' , 'on'); 
        set(handles.txAcquisitionTime , 'Enable' , 'on'); 
        set(handles.txAcquisitionsPerStep , 'Enable' , 'on'); 
        set(handles.comboAcquisitionUnit , 'Enable' , 'on'); 
         
        set(handles.btStart , 'Enable' , 'on'); 
        set(handles.btGoToStep , 'Enable' , 'on');         
        set(handles.btReset , 'Enable' , 'off'); 
        set(handles.btStop , 'Enable' , 'off'); 
    case 'finished' 
         
        set(handles.btSetCorner1 , 'Enable' , 'on'); 
        set(handles.btSetCorner2 , 'Enable' , 'on'); 
  
        set(handles.txHorizontalStep , 'Enable' , 'on'); 
        set(handles.txVerticalStep , 'Enable' , 'on'); 
        set(handles.txAcquisitionTime , 'Enable' , 'on'); 
        set(handles.txAcquisitionsPerStep , 'Enable' , 'on'); 
        set(handles.comboAcquisitionUnit , 'Enable' , 'on'); 
         
        set(handles.btStart , 'Enable' , 'on'); 
        set(handles.btGoToStep , 'Enable' , 'on');         
        set(handles.btReset , 'Enable' , 'on'); 
        set(handles.btStop , 'Enable' , 'off');         
end 
  
  
     
     
% --- Executes on button press in btStart. 
function btStart_Callback(hObject, eventdata, handles) 
% hObject    handle to btStart (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
    [handles , inputOK] = checkInput(handles); 
  
    % If some input is not valid, quit now 
    if ischar(inputOK);    popupErrorMessage(inputOK);     return;   
end 
     
    % The path of the motors have already been buildt. Retrieve the 
array  
    % to keep track of how many scans have been done 
    ScansDone = getappdata(handles.GUI_Motor_and_camera , 
'ScansDone'); 
    N = length(ScansDone); 
     
    % DETERMINE NEXT POSITION TO SCAN 
    nextPosition = find(ScansDone , 1 , 'last') + 1; 
    if isempty(nextPosition);   
        nextPosition = 1 ;     
    elseif nextPosition >= N 
        enableGUI(handles , 'paused'); 
        popupErrorMessage('The job was completed; please press Reset 
before starting a new one'); 
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        return 
    end 
     
    enableGUI(handles , 'running'); 
    % Move to next (first?) position and scan 
    result = moveAndScan(handles , nextPosition); 
    if result ~= 0;     
        enableGUI(handles , 'idle');    
        return;     
    end   % Quit if something went wrong 
     
    ScansDone(nextPosition) = 1; 
    setappdata(handles.GUI_Motor_and_camera , 'ScansDone' , 
ScansDone); 
     
    % Timer object 
    out = timerfind('Tag' , 'GUI_Motor_and_camera'); 
    handles.hScanTimer = timer('ExecutionMode' , 'fixedSpacing' , ... 
           'StartDelay' , handles.AcquisitionTime, 'Period' , 
handles.AcquisitionTime , ... 
           'TimerFcn' , @scanFinished , 'Tag' , 
'GUI_Motor_and_camera'); 
     
        
    setTimeRemaining(nextPosition , N , handles.hScanTimer.Period, 
handles.txEstimatedTime); 
    set(handles.hProgressBar , 'Position' , [0 , 0 , nextPosition / N 
, 1]); 
  
    guidata(hObject , handles); 
  
    start(handles.hScanTimer); 
    updateJobStatus(handles); 
     
     
     
     
function updateJobStatus(handles) 
  
    ScansDone = getappdata(handles.GUI_Motor_and_camera , 
'ScansDone'); 
    currentPosition = find(ScansDone , 1 , 'last'); 
     
    if isempty(currentPosition) 
        set(handles.txJobRunning , 'String' , 'Job not running' , 
'ForegroundColor' ,'r'); 
        set(handles.btStart , 'Enable' , 'on'); 
    elseif currentPosition < length(ScansDone)         
        if ~isempty(handles.hScanTimer) && isvalid(handles.hScanTimer) 
&& ... 
                strcmpi(handles.hScanTimer.Running , 'on') 
         
            set(handles.txJobRunning , 'String' , 'Job running' , 
'ForegroundColor' , [204,204,0]/255); 
            set(handles.btStart , 'Enable' , 'off'); 
        else 
            set(handles.txJobRunning , 'String' , 'Job paused' , 
'ForegroundColor' , 'r'); 
            set(handles.btStart , 'Enable' , 'on'); 
        end 
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    else 
        set(handles.txJobRunning , 'String' , 'Job done!' , 
'ForegroundColor' ,'g'); 
        set(handles.btStart , 'Enable' , 'on'); 
    end 
  
     
     
     
function   result = moveAndScan(handles , positionN) 
  
    % Move to step 
    result = moveToStepN(handles , positionN); 
        
    if result ~= 0 
        popupErrorMessage(['Could not move motors to position N. ' , 
num2str(positionN)]) 
    end 
     
    result = sendSynch(handles); 
     if result ~= 0 
        popupErrorMessage('Could not synch scan') 
    end 
           
     
     
     
function result = moveToPosition(handles, coordinates) 
  
     
    if handles.DEBUGMODE; 
        result = 0; 
        return 
    end 
     
    state_UP = ximc_get_status(handles.device_idUP); 
    state_LR = ximc_get_status(handles.device_idLR); 
     
    coordinates = mm2step(coordinates); 
     
    if state_UP.CurPosition == coordinates(1) && ... 
       state_LR.CurPosition == coordinates(2) 
         
        % Already in position 
        result = 0; 
        return 
    end 
     
    result(1) = calllib('libximc','command_move', handles.device_idUP, 
coordinates(1) , 0); 
    result(2) = calllib('libximc','command_move', handles.device_idLR, 
coordinates(2) , 0); 
  
    result = ~all(result == 0); 
    if result ~= 0 
        popupErrorMessage('Error when moving motors!'); 
        return 
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    end 
     
  
  
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    calllib('libximc','command_wait_for_stop', handles.device_idUP, 
300); 
    calllib('libximc','command_wait_for_stop', handles.device_idLR, 
300); 
  
  
     
     
     
  
function result = moveToStepN(handles , nStep) 
  
    MotorPath = getappdata(handles.GUI_Motor_and_camera , 
'MotorPath'); 
    result    = moveToPosition(handles, MotorPath(nStep , :)); 
     
  
     
     
  
  
     
function handles = jobFinished(handles) 
  
  
  
  
  
  
function scanFinished(obj, event) 
    % One scan has finished 
     
    % Measure time required to move motors and send synch 
    tic 
     
    % Retrieve handles 
    h = findall(0,'Type','figure' , 'Tag' , 'GUI_Motor_and_camera'); 
    handles = guidata(h(1)); 
  
  
    ScansDone = getappdata(handles.GUI_Motor_and_camera , 
'ScansDone'); 
     
     
    % Determine NEXT POSITION TO SCAN 
    N = length(ScansDone); 
    nextPosition = find(ScansDone , 1 , 'last') + 1; 
    if isempty(nextPosition);   
        nextPosition = 1;     
    elseif nextPosition > N 
        stop(obj); 
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        delete(obj); 
        enableGUI(handles , 'finished'); 
         
        updateJobStatus(handles); 
        setTimeRemaining(nextPosition , N , obj.Period, 
handles.txEstimatedTime); 
        guidata(h(1) , handles); 
        return; 
    end 
     
    % Move to next position and scan 
    result = moveAndScan(handles , nextPosition); 
     
     
    if result ~= 0;    obj.stop;  return;    end   % Quit if something 
went wrong 
  
    % Output to microscope scanner right after movement 
    result = sendSynch(handles); 
     
    if result ~= 0;    obj.stop;  return;    end   % Quit if something 
went wrong 
     
    ScansDone(nextPosition) = 1; 
    setappdata(handles.GUI_Motor_and_camera , 'ScansDone' , 
ScansDone); 
     
    handles = updateGraph(handles); 
     
    set(handles.hProgressBar , 'Position' , [0 , 0 , min([0.01 , 
nextPosition / N]) , 1]); 
     
    ScanDuration = obj.Period + toc; 
     
    setTimeRemaining(nextPosition , N , ScanDuration, 
handles.txEstimatedTime); 
     
     
     
  
function result = sendSynch(handles)     
     
    if handles.DEBUGMODE; 
        result = 0; 
        return 
    end 
     
     
    % Read settings to automatically get the output structure 
sync_settings 
    sync_settings = struct('SyncOutFlags', 0, 'SyncOutPulseSteps', 0, 
'SyncOutPeriod', 0, 'Accuracy', 0, 'uAccuracy', 0); 
    [result, sync_settings] = 
calllib('libximc','get_sync_out_settings', handles.device_idUP, 
sync_settings); 
    
    % What I want: 00100001 (Enabled + synch when motor stop + 
duration in ms) 
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    % SYNCOUT_ENABLED   0X01  // 00000001  // Synchronization out pin 
follows the synchronization logic, if set. 
    % SYNCOUT_STATE     0X02  // 00000010  // When output state is 
fixed by negative SYNCOUT_ENABLED flag, the pin state is in accordance 
with this flag state. 
    % SYNCOUT_INVERT    0X04  // 00000100  // Low level is active, if 
set, and high level is active otherwise 
    % SYNCOUT_IN_STEPS  0X08  // 00001000  // Use motor steps/encoder 
pulses instead of milliseconds for output pulse generation if the flag 
is set 
    % SYNCOUT_ONSTART   0X10  // 00010000  // Generate synchronization 
pulse when movement starts. 
    % SYNCOUT_ONSTOP    0X20  // 00100000  // Generate synchronization 
pulse when movement stops. 
    % SYNCOUT_ONPERIOD  0X40  // 01000000  // Generate synchronization 
pulse every SyncOutPeriod encoder pulses 
    % hexToBinaryVector('0x20') 
  
    sync_settings.SyncOutFlags  = bin2dec('00101101');  % Synch 
enabled, on stop, motor steps/encoder pulses instead of milliseconds 
    sync_settings.SyncOutPeriod = 100;  % ms 
    sync_settings.Accuracy = 0;  % distance to the target position. As 
soon as the distance to 
                                 % target on approach is less than or 
equal to this distance  
                                 % a synchronizing pulse will be 
generated if "on stop" option is used. 
  
    result(1) = calllib('libximc','set_sync_out_settings', 
handles.device_idUP, sync_settings); 
    result(2) = calllib('libximc','set_sync_out_settings', 
handles.device_idLR, sync_settings); 
  
    if ~all(result == 0) 
        popupErrorMessage('Error writing motor setup'); 
        return 
    end 
     
    % Wait a little 
    pause(0.5) 
         
    % Switch it off 
    sync_settings.SyncOutFlags  = bin2dec('00000000');  % Synch 
disabled 
     
     
    result(1) = calllib('libximc','set_sync_out_settings', 
handles.device_idUP, sync_settings); 
    result(2) = calllib('libximc','set_sync_out_settings', 
handles.device_idLR, sync_settings); 
  
    result = ~all(result == 0); 
     
    if result 
        popupErrorMessage('Error writing motor setup'); 
        return 
    end 
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function setTimeRemaining(currentPosition , N , Period , h) 
  
    currentTimeRemaining = (N - currentPosition + 1) * Period; 
     
    if currentTimeRemaining <= 0 
        T = 'Job done!'; 
        set(h , 'String' , T); 
        return 
         
    elseif currentTimeRemaining < 60  % Seconds 
        currentTimeRemaining = round(currentTimeRemaining , 1); 
        T = ['Estimated time: ' num2str(currentTimeRemaining) ' s']; 
         
    elseif currentTimeRemaining < 60*60  % minutes 
        currentTimeRemaining = round(currentTimeRemaining / 60 , 1); 
        T = ['Estimated time: ' num2str(currentTimeRemaining) ' min']; 
     
    else   % Hours 
        currentTimeRemaining = currentTimeRemaining / 60 / 60; 
         
        T = ['Estimated time: ' num2str(floor(currentTimeRemaining)) 
'h ' ... 
            num2str(round(60 * (currentTimeRemaining - 
floor(currentTimeRemaining)))) 'min']; 
    end 
     
    T = {T ; ['Scanning N. ' num2str(currentPosition) '/' 
num2str(N)]}; 
     
    set(h , 'String' , T); 
     
     
  
     
  
% --- Executes on button press in btStop. 
function btStop_Callback(hObject, eventdata, handles) 
% hObject    handle to btStop (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
    if ~isempty(handles.hScanTimer) 
        stop(handles.hScanTimer); 
  
        delete(handles.hScanTimer); 
        handles.hScanTimer = []; 
    end 
     
    enableGUI(handles , 'paused'); 
    updateJobStatus(handles); 
    guidata(hObject , handles); 
  
     
     
% --- Executes on button press in btReset. 
function btReset_Callback(hObject, eventdata, handles) 
% hObject    handle to btReset (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
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    answer = questdlg('Are you sure you want to lose all scans?' , 
'Reset', 'Yes' , 'No' , 'Cancel' , 'Cancel'); 
  
    if ~strcmp(answer , 'Yes');    return;   end 
     
    % Reset number of scans done 
    ScansDone = getappdata(handles.GUI_Motor_and_camera , 
'ScansDone'); 
    ScansDone = ScansDone .*0; 
    setappdata(handles.GUI_Motor_and_camera , 'ScansDone' , 
ScansDone); 
     
    handles = updateGraph(handles); 
  
     
    % Stop timer if it was running 
    if ~isempty(handles.hScanTimer) && isvalid(handles.hScanTimer) 
        stop(handles.hScanTimer) 
  
        delete(handles.hScanTimer) 
        handles.hScanTimer = []; 
    end 
     
    updateJobStatus(handles); 
    enableGUI(handles , 'idle'); 
    guidata(hObject , handles); 
     
  
  
% --- Executes when user attempts to close GUI_Motor_and_camera. 
function GUI_Motor_and_camera_CloseRequestFcn(hObject, eventdata, 
handles) 
% hObject    handle to GUI_Motor_and_camera (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hint: delete(hObject) closes the figure 
% Close devices 
     
    if ~handles.DEBUGMODE 
        device_id_ptr = libpointer('int32Ptr', handles.device_idUP); 
        calllib('libximc','close_device', device_id_ptr); 
        device_id_ptr = libpointer('int32Ptr', handles.device_idLR); 
        calllib('libximc','close_device', device_id_ptr); 
    end 
  
    delete(hObject); 
  
  
  
function out = checkStrNumber(str) 
  
  
    out = all(ismember(str, '0123456789+-.')); 
    out = out && ~isnan(str2double(str)); 
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% --- Executes on button press in btGoToStep. 
function btGoToStep_Callback(hObject, eventdata, handles) 
% hObject    handle to btGoToStep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
    ScansDone = getappdata(handles.GUI_Motor_and_camera , 
'ScansDone'); 
    N = length(ScansDone); 
     
    Nstep = inputdlg(['Enter step number [1 - ' num2str(N) ']:'] , 'Go 
to step #' , 1); 
    if isempty(Nstep);    return;    end 
     
    checkstr = checkStrNumber(Nstep{1}); 
    Nstep = str2double(Nstep{1}); 
  
    if checkstr ~= 1 || Nstep == 0 || Nstep > N || Nstep < 1;   
        msgbox(['Please enter a number between 1 and '  num2str(Nstep) 
' !']);    
        return;    
    end 
     
     
    ScansDone = ScansDone .* 0; 
    if Nstep > 1;  ScansDone(1 : Nstep - 1) = 1;   end 
     
     
    setappdata(handles.GUI_Motor_and_camera , 'ScansDone' , 
ScansDone); 
  
    updateROIstatus(handles); 
    handles = updateGraph(handles); 
    setTimeRemaining(Nstep , N , handles.AcquisitionTime, 
handles.txEstimatedTime); 
    set(handles.hProgressBar , 'Position' , [0 , 0 , (Nstep - 1) / N , 
1]); 
  
     
    enableGUI(handles , 'idle'); 
    % Move to next (first?) position and scan 
  
  
% -------------------------------------------------------------------- 
function uiSave_ClickedCallback(hObject, eventdata, handles) 
% hObject    handle to uiSave (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
    DefaultName = clock; 
    DefaultName = [num2str(DefaultName(1)) ' ' num2str(DefaultName(2)) 
' ' num2str(DefaultName(3))... 
               ' - ' num2str(DefaultName(4)) '_' 
num2str(DefaultName(5)) '.mat']; 
  
            
    if ~isempty(handles.lastSavePath) && exist(handles.lastSavePath , 
'file') 
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        cd(handles.lastSavePath); 
    end 
     
     
    [FileName,PathName] = uiputfile('*.mat','Save 
scan...',DefaultName); 
  
    if FileName == 0; 
        return 
    end 
  
    handles.lastSavePath = PathName; 
    writeConfig(handles)    
     
     
    ScansDone = getappdata(handles.GUI_Motor_and_camera , 
'ScansDone'); 
    MotorPath = getappdata(handles.GUI_Motor_and_camera , 
'MotorPath'); 
     
    StepSizeHorizontal_mm = handles.StepSizeHorizontal; 
    StepSizeVertical_mm   = handles.StepSizeVertical; 
     
    ScanTime_seconds = handles.AcquisitionTime; 
  
    save([PathName FileName] , 'ScansDone' , 'MotorPath' ,... 
        'StepSizeHorizontal_mm' , 'StepSizeVertical_mm' , 
'ScanTime_seconds'); 
     
    guidata(hObject , handles); 
  
     
     
function handles = loadConfig(handles) 
  
    configFile = [fileparts(mfilename('fullpath')) '\config_GUI.mat']; 
    if ~exist(configFile, 'file') 
        return; 
    end 
     
    load(configFile) 
     
    handles.lastSavePath = lastSavePath; 
     
     
  
  
function writeConfig(handles) 
     
    configFile = [fileparts(mfilename('fullpath')) '\config_GUI.mat']; 
  
    lastSavePath = handles.lastSavePath; 
  
    save(configFile , 'lastSavePath'); 
  
  
% --- Executes on button press in pushbutton7. 
function pushbutton7_Callback(hObject, eventdata, handles) 
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% hObject    handle to pushbutton7 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
  
function txAcquisitionsPerStep_Callback(hObject, eventdata, handles) 
% hObject    handle to txAcquisitionsPerStep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of 
txAcquisitionsPerStep as text 
%        str2double(get(hObject,'String')) returns contents of 
txAcquisitionsPerStep as a double 
     
  
    handles = parseInput(handles); 
    guidata(hObject , handles); 
  
     
     
% --- Executes during object creation, after setting all properties. 
function txAcquisitionsPerStep_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to txAcquisitionsPerStep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
Measure Peak 
function MeasurePeak_V01 
    if exist('\\isad.isadroot.ex.ac.uk\UOE\User\MATLAB' , 'file') 
        cd('\\isad.isadroot.ex.ac.uk\UOE\User\MATLAB') 
    end 
        cd('\\isad.isadroot.ex.ac.uk\UOE\User\MATLAB') 
     
     
    [FileName,PathName] = uigetfile('*.fig' , 'Open File' , 
'MultiSelect', 'on'); 
    %FileName = fullfile(PathName, FileName); 
    if iscell(FileName) 
        if FileName{1} == 0;  return;   end      
         
         
        for k = 1 : length(FileName) 
            openfig([PathName FileName{k}]); 
            set(gca,'ButtonDownFcn',@ButtonClicked); 
        end 
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    else 
        if FileName == 0;  return;   end 
         
        FileName = [PathName FileName]; 
  
        openfig(FileName); 
        set(gca,'ButtonDownFcn',@ButtonClicked); 
         
    end 
     
     
function ButtonClicked(hObject , eventdata) 
    disp('yay') 
    cp = get(gca,'CurrentPoint'); 
    cp = cp(1 , 1:2); 
     
        
    % Find the line in the figure 
    objLine = get(hObject,'Children');  
    objLine = findobj(objLine , 'Type' , 'line' ,'-
not','Tag','MeasurePeak');  
    XData   = get(objLine,'XData'); %get the x data 
    YData   = get(objLine,'YData'); %get the y data 
     
     
    % Find highest peak near the clicked point 
    where = XData > (cp(1) - 30) & XData <( cp(1) + 30); 
     
    % Smooth data to detect points 
    YData_smooth = moving_average2(YData,2); 
  
    % Remove points far away from click 
    YData_clicked = YData_smooth; 
    YData_clicked(~where) = NaN; 
    [PeakValue , posMax] = nanmax(YData_clicked); 
     
    % Keep the actual max value, not the smoothed one  
    YData_clicked = YData; 
    YData_clicked(~where) = NaN; 
    PeakValue = nanmax(YData_clicked); 
     
    % Show detected peak 
    hold(hObject , 'on'); 
    plot(hObject , XData(posMax) , PeakValue , 'ro' , 'Tag' , 
'MeasurePeak'); 
     
     
    % Now find a change of derivative sign before the peak... 
    plot(XData , YData_smooth , 'g-', 'Tag' , 'MeasurePeak'); 
    D = diff(YData_smooth); 
    posMin1 = find(D(1 : posMax - 1) < 0 , 1 , 'last'); 
     
    % ...And after the peak 
    posMin2 = find(D(posMax + 1 : end) > 0 , 1 , 'first') + posMax; 
     
    YValueBefore = YData(posMin1); 
    YValueAfter  = YData(posMin2); 
     
    % Peak difference from background 
    PeakMagnificence = PeakValue - mean([YValueBefore , YValueAfter]); 
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    % Plot the baseline just because 
    plot(XData([posMin1 , posMin2]) , [YValueBefore , YValueAfter] , 
'r-' , 'Tag', 'MeasurePeak') 
    plot(XData([posMin1 , posMin2]), YData([posMin1 , posMin2]) , 'ro' 
, 'Tag', 'MeasurePeak') 
     
     
    % Print the text 
    xtext = XData(posMin2); 
    ytext = mean([YValueBefore , YValueAfter]) + PeakMagnificence / 2; 
    t = {['Height = ' num2str(PeakMagnificence)] ;... 
         ['Absolute height = ' num2str(PeakValue)]  ;... 
         ['Foot values = ' num2str([YData([posMin1 , posMin2])])]}; 
    disp(t) 
    text(xtext , ytext , t , 'Tag', 'MeasurePeak') 
    %text(hObject , xtext , ytext , t , 'Tag', 'MeasurePeak'); 
     
     
    % Store result in workspace 
    W = evalin('base','whos'); 
     
    if any(ismember('Peak_Height',[W(:).name])) 
        Peak_Height = evalin('base' , 'Peak_Height'); 
    else 
        Peak_Height = []; 
    end 
     
    Peak_Height = [Peak_Height ; [PeakMagnificence , PeakValue , 
YData([posMin1 , posMin2])]]; 
     
    assignin('base' , 'Peak_Height' , Peak_Height); 
     
     
     
function [ signal ] = moving_average2( signal , points ) 
% 2-pass moving average filter 
  
    if points==1;   return;   end; 
  
    b = ones(1,points)/points; 
    L=length(signal); 
  
  
    BORDER=2*points; 
  
  
    if size(signal,1)~=1 
        signal=signal'; 
        signal=filter(b,1,[zeros(1,BORDER)+signal(1) signal 
zeros(1,BORDER)+signal(L)]); 
        signal=fliplr(filter(b,1,fliplr(signal))); 
        signal=signal(BORDER+1:length(signal)-BORDER); 
        signal=signal'; 
    else 
        signal=filter(b,1,[zeros(1,BORDER)+signal(1) signal 
zeros(1,BORDER)+signal(L)]); 
        signal=fliplr(filter(b,1,fliplr(signal))); 
        signal=signal(BORDER+1:length(signal)-BORDER); 
 240 
 
    end 
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